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Pharmaceuticals have been identified as emerging contaminants of concern due to their 
widespread occurrence in the aquatic environment and potential to be biologically active, 
yet the implications of their presence in the environment is not fully known. There is a 
plethora of pharmaceuticals commercially available making it unfeasible to carry out 
detailed investigations on all of these compounds, and prioritisation schemes can provide 
a useful tool to determine how best to direct resources. Different prioritisation schemes 
were carried out on the fifty most prescribed drugs in the UK, and their results were 
compared in order to assess the efficacy of these schemes. Many failed to accurately 
identify these risks, but a holistic approach using more than one method to generate a 
priority list of compounds, may provide better protection for the environment. To date, 
most monitoring and ecotoxicological studies have focused on pharmaceuticals in 
freshwater, and there is less understanding of their occurrence and effects in estuaries. 
In order to gain insight into their spatio-temporal patterns, five pharmaceuticals were 
monitored in the Humber Estuary every other month for twelve months. Patterns in their 
spatial and temporal occurrence were related to source points, consumption patterns 
and environmental conditions. Eleven further estuaries were monitored to give an overall 
picture of pharmaceutical pollution in the UK. The Humber Estuary contained highest 
levels of pharmaceuticals and concentrations of ibuprofen were the highest measured 
globally. Finally, ragworms (Hediste diversicolor) were exposed to diclofenac and 
metformin in a controlled experimental exposure, and the expression of selected target 
genes, ATP synthase and c-amp activated protein kinase was measured. Highest levels 
of metformin (1 µg l-1) were found to significantly increase expression of ATP synthase, 
indicating that this drug induces environmental stress in H. diversicolor. Overall, this body 
of research has further contributed to the knowledge of pharmaceuticals as emerging 
contaminants in estuaries, and information on the occurrence, current levels and 
biological effects of the drugs studied may be of interest to regulators in their 
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Chapter 1: Introduction 
 
This introductory chapter seeks to place the thesis into context by providing background 
information and reviewing previous research conducted on pharmaceuticals as emerging 
contaminants. Pharmaceuticals are consumed in large quantities, with annual production 
for the most widely consumed pharmaceuticals in the kiloton range (Beretta et al. 2014). 
The average global per capita consumption is 15 g of drugs per day with developed 
countries consuming 3 - 10 times more pharmaceuticals than less economically developed 
ones (Pal et al. 2010). In addition to compounds used in human medicine, pharmaceuticals 
are also available for veterinary use (Capleton et al. 2006). Pharmaceuticals are unique 
contaminants, as they are designed to be biologically active, and are therefore likely to 
have an effect in non-target organisms (Küster and Adler 2014). This review aims to bring 
together research on the occurrence and ecotoxicology of pharmaceuticals in the marine 
and estuarine environments and identify potential knowledge gaps.  
Pharmaceuticals have the potential to enter the aquatic environment as a mixture of parent 
compounds, metabolites and transformation products (Backhaus 2014). After 
consumption, a proportion of the drug is used by the body, and then is excreted into the 
sewage system via urine and faeces (Figure 1.1; Hutchinson et al. 2014). Topical 
pharmaceuticals may also enter sewage systems after being washed off or directly into 
the aquatic environment (Ruhoy and Daughton 2008). It has been estimated that 
approximately 30% of topical ointments applied to the skin will be washed off and not 
absorbed into the body, however, these products only make up a small proportion of 
pharmaceuticals available on the market (Bound and Voulvoulis 2006). Some 
pharmaceuticals, such as sertraline, are excreted as less than 1% of the parent compound, 
whereas other such as gabapentin are excreted largely unchanged (Drugbank, 2018). 
Drugs may also enter sewage through improper disposal of unused or out of date 
pharmaceuticals, however, data is insufficient to determine if this is a significant route of 
entry (Ruhoy and Daughton 2008). Bound and Voulvoulis (2005) found 64% of surveyed 
people in the US had disposed of medicines through household waste, and the amount of 
incorrectly disposed pharmaceuticals is estimated to be as high as 2.3% of those sold in 
the US (Ruhoy and Daughton 2008). Wastewater treatment plants (WWTPs) may further 
remove some pharmaceuticals through bacterial degradation, UV degradation or 
absorption to sludge (Boreen et al. 2003; Cuong et al. 2011). Pharmaceuticals have 
different sorption properties and those with a low sorption coefficient (Kd) are more likely 
to enter the environment as they will not bind to suspended solids as easily (Liu et al. 
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2013). Biodegradation is the most prominent form of removal in WWTPs, with sludge 
retention time and compound structure, the most important factors in determining the 
efficiency of this (Sipma et al. 2010). Even the most advanced WWTPs will be unable to 
completely remove all pharmaceuticals, which can lead to the continuous input of low 
levels into the aquatic environment (Fabbri 2015). 41% of the global population lives in 
coastal areas, and as a result, a high amount of sewage is being released into coastal 
waters or estuaries (Gaw et al. 2014). Sewage may also be discharged from ships and 
cruise liners, therefore there is the potential for drugs to be found in marine waters further 
from the coast, however these concentrations are likely to be small (Backhaus 2014).  
Agriculture and aquaculture provide another route of entry into the aquatic environment 
(Figure 1.1; Pal et al. 2010). Many of the pharmaceuticals used in these industries, 
particularly antibiotics are also registered for human use (Kim et al. 2016). Veterinary 
pharmaceuticals also have the potential to enter the aquatic environment and pose a 
threat. However, the scope of this review will only focus on those which are registered for 
human use.  In offshore aquaculture, up to 75% of medicines administered can be lost to 
surrounding waters and in some areas of Asia, fish in aquaculture are fed with treated 
sewage sludge, which will contain low levels of pharmaceuticals (Gaw et al. 2014). The 
spreading of manure contaminated with pharmaceuticals, and runoff from agriculture can 
also contribute to their entrance into the aquatic environment.  
 
Figure 1.1: Diagram outlining the sources of pharmaceuticals in the aquatic environment. 
Pharmaceuticals can enter the aquatic environment through the manufacturing process, human 
consumption, improper disposal, aquaculture, run off from agriculture and the spreading of manure.  
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Once in the aquatic environment, pharmaceuticals may absorb to sediment or suspended 
particles, enter biological organisms or be further degraded or transformed (Yang et al. 
2011; Liu et al. 2013). In surface waters, photodegradation is the most efficient form of 
removal, as it is likely that many of the pharmaceuticals present have already experienced 
biodegradation in WWTPs and will therefore be resistant to this (Boreen et al. 2003; Cuong 
et al. 2011). The efficiency of photodegradation depends on the chemical structure of the 
compound and light intensity, and therefore is likely to be more efficient in some seasons 
and geographical areas than others (Cuong et al. 2011). Sorption to sediment is the other 
main method of pharmaceutical removal from surface waters, however, there is limited 
data on the fate of pharmaceuticals once they reach aquatic sediment (Maskaoui and Zhou 
2010; Liu et al. 2013). They are likely to become bioavailable to different organisms, but 
depending on the biogeochemistry may become buried or resuspended (Beretta et al. 
2014).  
There are many parameters which can affect the partitioning of pharmaceuticals between 
water and sediment (Oh et al. 2016).Pharmaceuticals with a high molecular weight and 
high octanol-water partition coefficient (LogKOW) are less soluble and more easily sorbed 
to sediments. However, this is not the only predictor of sorption to sediment, and 
pharmaceuticals with a low logKOW, such as trimethoprim (logKOW <1), have been detected 
in sediments (Lara-Martín et al. 2014). This partitioning of pharmaceuticals between 
sediment and water is not only determined by chemical properties, but also environmental 
factors, and sediment properties. Pharmaceuticals often have one or more ionisable 
groups and the ionisation of these compounds is often pH dependent (Martínez-
Hernández et al. 2014). As a result, sorption to sediment can also be influenced by water 
and sediment pH. When the pH of a compound is less than its dissociation constant (pKa) 
then it will be protonated, and more likely to absorb to sediment (Yamamoto et al. 2009). 
As a result acidic (pKa < 7) pharmaceuticals such as ibuprofen and diclofenac have 
showed lower affinity to bind to suspended solids in the environment in comparison to 
compounds with basic characteristics such as antidepressants (Zenker et al. 2014; Oh et 
al. 2016).  For instance, ibuprofen has a pKa of 4.5 and in experimental studies, has been 
shown to have a higher sorption tendency to sediment with a pH below this, and almost 
no sorption to sediment at pH 7 due to increased solubility and decreased logKOW (Oh et 
al. 2016). A linear relationship between the organic content of sediment and the KD of a 
compound has been observed. Al-Khazrajy and Boxall (2016) assessed the sorption 
behaviour of amitriptyline, atenolol, cimetidine, diltiazem and mefenamic acid to ten types 
of sediment and found that there was a positive relationship between sorption of cimetidine 
(pKa 6.8) to the organic and clay content of sediment, as the result of a greater presence 
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of the neutral form fraction. These characteristics will also influence the uptake of 
pharmaceuticals by aquatic organisms. LogKOW is often used as a predictor of 
pharmaceutical bioaccumulation, however, due to the ionisation of these compounds, is 
often found to be inaccurate, and the potential for bioaccumulation of pharmaceuticals is 
dependent on pH (Schreiber et al. 2011). Whilst lipophilicity of pharmaceuticals plays a 
role in the uptake of pharmaceuticals, this can differ between tissue type and organisms 
(Moreno-González et al. 2016; Ojemaye and Petrik 2019).   
Current research on the fate of pharmaceuticals in the aquatic environment has focused 
on freshwater. However, this may not be transferable to the marine and estuarine 
environments due to different physical-chemical properties (Gaw et al. 2014). Changes in 
pH and salt within an estuary will have an influence on the ionisation of many compounds 
which can lead to changes in solubility and sorption (Fabbri and Franzellitti 2016). 
Typically, seawater has a pH of 8, which may increase the lipophilicity of compounds, 
leading to enhanced affinity to be absorbed to sediment or taken up by organisms. 
Additionally, the increased salt content will decrease the solubility of neutral compounds 
as the result of the salting-out effect (Turner 2003).  Tides and currents are key process in 
these environments and are likely to play a role in the transport of pharmaceuticals, 
changes in pH, and interaction of pharmaceuticals with suspended sediment (Zhao et al. 
2015).   
1.1 Prioritisation of pharmaceuticals 
In 2004 the first pieces of legislation (2004/27/EC and 2004/28/EC) to require an 
environmental risk assessment (ERA) for pharmaceutical compounds came into effect, 
requiring an ERA assessment to be completed for all new marketing authorisation 
applications under regulation for Registration, Evaluation, Authorisation and Restriction of 
Chemicals (REACH; Adler et al. 2008). Under REACH, an ERA must include an 
assessment on the risk and hazards of the given compound in aquatic and terrestrial 
compartments (Tarazona et al. 2007). A risk-benefit analysis for veterinary drugs was 
introduced where compounds could be banned from use if the environmental risks 
outweighed the potential benefits, however, the benefit to human medicine is always seen 
to outweigh the potential environmental risks  (Küster and Adler 2014). Under this 
legislation, ERAs must include an assessment of the amount of the compound in different 
compartments (e.g. freshwater, terrestrial and marine environments) and if a trigger level 
is reached an assessment on the risk to biota in these compartments must be undertaken 
(Tarazona et al. 2007). In the aquatic environment this usually comprises of predicted no 
effect concentrations (PNEC) or acute toxicity tests with Daphnia magna, green algae and 
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zebrafish (Danio rerio; Tarazona et al. 2007). Prior to this, compounds were released into 
the environment unregulated with little to no knowledge of their potential hazards (Roos et 
al. 2012). Currently, human pharmaceuticals must be disposed of through hazardous 
waste, but there are not any regulations surrounding their usage and environmental 
consequences. Since this legislation came into effect, approximately 10% of 
pharmaceuticals were found to pose an environmental risk (Kuster and Adler, 2014). 
Diclofenac and ethinylestradiol are examples of compounds which pose a risk to the 
aquatic environment (Adler et al. 2008). They were added to priority watch lists under the 
water framework directive in 2013, recognising for the first time that pharmaceuticals have 
the potential to be a serious environment risk (Mavragani et al. 2016).   
There is still a lot of uncertainty surrounding the occurrence of pharmaceuticals in the 
aquatic environment, and their environmental risk. There is evidence that they are 
occurring in the environment (Hughes et al. 2013; Fabbri and Franzellitti 2016), however, 
the implications of this is not yet fully understood (Taylor and Senac 2014). It is only within 
recent years that analytical methods have been able to detect these compounds, and prior 
to this, little research was conducted on pharmaceuticals as environmental contaminants. 
Despite the widespread and ubiquitous usage of pharmaceuticals, we know relatively little 
about their environmental impacts. Unlike other pollutants, there is already extensive 
knowledge surrounding the pathways of pharmaceuticals in vertebrates, but there is some 
uncertainty over the potential effects on non-target organisms (Fabbri 2015). With so many 
pharmaceuticals commercially available, it would use a great deal of resources to monitor 
their occurrence in the environment and determine the effects in non-target organisms. 
Prioritisation schemes are frequently used in the literature to identify a smaller subset of 
compounds which are likely to be found in the environment and pose a risk (Mansour et 
al. 2016).  This can help direct resources and determine where scientific research should 
be invested. Further research into the environmental effect of pharmaceuticals can impact 
legislation, by further determining those which need to be regulated.  
1.1.1 Exposure assessment 
Many prioritisation schemes use predicted environmental concentrations (PECs) as a 
basis to these assessments, assuming that if the compound is not found in the 
environment, or is found at low concentrations then there is no risk. Most prioritisation 
schemes include the assessment of pharmaceutical concentrations in surface water, but 
not other compartments (Besse and Garric 2008). The EU technical guidance advises that 
PECs are calculated by modelling discharge and fate processes or that measured 
environmental concentrations (MECs) are used where available (Ehrlich et al. 2011). 
Guidelines are also given on assessing concentrations in other compartments such as 
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sediment. The use of MECs is often difficult for pharmaceuticals as there aren’t many 
monitoring schemes in place and fate of pharmaceuticals in the aquatic environment is not 
fully understood (Fabbri and Franzellitti 2016). PECs used in the prioritisation literature are 
often simplified versions of those found in ERAs. Most PECs are calculated from usage 
data on the volume of drugs produced per year or number of prescriptions filled and then 
are refined based on metabolism, removal in WWTPs and dilution (Ashton et al. 2004; 
Besse et al. 2008). Dilution is a key process affecting the fate of pharmaceuticals in the 
aquatic environment, and some studies have included localised data into these equations 
(Ferrari et al. 2004; Burns et al. 2017). Other schemes have estimated that 5 to 15% of 
oral pharmaceuticals and 30% of topical pharmaceuticals will never be consumed (and 
therefore not enter the environment) and have been included into PEC calculations 
(Kostich and Lazorchak 2008). Prescription data and usage of over the counter (OTC) 
medicines are not available in many regions, making it difficult to predict environmental 
concentrations. The European medicines agency (EMEA) guidelines advise use of a PEC 
calculation which does not require prescription data, as it involves predicting 
environmental concentrations from the maximum dosage per person and market 
penetration (EMEA 2006).  
Few prioritisation schemes include the assessment of pharmaceuticals in sediment. This 
is reflected in the literature, with most environmental monitoring having been carried out 
in effluent and surface waters (Fabbri and Franzellitti 2016). The KD of pharmaceuticals is 
often used to determine the likelihood of their presence in sediment, however, this value 
is heavily influenced by temperature and pH, which will differ between regions (Al-Khazrajy 
and Boxall 2016). The EMEA requires a risk assessment on the fate of pharmaceuticals 
in sediment, however, experimental data does not currently exist for many compounds 
(EMEA, 2006).   
1.1.2 Predicting toxicity 
Many prioritisation schemes assess the risk of pharmaceuticals using traditional ERAs. 
Risk quotients using a ratio of PEC:PNEC are calculated and if the result is greater than 
1, then it is deemed to pose a threat (Hoyett et al. 2016). PNECs are usually calculated by 
selecting the most sensitive LC50 and applying an assessment factor (Thomas Backhaus 
and Faust 2012). Such experimental data is often unavailable in the literature and is time 
consuming to generate for  prioritisation schemes. Many authors have used quantitative 
structure-activity relationships (QSARs), which are allowed under REACH and US 
environmental protection agency (EPA) guidelines to model the potential toxicity of these 
compounds (Sanderson et al. 2004; Ortiz de García et al. 2013). These models predict the 
physico-chemical properties of an unknown chemical  by comparing them to other known 
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chemicals based on their structure (Guillén et al. 2012). There are many different software 
packages which can be used in these assessments, of which, ECOSAR is the most widely 
used in the prioritisation literature (Guillén et al. 2012). The use of QSARs to model toxicity, 
has been widely debated, and has been found to be a poor predictor of toxicity for many 
compounds (de Roode et al. 2006). Ashton et al. (2004) estimated PNECs using a different 
method, taking the maximum therapeutic dose in humans and applying an assessment 
factor of 1000. The rationale of which is that there are many conserved drug targets 
between humans and non-target organisms, and those which are more biologically active 
in humans, may be so in other organisms (Gunnarsson et al. 2008). 
Persistence, bioaccumulation and toxicity (PBT) assessments are alternatives to risk 
quotients for ERAs under REACH (Ehrlich et al. 2011). In prioritisation schemes, PBT 
assessments are often used alongside PECs. Most commonly, this is assessed through 
the half-life of compounds in the environment (persistence), bioconcentration factor (BCF; 
bioaccumulation) and no-observed effect concentrations (NOECs) or PNECs (toxicity), 
however where data is lacking it allows flexibility, and different approaches have been 
used within the prioritisation literature (Ortiz de García et al. 2013). For example, Sangion 
and Gramatica (2016) used modelled PBT data using QSARs, whilst Daouk et al. (2015) 
used removal in wastewater to determine the persistence of compounds in effluent. 
Due to difficulty in obtaining experimental data on PBT of compounds and the limitations 
of QSARs in modelling toxicity, several studies have suggested modelling the effects of 
pharmaceuticals on aquatic species by utilising information on pathways of these 
pharmaceuticals in mammals. Due to difficulty in obtaining experimental data on PBT of 
compounds and the limitations of QSARs in modelling toxicity, several studies have 
suggested modelling the effects of pharmaceuticals on aquatic species by utilising 
information on pathways of these pharmaceuticals in mammals. The under-pinning 
assumption in these models, is that drug-targets in mammals are conserved across other 
species and function in the same way, however, novel functions may arise as the result of 
evolution of such targets and it may not always be possible to translate the effects seen in 
vertebrates to non-target organisms (Thornton 2000; Ankley et al. 2010). There is 
conflicting evidence as to the conserved function of these targets across species, and the 
ability to extrapolate this information has been debated (Adler et al. 2008). Gunnarsson et 
al. (2008) looked at 1318 drug targets across 16 species and determined that 86% were 
conserved in zebrafish, 61% in daphnia and 35% in green algae, suggesting that the 
pathways of pharmaceuticals could be predicted in a variety of species. They also found 
that whilst enzymes are well conserved across species, the function of receptors are not. 
Whilst many of these receptors are present in other species, there is often a poor 
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mechanistic understanding, and when differences in their function arise, it can be difficult 
to translate effects to other organisms (Rand-Weaver et al. 2013). For example, an 
estrogen receptor (ER) ortholog has been described in some molluscs, but is not activated 
by estrogen (Bannister et al. 2000; Thornton et al. 2003). Furthermore, steroid hormones 
have been characterised in molluscs, however, there function is poorly understood, and 
there is not a consensus in the scientific literature as to their role in reproduction (Scott et 
al. 2013). Despite this, ethinylestradiol has caused reproductive changes in molluscs, such 
as increased vitellogenin and increased egg laying (Jobling et al. 2004; Ciocan et al. 2010; 
Benstead et al. 2011). This suggests that ethinylestradiol could mediate its effect through 
a non-ortholog receptor or through conserved pathways that have yet to be characterised. 
Regardless, this highlights the limitations of methods which are underpinned by assuming 
the conservation of drug-targets. 
The fish plasma model (FPM), which was originally developed by Huggett et al. (2003), is 
one method which utilises information on the activity of pharmaceuticals in mammals. It 
estimates the plasma concentration in fish based upon the human therapeutic plasma 
concentration of a pharmaceutical. This is compared to environmental concentrations and 
is often used as an alternative to RQs in prioritisation schemes (Fick et al. 2010, Schrieber 
et al. 2011, Roos et al. 2012). There are two main assumptions with this model: that drug 
targets are conserved across human and fish species, and that the therapeutic 
concentration at which an effect is exerted is the same (Schreiber et al. 2011). Brown et 
al. (2014) determined the conservation of 459 drug targets across 14 fish species and 
found that between 65 and 86% were conserved, which suggests the difficulty in 
translating the effects of pharmaceuticals between fish species.  
Many authors have also suggested the use of adverse outcome pathways (AOPs) for 
prioritising pharmaceuticals (Ankley et al. 2010, Caldwell et al. 2014). AOPs look at the 
effect of a chemical at a molecular, cellular, individual and population level, linking an effect 
with a molecular initiating event (Figure 1.2). For example, a molecular initiating event may 
be an estrogen receptor (ER) antagonist, which will lead to a decline in vitellogenin 
synthesis and concentrations which ultimately leads to decreased spawning and fecundity 
in females, and ultimately a declining population (Ankley et al. 2010, Figure 1.2). This 
allows for better cross-species prediction, which is particularly useful for pharmaceutical 
assessments as pathways of pharmaceuticals in humans are relatively well understood 
(Caldwell et al. 2014, LaLone et al. 2014). However, there is often complexity in linking 
molecular initiating events with a population effect, which is further complicated by 
uncertainty surrounding the conservation of drug targets across species. A number of 
pharmaceuticals, such as tamoxifen and ethinylestradiol are known ER antagonists and 
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have the potential to have an effect on fish populations. However, even with a well-defined 
AOP, experimental exposures often lack information on plasma concentrations, which can 
make it difficult to support models such as FPM (Rand-Weaver et al. 2013). As evidenced 
with the example of estrogen receptors in molluscs, such pathways may not be as well 
defined or understood in other species.  
 
 
Figure 1.2 Process of adverse outcome pathways, which link a molecular initiating event to effect 
at a population level. Estrogen receptor antagonism in female fish as an example of how an AOP 
can be used to link a molecular initiating event to a population effect.  
 
1.2 Occurrence of pharmaceuticals in estuaries 
1.2.1 Surface Water 
Reviews have previously summarised the occurrence of pharmaceuticals in fresh (Hughes 
et al. 2013) and marine waters (Fabbri and Franzellitti 2016); 155 published studies have 
been conducted in 41 countries and 46 published studies have been carried out in 22 
countries, respectively. In contrast, 29 studies across 9 countries (China, USA, Portugal, 
Australia, UK, Germany, Belgium, France and Spain) have been carried out in the 
estuarine environment, with sulfamethoxazole being the most monitored compound (Table 
1.1). It has only been within recent years, that the occurrence of pharmaceuticals in 
estuaries has gained more attention, as only 5 of these studies were conducted prior to 
2011 (Thomas and Hilton 2004, Wiegel et al. 2004, Benotti and Brownawell 2007, Noppe 
et al. 2007, Tamtam et al. 2008). In total 126 of 181 target pharmaceuticals have been 
detected in estuarine surface waters, with median concentrations generally less than 100 
ng l-1 (Appendix 1.1). Only five compounds (oxytetracycline, tetracycline, trimethoprim, 
salbutamol and phenytoin) have been found in the µg l-1 range (Benotti and Brownawell 
2009; Hui Chen et al. 2015; Mijangos et al. 2018). Of these, the highest concentration was 
the antibiotic oxytetracycline, which was detected in China (Table 1.1). Antibiotics were 
the most studied compound type, comprising of approximately 30% of those monitored in  
estuaries (Table 1.2), most of which were carried out in China. China is the largest 




























concentrations have been seen here  (Bu et al. 2013). Approximately 200,000 tons of 
antibiotics are produced annually in China, compared to approximately 9,000 tons in USA 
(Daghrir and Drogui 2013). Many of these antibiotics are also used in veterinary medicine 
and as growth promoters in agriculture, which can account for their high occurrence and 
detection frequencies (Guo et al. 2019). Antidepressants, antihypertensives, nonsteroidal 
anti-inflammatories (NSAIDs) and pain killers made of a further 50% of the compounds 
studied, with the remaining 20% made up of 19 different classes (Table 1.2). Although the 
literature has covered a wide range of compounds, there is often little overlap between 
studies, with some pharmaceuticals having only been measured in a few areas (Appendix 
1.1). As a result, it is difficult to establish trends in their occurrence. 
The concentrations of pharmaceuticals varied between these estuaries, with the main 
sources differing between geographical areas. Most of the studies in the USA and Europe 
attributed the input of pharmaceuticals to mostly be the result of the discharge of domestic, 
industrial and hospital wastewater (Beretta et al. 2014). In China on the other hand, 
discharge of untreated sewage and presence of agriculture and fish farming were found 
to be a greater source of pharmaceuticals (Cui et al. 2019; Guo et al. 2019). The elevated 
concentrations of some pharmaceuticals were the result of proximity to these sources.  
In terms of spatial distribution, most pharmaceuticals have a negative correlation with 
salinity, declining in concentration from source to mouth of an estuary (Liang et al. 2013; 
Sun et al. 2014). These concentrations have been observed to vary as the result of flow 
rate, tides and currents, and as a result, dilution has been named as the biggest factor 
influencing the fate of these pharmaceuticals in estuaries (Cantwell et al. 2017). 
Additionally, concentrations are generally highest at low and ebb tide, when salinity is 
lowest (Lara-Martín et al. 2014), however, Munro et al. (2019) observed the opposite in 
the Thames Estuary, as high tide coincided with untreated effluent discharge from 
combined sewer overflows (CSOs), causing transport of the compounds further upstream 
the estuary. The variations in concentrations of pharmaceuticals between estuaries is also 
likely the result of flushing time, as those with a higher flushing rate are less likely to retain 
pharmaceuticals (Cantwell et al. 2017).    
Concentrations of pharmaceuticals were also found to vary temporally as the result of 
changes in environmental conditions and fluctuations in input. In wastewater effluent 
dominated estuaries, temporal fluctuations may have been the result of seasonal 
differences in population or consumption patterns (Mijangos et al. 2018). Golovko et al. 
(2014a, 2014b) looked at seasonal variations in pharmaceutical concentrations in 
WWTPs. Antibiotics were found to be seasonal with concentrations highest in winter, likely 
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due to the increase in colds and infections (Golovko et al. 2014b). Antidepressants and 
lipid lowering agents were also highest during this time (Golovko et al. 2014a). However, 
due to the usage of these drugs to treat chronic conditions, the seasonal differences in 
their occurrence are more likely the result of low temperatures which leads to lower 
degradation and reduced input  (Gonzalez-Rey et al. 2015). In general, overall 
concentrations were higher in estuaries during winter as the result of reduced degradation 
due to low temperatures and low irradiance (Hedgespeth et al. 2012). This pattern did not 
apply to all regions, and some areas exhibited higher concentration in the summer as the 










Few studies have determined the occurrence of pharmaceuticals in estuarine sediments 
in comparison to surface water. A total of 11 studies have been carried out in four countries 
(Brazil, USA, China, New Zealand), comprising of 79 pharmaceutical compounds (Table 
2; Appendix 1.2). Similar to studies conducted on surface water, antibiotics were the most 
studied compounds class (Table 1.2). Concentration of pharmaceuticals were often lower 
in sediment than those found in surface, with only ofloxacin, chlortetracycline and 
oxytetracycline, detected at concentrations above 100 ng l-1, and only ten pharmaceuticals 
were detected above 25 ng l -1 (Table 1.3). Of the antibiotics measured, sulfanomides, 
such as sulfamethoxazole showed low sorption capacity, and were mostly absent from 
sediment, which could account for their high presence in surface water (Shi et al. 2014).  
Few studies have looked at the spatial and temporal patterns of pharmaceuticals in 
sediments. Many of the compounds measured, exhibited trends similar to those observed 
in surface water, with the presence of pharmaceuticals related to consumption patterns 
and highest concentrations occurring in regions with higher populations and at sites in 
closer proximity to sources (Beretta et al. 2014).  The presence of pharmaceuticals in 
sediment is dependent on their KD, however these values are highly dependent on pH and 
temperature, suggesting that removal of pharmaceuticals to sediment could differ 
seasonally (Al-Khazrajy and Boxall 2016). The sorption capacity of estrone was found to 
increase with increasing salinity in the Scheldt Estuary, and as a result, concentrations in 
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the dissolved phase were lower further downstream the estuary (Noppe et al. 2007). The 
sorption capacity of pharmaceuticals has also been observed to differ with sediment type, 
with a positive correlation between sorption and the percentage of clay in the sediment 








1.3 Biological Effects 
The ecotoxicological effects of pharmaceuticals have been extensively studied in 
freshwater organisms (Crane et al. 2006; Fent et al. 2006; Fabbri 2015). Studies in marine 
organisms are sparser, and have been summarised in Table 1.4. Despite this, there are 
similarities in biological systems of organisms found in both of these systems. However, 
differences may occur in physiology between marine and fresh water organisms, for 
example, to be able to cope with saline conditions, and organisms present in estuaries are 
often living at the edge of their tolerance zones, which can make them more sensitive to 
contaminants (Scaps 2002). 
The effects of 38 different compounds have been assessed on marine species, with 
carbamazepine and fluoxetine dominating these studies, and bivalves were the most 
commonly studied taxa in ecotoxicity studies (Table 1.4). Bivalves are commonly used in 
ecotoxicology experiments as they are long-living, sessile, and filter high volumes of water, 
and as a result can be particularly susceptible to contaminants (Gagné et al. 2010). They 
are also abundantly available, of commercial importance and easy to maintain in a 
laboratory setting. Despite the numerous studies which have spanned a broad range of 
taxa and pharmaceuticals, there are still many questions about the effects and pathways 
of these chemicals. Many experiments use concentrations much higher than 
environmental ones and simple endpoints such as mortality and growth. Although these 
are important to know, it is essential to have a deeper understanding of pathways of 
pharmaceuticals in order to determine toxicity that has the potential to effect populations, 
and therefore is of more interest to regulators (Ankley et al. 2010). Almost all types of 
pharmaceuticals have been found to cause oxidative stress where reactive oxygen 
species (ROS) are produced as the result of pharmaceutical metabolism (Diniz et al. 
2015). ROS can cause oxidation of proteins and lipids, alter gene expression, and damage 
cells (Diniz et al. 2015). Many organisms have developed mechanisms to minimise the 
damage by producing anti-oxidants such as catalase (CAT), superoxide dismutase (SOD), 
and Glutathione. This demonstrates that these pharmaceuticals have the potential to 

































The greatest threat of antibiotics to aquatic ecosystems is the potential to cause antibiotic 
resistant bacteria and genes, which can cause the spread of antibiotic resistant infections, 
having implications on human and veterinary health (Cizmas et al. 2015). Antibiotics are 
toxic to bacteria, which can also have implications on the immunology of aquatic species 
(Guardiola et al. 2012). Microbes play an important role in marine ecosystems, and the 
presence of antibiotics could disrupt these. Antibiotics have been observed to disrupt 
microbial processes such as denitrification, nitrogen fixation and organic breakdown, 
which could have implications on water quality and aquatic health (Costanzo et al. 2005).  
The literature on antibiotic toxicity has focused on antibiotic resistance, however, there is 
an indication that they may exert effects on aquatic organisms in different ways (Daghrir 
and Drogui 2013). Many bacteria have symbiotic relationships with algae, supplying them 
with nutrients in return for a protective environment, and inhibition of these bacteria to form 
biofilms as the result of antibiotic exposure could result in limited algal growth and nutrient 
deficiency (Guo et al. 2015). Antibiotics also cause oxidative stress in a range of species 
(Table 1.4). Trimethoprim and erythromycin were found to cause DNA damage in the 
mussels, Mytilus edulis and Dreissena polymorpha (Lacaze et al. 2015). This is in part, 
attributed to oxidative stress, but also to also to the ability of these drugs to interfere with 
DNA synthesis and replication, respectively. Oxytetracycline and amoxicillin inhibited CAT 
and induced GST in zebrafish at high concentrations (Oliveira et al. 2013). Oxytetracycline 
also caused an increase in lactate dehydrogenase (LDH) a key enzyme in energy 
production, and an indicator of stress (Oliveira et al. 2013).   
1.3.2 Anticonvulsants 
Carbamazepine is one of the most prolific pharmaceuticals in the literature. It is a 
psychiatric drug used to treat epilepsy, bipolar disorder, chronic nerve conditions and 
addiction by blocking sodium channels and reducing the firing of neurones (Jarvis et al. 
2014).  Due to its high consumption, low removal and long half-life, high concentrations 
have been found in estuaries globally (Almeida et al. 2015). It has also been found to 
bioaccumulate at high concentrations in bivalves, algae and crustaceans, but not cnidarian 
(Vernouillet et al. 2010; Almeida et al. 2015). Carbamazepine has the potential to alter 
behaviour leading to changes in reproduction, predator avoidance and locomotion (De 
Lange et al. 2006; Brandão et al. 2013; Chen et al. 2014). It reduces fecundity, breeding 
success, alters courtship behaviour and sperm morphology in fish (Overturf et al. 2015). 
In bivalves, carbamazepine caused reduction in siphoning behaviour and valve movement, 
which plays an important role in nutrition, defence and reproduction (Chen et al. 2014). 
Reduction in siphoning is a response to chemical stress which can lead to ammonia 
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accumulation in the tissue, reduction in oxygen and reduced feeding, and chronic 
exposure to carbamazepine could eventually lead to death. Low concentrations of 
carbamazepine also cause oxidative stress in fish and bivalves, and caused reduced LMS 
in the haemocytes of the crab, Carcinus maenas (Aguirre-Martínez et al. 2013; Brandão 
et al. 2013; Almeida et al. 2015). Carbamazepine caused changes of the enzymes LDH, 
glutamate pyruvate transamine, and glutamate oxaloacetate transamine in the gill, liver 
and muscle leading to tissue hypoxia and damage (Malarvizhi et al. 2012). Another anti-
epileptic phenytoin caused oxidative stress in the pumpkinseed sunfish, Lepomis 
gibbosus, but did not alter behaviour (Brandão et al. 2013).  Despite high concentrations 
of phenytoin found in estuaries (1.4 µg l-1), effects on aquatic organisms is relatively 
unknown (Mijangos et al. 2018). 
1.3.3 Antidepressants 
Antidepressants, which include tricyclics, monoamine oxidise inhibitors and selective 
serotonin reuptake inhibitors (SSRIs), account for approximately 4% of pharmaceuticals 
detected in the environment (Fong and Ford 2014). The main concern surrounding 
antidepressants is their role as endocrine disruptors due to the alteration of serotonin and 
dopamine which stimulate hormone production (Fong and Ford 2014).  As a result, they 
are often used in aquaculture to speed up growth and reproduction (Fong and Ford 2014). 
The chemical structure of antidepressants has several potentially mutagenic effects as 
DNA damage can be caused directly by the aromatic ring and/or flyorobenzene group 
(Lacaze et al. 2015). Serotonin and dopamine have similar metabolic pathways in aquatic 
invertebrates and fish to humans (Gagné et al. 2010).  As a result, the side effects seen in 
humans such as changes in behaviour and aggression have been observed in such biota 
(Weinberger and Klaper 2014). 
SSRIs are the most widely prescribed antidepressant (Fong and Ford 2014; Lacaze et al. 
2015). They exert a therapeutic effect by inhibiting the reuptake of serotonin and therefore 
increasing concentrations in the body (Overturf et al. 2015). Fluoxetine has been studied 
most prolifically, however citalopram and venlafaxine have now surpassed fluoxetine 
prescriptions in the USA and Canada (Fong and Ford 2014; Lacaze et al. 2015), and 
citalopram is prescribed more than fluoxetine in the UK (National Health Service 2017). 
Serotonin plays an important role in reproduction in both vertebrates and invertebrates, 
and SSRIs have been found to negatively impact reproductive processes in many species 
(Dorelle et al. 2017). Exposure of fluoxetine (20 - 200 ng l-1) to D. polymorpha caused 
decreased oocytes  and spermatozoan in male and female gonads, as well as increased 
levels of estradiol (Lazzara et al. 2012). It also caused increased vitellogenin levels in the 
Mediterranean mussel, Mytilus galloprovincialis (Gonzalez-Rey and Bebianno 2013). In 
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fish, fluoxetine has caused decreased sperm production and caused aggressive behaviour 
(Weinberger and Klaper 2014). Fathead minnows, Pimephales promelas,  were exposed 
to 1 - 100µg l-1 fluoxetine for four weeks, which caused changes in reproductive behaviour 
(Weinberger and Klaper 2014). In this species males are responsible for nest preparation 
and egg care; some males did not engage in reproductive behaviour, whilst others were 
aggressive and attacked females. Those which did mate successfully exhibited aggressive 
nest cleaning behaviour resulting in broken eggs. However, similar levels of the SSRI 
citalopram in guppies, Poecilia reticulata, did not induce changes in sexual behaviour 
(Holmberg et al. 2011).  
SSRIs also cause other effects in aquatic organisms which are unrelated to the endocrine 
system. Serotonin controls ciliary pedal activity, pedal muscle contraction and swimming 
movement in gastropods (Lewis et al. 2011). Serotonin will increase these movements, 
which could result in altered locomotion which is vital to feeding, reproduction and predator 
avoidance (Estévez-Calvar et al. 2017). Exposure to SSRIs also resulted in changes in 
behaviour; fluoxetine also reduced learning and memory in cuttlefish, Sepia officinalis, at 
concentrations as low as 1ng l-1 (Di Poi et al. 2013).  Fluoxetine, sertraline and venlafaxine 
have caused reduced predator avoidance in P. promelas (Painter et al. 2009). A variety of 
antidepressants: fluoxetine, paroxetine, amitriptyline and clomipramine cause 
immunotoxicity at environmentally relevant concentrations (Minguez et al. 2014).  
Paroxetine and fluoxetine also caused DNA strand breakage, cytotoxicity and 
immunotoxicity in M. edulis haemocytes (Lacaze et al. 2015).  
The toxicity of other types of antidepressants aren’t as prevalent in the literature. Tricyclics 
(such as amitriptyline) block serotonin and norepinephrine reuptake transporters reducing 
the hyperactivity of the hypothalamo-pituitary-adrenocortical axis present in depression 
(Yang et al. 2014). Neurotoxic side effects of tricyclics in aquatic life have been reported. 
Amitriptyline caused a reduction in nitric oxide (NO) production which compromised the 
immune system (Yang et al. 2014). The anti-inflammatory activity of amitriptyline is 
suggested to be associated with the inhibition of pro-inflammatory cytokines from immune 
cells and a decrease in NO (Yang et al. 2014).  
1.3.4 Antihypertensives 
There are many different anti-hypertensives including, angiotensin-converting-enzyme 
inhibitors, calcium channel blockers, angiotensin II receptor antagonists (sartans) and β-
blockers. The most widely studied of these are β-blockers, which are the most consumed, 
and found in the highest concentrations in the aquatic environment (Godoy et al. 2015). A 
total of 34 anti-hypertensives (20 in estuaries; Appendix 1.1) have been detected globally 
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in aquatic ecosystems, however, ecotoxicology studies have only been conducted on 16 
(4 in marine species) of these (Godoy et al. 2015). β -blockers function by binding to β-
adrenergic receptors to block the binding of norepinephrine and epinephrine, resulting in 
decreased blood pressure (Maszkowska et al. 2014). β-blockers can either be selective, 
binding to a particular β-adrenergic receptor (e.g. metoprolol and atenolol) or non-selective 
(e.g. propranolol; Massarsky et al. 2011). β-adrenergic receptors are present in mussels 
and vertebrates, but not in crustaceans or echinoderms, however deleterious effects have 
been observed in all of these groups (Franzellitti et al. 2013).   
There is debate in the literature as to the toxicity of β-blockers, with a few reaching the 
consensus that environmental concentrations of β-blockers do not pose a significant risk 
to aquatic life (Winter et al. 2008, Godoy et al. 2015). Exposure to propranolol at 
environmentally relevant concentrations (0.3 – 500 ng l-1) caused oxidative stress and 
disrupted cell signalling in M. galloprovincialis (Solé et al. 2010, Franzellitti et al. 2013) and 
ragworm, Hediste diversicolor (Maranho et al. 2014). Sun et al. (2015) looked at the 
regulation of genes involved in antioxidant and detoxification responses in zebrafish to 
propranolol and metoprolol. Responses were not significant below 3mg l-1, which is far 
above concentrations found in the freshwater (Hughes et al. 2013), estuaries (Appendix 
1.1) or oceans (Gaw et al. 2014). β-blockers appear to have the potential to disrupt 
reproductive function, and affect early life stages, which could have implications at a 
population level. It is thought that β-adrenergic receptors may play a role in larval 
metamorphosis in bivalves, and as a result β-blockers could have an effect on this (Solé 
et al. 2010). Medaka exposed to propranolol, metoprolol and nadolol produced less viable 
embryos after 4 weeks, however no significant difference from the control was seen at 2 
weeks (Huggett et al. 2002). In the same study, these drugs caused reproductive effects 
to Daphnia magna, Hyalella azteca and Ceriodaphnia dubia, however, due to the high 
concentrations at which these effects were observed, it is unlikely concentrations currently 
observed in the environment would have significant impacts on populations. 
Norepinephrine also plays a role in stimulating or inhibiting hormones and β-blockers have 
been found to decrease testosterone and luteinising hormone in fish indicating their 
potential as endocrine disruptors (Massarsky et al. 2011; Godoy et al. 2015).  
Interestingly, propranolol is one of the few pharmaceuticals to be involved in mesocosm 
experiments studying inter-species dynamics in the presence of this drug. Oskarsson et 
al. (2014) exposed a model Baltic Sea community composed of macroalgae, mussels and 
amphipods to 100 and 1000µg l-1 propranolol. Mussels were the most sensitive, which led 
to a feeding shift from the algae to the mussel by the amphipod. The amphipods did not 
suffer negative effects and it was thought that the higher nutritious food may have 
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counteracted this. This shift was beneficial in turn to algae as they were no longer 
consumed.  
Ecotoxicology studies on other types of anti-hypertensives are not as common. Calcium 
channel blockers block L-type calcium channels preventing the influx of calcium ions into 
the vascular system, reducing myocardial contractions and vascular relaxation, resulting 
in reduced blood pressure (Palande et al. 2015). There is evidence that the mode of action 
(MoA) of calcium channel blockers in fish is similar to that in humans; verapamil caused a 
reduced heart rate in common carp (Cyprinus carpio) embryos and larvae (Steinbach et 
al. 2013). At high levels, calcium channel blockers can cause toxicity to other organs such 
as kidneys due to difficulty in metabolising this drug. These drugs also block neuronal 
calcium channels resulting in altered behaviour. Exposure of goldfish (Carassius auratus) 
to verapamil caused loss of balance, increased ocular movement, increased swimming 
rate and caused capsizing (Palande et al. 2015). It has been suggested that calcium 
channel blockers may also impact K+ and Na+ channels, which would negatively affect the 
osmoregulatory capacity of fish (Palande et al. 2015). Verapamil caused pericardial 
oedemas in carp embryos, which is often indicative of osmoregulatory disruption 
(Steinbach et al. 2013). However, this was only seen at concentrations much higher than 
those found in the environment.   
1.3.5 Lipid Lowering Agents 
There are two types of lipid lowering medications: fibrates and statins. Fibrates are the 
most targeted for analytical and ecotoxicological studies (Fent et al. 2006, Overturf et al. 
2012). Statins lower blood plasma lipids, whilst fibrates lower both lipids and triglycerides 
(Fent et al. 2006). Fibrates bind to peroxisome proliferator-activated receptors which cause 
them to stimulate fatty acid uptake and regulate the expression of several lipid regulatory 
proteins (Canesi et al. 2007b). In fish, steroid hormones are derived from cholesterol, and 
it’s reduction caused by fibrates can disrupt steroidogenesis and spermatogenesis 
(Velasco-Santamaría et al. 2011). Gemfibrozil causes reduced growth and in turn lower 
fecundity, altered reproductive behaviour and sperm morphology leading to reduced 
reproductive success in fish (Overturf et al. 2015). D. rerio exposed to Bezafibrate altered 
the expression of the testis gene, suggesting it also had an effect on reproduction 
(Velasco-Santamaria et al. 2011). Bezafibrate had no effect on lowering cholesterol levels 
in P. promelas, however it’s metabolite Clofibric acid increased the activity of fatty acetyl-
coenzyme-A which plays a role in the oxidation of fatty acids (Weston et al. 2009). Clofibric 
acid also reduced egg production. Fibrates appear to negatively impact the immune 
system of some organisms. Bezafibrate and gemfibrozil injected into M. galloprovincialis 
haemocytes caused lysosomal destabilisation, NO production and decreased phagocytic 
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activity (Canesi et al. 2007b). Fibrates also affected the haemocyte function of freshwater 
bivalve Elliptio compalnata (Gagné et al. 2006). 
Statins block mevalonic acid pathways thereby inhibiting the synthesis of cholesterol 
(Ellesat et al. 2010). Atorvastatin and simvastatin are prodrugs which are inactive, and are 
metabolised by the body into the active compound, as a result, it is their metabolites which 
pose the largest risk (Besse and Garric 2008). To date exposure experiments have 
included the parent compound, and it not known if they will be metabolised in the same 
way in non-target organisms. Despite this, exposure of some species to statins have 
resulted in deleterious effects. Atorvastatin caused upregulation of genes involved in 
membrane transport, oxidative stress, apoptosis and biotransformation at concentrations 
as low as 200ng l-1 in  O.mykiss (Ellesat et al. 2012). These effects were observed in the 
gill, but not the liver despite this being a target organ of statins in humans. This is likely 
due to cholesterol levels being highest in fish gills. In humans, statin toxicity includes 
inhibition of membrane transport, however, Ellesat et al. (2012) did not observe any 
change in Na+/K+ -ATPase. Statins also caused impairment to reproduction. Simvastatin 
negatively affected reproduction of Gammarus locusta by disrupting the hormone methyl 
farnesoate (MF) and causing reduced gonadal development at concentrations as low as 
320ng l-1 (Neuparth et al. 2014). MF is an important hormone in crustaceans and is 




There are many different types of analgesics, which can be broadly split into two 
categories: NSAIDs and painkillers (Overturf et al. 2015). These are among the most 
prolifically used pharmaceuticals as they are widely prescribed and readily available OTC 
(Fent et al. 2006). Ibuprofen and diclofenac, are the most commonly used and studied 
NSAIDs (Table 1.4). NSAIDs reduce pain and inflammation by inhibiting the production of 
prostaglandins at the site of an injury, which are produced through the oxidation of 
arachidonic acid by cyclooxygenases (COX), resulting in pain and inflammation (Gan 
2010). There are two isoforms of this enzyme: COX I and COX II, which are non-selectively 
inhibited by NSAIDs (Gravel et al. 2009). Prostaglandins are involved in other physiological 
processes, including thermoregulation, ovulation, sexual behaviour, homeostasis, ion 
transport and kidney filtration (Miller 2006). COX I is responsible for the baseline levels of 
prostaglandins involved in these processes, whilst COX II produces prostaglandins at the 
point of a stimulus such as an injury (Gan 2010).  Prostaglandin function is similar in fish 
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to other vertebrates, but they are also found in cnidarian, bivalves and crustaceans 
(Ruggeri and Thoroughgood 1985; Courant et al. 2017). As both of these isoforms are 
inhibited by NSAIDs, there is a potential that these physiological processes could be 
disrupted. NSAIDs have caused toxicity in the liver and kidneys in humans, and similar 
toxic effects have been seen in fish (Triebskorn et al. 2004). 
Diclofenac induced Acetylcholinesterase (AChE) activity in the gills of the M.  
galloprovincialis (Gonzalez-Rey and Bebianno 2014). AChE is released after cell 
membrane disruption, causing apoptosis and plays a role in the neuromuscular system by 
preventing continuous muscle contraction (Milan et al. 2013). This indicated the potential 
of NSAIDs to cause apoptosis. In humans, they have been studied as a candidate for 
cancer prevention as they have the potential to enhance cell proliferation and enhance 
apoptosis (Milan et al. 2013). This could be problematic in aquatic organisms and have 
the potential to cause neurotoxic effects. In some species, AChE activity has been linked 
to the disruption of estrogenic receptors, however, the endocrine disruption of NSAIDs 
needs to be further investigated (Gonzalez-Rey and Bebianno 2014). Experimental 
exposure to NSAIDs has led to altered reproduction. Ibuprofen caused increased ovary 
maturation in female marine shrimp (Litopenaeus spp.) and lowered sperm abnormalities 
in males (Alfaro-Montoya 2015). Whilst this could be beneficial in aquaculture, in the 
natural environment this could lead to poor fecundity and decreased reproductive success. 
Ibuprofen (<100µg l-1) altered reproductive timing in medaka, Oryzuas latipes (Flippin et 
al. 2007); exposure for six weeks increased fecundity but decreased the amount of 
spawning events. Osmoregulatory processes are important for physiology of marine and 
estuarine species, and there is indication that this could be interrupted by NSAIDs. 
Diclofenac disrupted osmoregulation in brown trout at 1g l-1 and at more environmentally 
realistic concentrations (10ng l-1) in C. maenas (Eades and Waring 2010). Ibuprofen and 
salicylic acid have also reduced osmoregulation capability in O. mykiss at concentrations 
(1 mg l-1) higher than those found in the environment (Gravel et al. 2009). 
1.3.6.2 Pain Killers 
Paracetamol also inhibits prostaglandin synthesis, but at a central nervous system level 
and it also blocks pain impulses, however, doesn’t have the same anti-inflammatory 
properties as NSAIDs (Ouellet and Percival 2001). The exact pathways of paracetamol 
are poorly understood. There is some evidence in vertebrates that there may be a third 
isoform of cyclooxygenase, COX III, which may be inhibited and account for differences in 
effects between paracetamol and NSAIDs (Chandrasekharan et al. 2002). However, it has 
been debated whether it is a target of paracetamol and it is not known if this isoform exists 
in aquatic species (Schwab et al. 2003; Graham et al. 2013). In humans, paracetamol is 
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metabolised in the liver, with high concentrations causing hepatotoxicity, and there is 
evidence that this may occur in fish as well (Graham et al. 2013; Guiloski et al. 2017). 
Paracetamol caused neurotoxicity in the freshwater shrimp, Neocaridina denticulata and 
planarian, Dugesia japonica (Wu and Li 2015). Paracetamol inhibited two enzymes, which 
are essential for normal neurological function: Cholinesterase and monoamine oxidase 
(MAO). It has also been found to indirectly inhibit Na+/K+ ATPase in the brain as the result 
of oxidative stress (Wu and Li 2015). Paracetamol also caused oxidative stressed in the 
European eel, Anguilla anguilla) which led to the inhibition of AChE (Nunes et al. 2015). A 
transcriptome analysis of gilthead bream (Sparus aurata) brains has shown that 
paracetamol may alter processes involved in gene regulation and DNA repair and may 
disrupt development of embryos (Hampel et al. 2017). There is also some evidence that 
paracetamol could impact reproductive processes in organisms; it reduced testosterone 
levels and inhibited spermatogenesis in male fish (Rhamdia quelen), at environmentally 
relevant concentration (>250 ng l-1), however, there is currently not any further evidence 
in these effects in other organisms (Guiloski et al. 2017).  
Opiates are another type of painkiller which have the potential to impact non-target 
organisms. Low levels of codeine, hydrocodone and tramadol have been found in 
estuaries (Benotti and Brownawell 2007; Klosterhaus et al. 2013; Birch et al. 2015; Sun et 
al. 2016,; Munro et al. 2019). Despite the high prescription rates and occurrence of opiates 
in aquatic systems, marine ecotoxicology studies are largely absent (Hughes et al. 2013; 
Rosi-Marshall et al. 2015). Opiates bind to opiate receptors causing the release of 
dopamine and reduction of serotonin which lessen pain (Gagné et al. 2010). It is likely that 
they would have an effect on reproduction in bivalves as dopamine plays a role oogenesis 
and serotonin in the maturation of gametes and spawning (Gagné et al. 2010). Morphine 
compromised the immune system of the freshwater mussel, Mytilus Elliptio, through the 
production of NO which downregulates immunocyte activity and inhibits phagocytosis 
(Gagné et al. 2006). 
1.3.7 Other compound classes 
The amount of pharmaceuticals with the potential to enter the marine environment is too 
numerous to be completely covered in this review. There are some pharmaceuticals which 
exist in current literature, and are relevant to this thesis, which are not included in the 
above sections.  Cimetidine and ranitidine are H2 receptor antagonists which inhibit the 
action of histamine at this site (Bergheim et al. 2012). As a result, these drugs inhibit acid 
production and are used to treat gastric ulcers and acid reflux (Bergheim et al. 2012). In 
humans, H2 receptors are also present in the brain, and have side effects affecting the 
nervous and endocrine systems (Fent et al. 2006). Some fish, such as C. carpio and cod 
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(Gadus spp.) have H2 receptors, whilst others such as D. rerio have H3 receptors (Fent 
et al. 2006). Toxicity data of cimetidine and ranitidine on freshwater or marine organisms 
mostly focuses on acute mortality, which is low (Isidori et al. 2009). Despite this, these 
pharmaceuticals have been highlighted as a potential of concern due to their high 
excretion rates, low removal from WWTPs and chronic presence in freshwater systems 
(Bergheim et al. 2012). Experimental exposures of ranitidine and cimetidine have caused 
a decrease in testosterone in males and intersex embryos in D. rerio exposed to low levels 
(298.25 ng l-1) of cimetidine (Lee et al. 2015). In humans cimetidine caused increases of 
luteinising hormone and follicle stimulating, but this was not seen in female D. rerio at such 
low levels (Lee et al. 2015). Ranitidine has effects on the endocrine systems of non-aquatic 
species; it lowered testosterone levels in rats and has the side effect of sexual dysfunction 
in humans (Lee et al. 2015). Histamines supress cellular immune response, and exposure 
of fish to cimetidine improved immune system function (Hosseinifard et al. 2013). As a 
result, it has been proposed that cimetidine should be used in aquaculture to prevent 
disease (Hosseinifard et al. 2013).    
Metformin was the eleventh most prescribed drug in 2014 and in the top 20 in the 
preceding five years (National Health Service, 2017). Few studies have monitored this 
compound in the aquatic environment, however, it has been found at concentrations above 
500 ng l-1 in freshwater (Burns et al. 2018) and estuaries (Meador et al. 2016).  Metformin 
is an antidiabetic drug also used in the treatment polycystic ovarian syndrome (PCOS) 
and cancer. Metformin primarily reduces glucose output in the liver, and secondary to this, 
stimulate glucose uptake in peripheral tissues (Joshi 2005). It’s MoA in patients with PCOS 
is poorly understood, but thought to be effective as insulin resistance is commonly 
experienced alongside PCOS (Sivalingam et al. 2014).  It has the potential as an endocrine 
disruptor, and caused increased levels of  vitellogenin  in male P. promelas, but not 
testosterone (Niemuth and Klaper 2015). It is thought that this is not due to the ability of 
the drug to bind hormone receptors, but the indirect disruption of steroidogenesis caused 
by the alteration of insulin signalling (Niemuth and Klaper 2015). Further evidence that 
metformin could increase vitellogenin has been seen in M. edulis, however the cause of 
this is unknown, and further research into its MoA is needed (Sumpter et al. 2016, 
Koagouw and Ciocan 2018). 
 
1.4 Aims and Objectives 
Pharmaceuticals are occurring in the environment, and many appear to be biologically 
active. This review highlights the gaps in the knowledge surrounding the spatio-temporal 
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distributions of pharmaceuticals in estuaries. Additionally, little is known about the MoA of 
these drugs to non-target organisms, and their effects at environmentally relevant 
concentrations. As a result, it is difficult to get an overall picture of the problem of 
pharmaceutical pollution. The key questions which guided this thesis were:  
1. Based on existing knowledge on the occurrence, fate and effects of 
pharmaceuticals in the aquatic environment, which compounds pose the greatest 
risk to the aquatic environment? 
2. At what concentrations are pharmaceuticals occurring in estuaries, and do these 
differ spatially and temporally? 
3. What are the effects of pharmaceuticals on non-target organisms?  
The primary aim of this thesis was to develop a deeper understanding of the occurrence 
and effects of pharmaceuticals in estuaries. The specific objectives were to: 
1. Explore the efficacy of prioritisation schemes used in the literature to predict the 
occurrence and toxicity of pharmaceuticals in the aquatic environment, through the 
comparison of these schemes using one dataset.   
2. Create a list of priority pharmaceuticals that pose a risk to the aquatic environment.  
3. Quantify the spatial and temporal occurrence of five pharmaceuticals in an estuary, 
and determine if they are representative of other geographical areas.   
4. Examine the biological effects of pharmaceutical exposures to H. diversicolor, 
through controlled experimental exposures and use of quantitative qPCR-based 
assays to determine expression of targeted genes.   
It is anticipated that this thesis will contribute to the sparse data on the presence of 
pharmaceuticals in estuaries and provide valuable insight into the patterns in their 
occurrence. It will also provide novel information on the effects of these contaminants to 
an understudied, yet ecologically important estuarine species.  
 
1.5 Thesis Outline 
A suite of methodologies were employed in order to address the aims and objectives 
detailed in section 1.4. The rest of this thesis contains the results of this research organised 
into three manuscripts, and final discussion chapter which considers the work as a whole. 
A summary of each chapter is described below:  
 Chapter 2: Method development for the analysis of pharmaceuticals in 




This chapter outlines the rationale behind selecting the pharmaceuticals used in 
monitoring (chapter 4) and ecotoxicological studies (chapter 5). It also details the 
methodological development in the preparation of environmental samples for 
analysis. 
 
 Chapter 3: Comparison of prioritisation schemes for human pharmaceuticals 
in the aquatic environment 
In this chapter, prioritisation schemes commonly used in the literature were carried 
out on the fifty most prescribed drugs in the UK, and their resulting rankings were 
compared in order to explore their efficacy. These schemes highlighted a number 
of priority compounds which warrant further study and may be of interest to 
regulators.  
 Chapter 4: Spatial and temporal occurrence of pharmaceuticals in UK 
estuaries  
 
In this chapter, five pharmaceuticals – ibuprofen, paracetamol, diclofenac, 
trimethoprim and citalopram were measured in the surface water of the Humber 
Estuary every other month over a twelve month period. In order to put the 
concentrations seen in the Humber Estuary into context, water samples from 
eleven further estuaries were analysed for the presence of these target 
compounds. 
 
 Chapter 5: Effects of metformin and diclofenac on the ragworm, Hediste 
diversicolor 
 
Two target genes ATP synthase (ATPS) and c-amp activated protein kinase 
(AMPK) were isolated from H. diversicolor, which had been experimentally 
exposed to metformin, diclofenac, or a control. Quantitative qPCR assays were 
optimised and carried out in order to determine differences in expression between 
these treatments.  
 
 Chapter 6: Discussion 
 
The results obtained from the preceding chapters were considered within the 
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Chapter 2: Method development for the analysis of pharmaceuticals 
in environmental samples 
 
2.1 Selection of Compounds 
Due to time and financial limitations it is not feasible to carry out monitoring of all 
pharmaceutical compounds. There are many prioritisation schemes in the existing 
literature which are used to determine the likelihood of a compound to enter the 
environment and cause potential harm to organisms. In order to determine which 
pharmaceuticals to focus on in the subsequent chapters, a prioritisation exercise was 
carried out. Compounds which are commonly prescribed in the UK or are present in the 
literature were included (National Health Service, 2014). Naturally occurring compounds, 
such as, caffeine and nicotine were not included, leaving 80 compounds (Appendix 2.1). 
This method was adapted from an assessment carried out by Daouk et al. (2015) where 
compounds were assigned a ranking of 1-5 based on their potential to enter the 
environment, persist, and be taken up by organisms and cause toxicity (Table 2.1).  
The potential to enter the environment was determined by calculating PECs. This is 
shown in Eq. 2.1, where A is the amount prescribed (kg year-1 calculated from National 
Health Service, 2014), E is the fraction of the compound excreted unchanged, V is the 
volume of waste water per capita per day (assumed to be 200 litres; EMEA 2006), P is 
the population of the UK in 2014 and D is the dilution of wastewater (assumed to be 10 
times; EMEA 2006). Excretion rates were obtained from peer reviewed literature or 
databases such as drugbank (http://www.drugbank.com) and compendium 
(http://www.compendium.ch). Excretion rates were often variable, so the highest value 
was used, and where data was not available, excretion was assumed to be 100%. A 
score of 1 to 5 was given to each of the compounds based on the calculated PEC (Table 
2.1).  
A ∗ E





Pharmaceuticals were then ranked 1-5 based on removal rates during wastewater 
treatment (Table 2.1). Removal rates were obtained from the literature and they were 
assumed to be 0, when no data was available or when removal rates were negative. 
These rates often varied depending on technology used so the lowest rate was chosen 
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for this exercise. Wastewater treatment plant (WWTP) removal rates were used for 
persistence criteria, as there was little available experimental data on the half-life of 
pharmaceuticals in the environment. WWTP was used instead, as compounds which 
have gone through this process, are more likely to be resistant to degradation processes 
(Kim et al. 2014). Daouk et al. (2015) used bioconcentration factor (BCF) to determine 
the bioavailability of a compound, however this data is often unavailable. Instead, the 
logKOW, which is often use in prioritisation schemes as a predictor of bioconcentration 
was used instead, and compounds were ranked based on this information (Table 2.1).  
In order to determine potential toxicity, compounds were ranked by a method adapted 
from Capleton et al. (2006) in order to determine how likely a compound is to exert a 
biological effect on aquatic organisms. Six categories of potential effects on different 
biological systems were chosen: reproductive health, neurotoxicity, endocrine disruption, 
immunotoxicity, antimicrobial and genotoxicity. Each compound was given a score 1 to 
5 (Table 2.1) to determine if the compound would have an effect on the selected systems. 
If it was unknown whether a compound exerted a particular effect, it was decided to 
distinguish between whether the effects were truly unknown (score 3) or whether it was 
suspected to have an effect (score 2). Suspected was defined as compounds which had 
had a mode of action (MoA) that was likely to occur in an aquatic species, or if another 
compound with a similar MoA had an effect on aquatic species.  
Finally, the rankings from the four categories were added together to create a final 
ranking. Those with the lowest score are more likely to occur in the environment and 
exert a biological effect, and therefore should be prioritised for study. This resulted in 
compounds with a ranking between 16 and 35. The top 20 ranked drugs are shown in 
Table 2.2, with the full scores presented in Appendix 2.1.   
 




Six compounds were selected for monitoring in the Humber Estuary: citalopram, 
diclofenac, paracetamol, ranitidine, metformin and trimethoprim. Compounds were 
chosen to incorporate a variety of classes and based on their overall score (Table 2.2) 
 
Table 2.2: Scores of priority compounds based on PECs, wastewater removal, logKOW and 
potential for toxicity. Selected target compounds for study are shaded in grey.  
 
2.2 Chemicals and Reagents 
Pharmaceutical standards were used to create working and stock solutions. Diclofenac 
sodium (≥98.5), paracetamol (≥99%), citalopram hydrobromide (≥98), ibuprofen (≥98%), 
metformin hydrochloride (≥98), ranitidine (>97%) and trimethoprim (≥98%) were supplied 
by Sigma-Aldrich Ltd. (Dorset, UK). A fresh Individual stock standard solution was 
prepared by weight in 100% methanol each day. Standards were prepared by 
appropriate dilution in 100% methanol immediately before each analytical run. Methanol, 
acetonitrile, hydrochloric acid, acetic acid, ammonium acetate and formic acid were 
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supplied by VWR chemicals (Leicestershire, UK). 0.1% Trifluoroacetic acid (TFA) in 
methanol was supplied by Fisher Scientific. (Loughborough, UK).  
2.3 Solid Phase Extraction 
There are several methods in the existing literature for the extraction of the target 
analytes from surface water samples, however, most of these are for determining 
occurrence in freshwater (Białk-Bielińska et al. 2016). A matrix effect is often seen in 
marine samples which can lead to poor analytical accuracy, requiring different methods 
than those used for freshwater samples (Vieira Madureira et al. 2009). As a result, the 
salinity gradient seen in estuaries can pose a challenge to the analysis of samples from 
this environment. In order to minimise cost and maximise efficiency, solid phase 
extraction (SPE) methods need to be suitable for as many of the target analytes as 
possible. Metformin provides an additional challenge, as it is a polar compound, and as 
a result requires a different analysis methods than the other compounds (Poole 2003).  
2.3.1 Cartridges 
The recovery of three SPE cartridges: Oasis HLB (6 cc, 150 mg; Waters Corporation, 
Milford, MA, USA), Oasis WXC (6 cc, 150 mg; Waters Corporation, Milford, MA, USA) 
and Strata-X (6 cc, 150mg; Phenomenex, Torrance, CA, USA) using five different 
methods was determined. Recovery was determined by dosing artificial seawater (20 
ppt, Tropic Marin Synthetic Sea Salt) with 1 µg l-1 of citalopram, diclofenac, metformin, 
paracetamol, ranitidine and trimethoprim. Prior to SPE, samples were filtered through a 
0.45 µm cellulose filter (Scientific Laboratory Supplies, Hessle, UK) under vacuum. The 
concentration for each compound was determined by comparing the peak area against 
a standard of the same concentration. Recovery experiments were carried out in 
triplicate with a blank sample (not containing pharmaceuticals). It was determined that 
Oasis HLB method two resulted in the best recovery for citalopram, diclofenac, 
trimethoprim, ranitidine and paracetamol, whereas Strata-X method two resulted in best 
recovery for metformin (Figure 2.1).  
2.3.1.1 Oasis HLB 
The first method was adapted from Petrovic et al. (2006), where HLB cartridges were 
used for the extraction of 27 pharmaceuticals including ranitidine, trimethoprim, and 
diclofenac. Cartridges were first conditioned with 5 mL 100% methanol followed 5 mL 
deionised water at a flow rate of 1 mL min-1. 500mL samples were then loaded onto the 
SPE cartridge at a flow rate of 10 mL min-1, during which care was taken to ensure the 
sorbent material did not dry out. Cartridges were then rinsed with 5 mL deionised water 
prior to being air dried under vacuum for 30 minutes. Elution of cartridges was then 
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performed with 5 mL 100% methanol twice at a flow rate of 1 mL min-1. The eluent was 
evaporated to dryness using a rotary evaporator (40ºC, speed 7) and reconstituted with 
1 mL 100% methanol. For the second method, conditioning and loading of samples was 
performed in the same way, but cartridges were eluted twice using 5 mL 0.1% 
trifluoroacetic acid (TFA) in methanol. The addition of TFA for elution improved recovery 
of all compounds except trimethoprim and metformin where it remained the same (Figure 
2.1) 
2.3.1.2 Oasis WCX 
Prior to SPE, samples were acidified to pH 4 using hydrochloric acid. 500 mL samples 
were loaded directly onto the cartridge at a flow rate of 10 mL min-1 and then rinsed with 
6 mL 5% ammonium hydroxide. Cartridges were left to dry under vacuum for 30 minutes, 
prior to elution with 6 mL 100% methanol followed by 6 mL 2% formic acid in methanol. 
The eluent was evaporated to dryness using a rotary evaporator (40ºC, speed 7) and 
reconstituted with 1 mL 100% methanol. This method resulted in moderate recovery (< 
80%) for diclofenac, paracetamol and trimethoprim, however, recovery for metformin and 
ranitidine was poor (< 10%; Figure 2.1) 
2.3.1.3 Strata-X 
SPE using strata-X cartridges were carried out using two different methods. First 
cartridges were conditioned with 5 mL 100% methanol, followed by 5 mL deionised 
water. 500 mL samples were loaded onto the cartridge at 5 mL min-1 and then were 
rinsed with 5 mL 50% methanol, prior to drying under vacuum for 30 minutes. The first 
method consisted of elution with 5 mL 2% formic acid in methanol, twice. The second 
method eluted using 5 mL 2% formic acid in methanol followed by 5 mL acetonitrile. The 
eluent was evaporated to dryness using a rotary evaporator (40ºC, speed 7) and 
reconstituted with 1 mL 100% methanol. The second method, yielded improved 




Figure 2.1 Mean recovery (±standard deviation) for target analytes: citalopram, diclofenac, 
metformin, paracetamol, ranitidine and trimethoprim using three SPE cartridges (n = 3).  
2.3.2 Salinity 
SPE recoveries can often differ between freshwater and marine samples, which can 
complicate analysing estuarine samples due to variable salinities (Vieira Madureira et al. 
2009). In order to determine if there was a difference in recovery between salinities, 
artificial seawater was made to two salinities (10 and 20 ppt) using deionised water. SPE 
was carried out by spiking 500 mL deionised water, 10 ppt and 20 ppt samples with 500 
ng of citalopram, diclofenac, paracetamol, ranitidine and trimethoprim. SPE was carried 
out using Oasis HLB cartridges as described in section 2.3.1.1, with 0.1% TFA in 
methanol as an elution solvent.  
There was little difference in the recovery of samples between 10 and 20 ppt for all 
compounds, except ranitidine where the mean recovery differed by 33% (Figure 2.2). 
Use of deionised water resulted in 12 – 48% difference in recovery from saline samples. 
The recovery of compounds in deionised water is likely to be different from freshwater, 
because freshwater will have a higher ionic strength which may increase sorption of 
compounds to the SPE column. Additionally, an increase in salinity will have a similar 
effect by increasing ionic strength, decreasing solubility, and as a result can improve 
recovery efficiency of hydrophobic compounds such as diclofenac (Zhang and Zhou 
2007). Conversely, an increase in pH as the result of salinity or other environmental 
differences at sites could affect the sorption of compounds and cause differences in 
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recovery. For example, the sorption of acidic compounds may decrease as they will not 
be ionised at a high pH. However, it was determined that the recovery seen with Oasis 
HLB cartridges would be sufficient for the analysis of estuarine samples, as most sites 
within the Humber had a salinity of 7-24 ppt, however variability in the recovery between 
the samples will be expected due to fluctuations in salinity and pH throughout the 
estuary.  
 
Figure 2.2 Mean recovery (±standard deviation) of target analytes: citalopram, diclofenac, 
metformin, paracetamol, ranitidine and trimethoprim in deionised water and artificial seawater (10 
and 20 ppt, n = 3s). 
2.3.3 Volume 
In order to determine the optimum volume of sample to be loaded onto the cartridge SPE 
of citalopram, ranitidine and trimethoprim in 250 mL, 500 mL, 800 mL and 1000 litres of 
artificial seawater (20 ppt) was determined using Oasis HLB cartridges as outlined in 
section 2.3.1.1. Samples were spiked with 500 ng l-1 citalopram, diclofenac, paracetamol, 
ranitidine and trimethoprim. 800 mL and 1000 mL samples containing diclofenac and 
paracetamol were not analysed. Samples for 250 mL samples were also partially 
analysed, however, an insufficient number of samples (n = 1) were analysed as the result 
of technical problems with the LC-MS/MS, but those which were showed lower recovery.   
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Studies frequently perform SPE on 1 litre samples collected from rivers (For example 
Camacho-Muñoz et al. 2009; Liu et al. 2017). However, a lower recovery was seen at 
800 and 1000 mL for citalopram, ranitidine and trimethoprim in comparison to 500 mL. 
The increased salt in the larger volumes clogged the cartridges and prevented complete 
filtration and sorption of the pharmaceuticals. However, at a lower volume (250 mL) 
recovery was lower due to lower concentrations of pharmaceuticals in these samples. 
As a result, 500 mL was chosen as the optimum volume for SPE.  
 
Figure 2.3 Mean recovery (±standard deviation) of target analytes citalopram, ranitidine and 
trimethoprim in 500 mL, 800 mL and 1000 mL artificial seawater (20 ppt) as well as diclofenac 
and paracetamol in 500 mL artificial seawater (20 ppt; n = 3). SPE of diclofenac and paracetamol 
in 800 mL or 1000 mL seawater were not analysed. 
Due to technical problems with the LC-MS/MS, it was not possible to determine recovery 
of different volumes or salinity for metformin. As the result of these ongoing difficulties, 
samples were sent for external analysis by colleagues at the Catalan Institute for Water 
Research, and due to financial limitations, it was only possible to analyse environmental 
samples for the presence of ibuprofen, paracetamol, diclofenac, trimethoprim and 
citalopram in the subsequent chapters.  
The recovery of these compounds in spiked water samples differed between this chapter 
and Chapter 4. Whilst the same SPE method was used, samples were reconstituted in 
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10:90 (methanol: water). The use of TFA in elution of the compounds, will have further 
acidified compounds such as diclofenac, and use of a higher aqueous solution will have 
resulted in lower solubility of this compound. Additionally, optimisation of SPE was 
performed on samples containing artificial seawater and environmental samples will 
contain more complex mixtures of organic matter, salinity and pH which can also account 
for differences in these salinities.  
2.4 Liquid Chromatography with tandem mass spectrometry (LC-MS/MS) 
Liquid chromatography (LC) was performed using Agilent 1100 series and the LC eluent 
was directly infused into the Z-spray electrospray source of a Bruker mass spectrometer. 
Tandem mass spectrometry (MS/MS) was initially performed for each compound 
alternating between positive ion (PI) and negative ion (NI) modes. MS/MS was then 
performed using multiple reaction monitoring (MRM) on target compounds identifying 
compounds based on run time, molecular weight of the compound and the molecular 
weight of one or two fragments (Table 2.3). Chromatograms for the target analytes are 
displayed in Figure 2.4. MS/MS method was optimised by trying different temperatures, 
backing pressures and flow rates. Once a method was optimised, spiked methanol 
standards using a standard solution in dilution series were analysed in order to determine 
method detection limits (MDL) and method quantification limits (MQL). These were 
calculated using Eq. 2.2, where the standard deviation of 20 blank samples is multiplied 
by a  factor of 3 and 10 for MDL and MQL respectively, SD is the standard deviation from 
20 blank samples and b is the slope of the regression line for each of the compounds 







Table 2.3 Precursor ion, MRM transitions and run time used for a positive identification of each 
of the target compounds. MDL and MQL were calculated as outlined in Eq. 2.2. Mean recovery 




Citalopram, ranitidine and trimethoprim were analysed in positive ion (PI) mode whilst 
diclofenac and paracetamol were analysed in negative ion (NI) mode using a C18 column 
(Water Corporation, Milford, MA, USA). These samples were analysed with a solvent 
system of acetonitrile + 0.1% formic acid (Buffer A) and water + 0.1% formic acid (Buffer 
B) at a flow rate of 0.3 mL min-1 and the column held at 35ºC. After 10 µl injection the 
gradient was increased from 0 to 100% A over 15 minutes. This was held for four minutes 
followed by a decline to 0% A over 30 seconds. Reequilibriation time was 5.5 minutes. 
A column wash in 100% acetonitrile was carried out between each sample injection. The 
LC eluent was directly infused into the MS, with a backing pressure of 35psi, electrospray 
desolvatation temperature of 150ºC and 9 l min-1. The lockspray frequency was set to 
scan 45ms for each ion.  
Metformin was analysed in PI mode using a HILIC column according to US EPA method 
1694 (EPA 2007). LC was performed using a solvent system of acetonitrile (solvent A) 
and 0.1% acetic acid in ammonium acetate buffer (solvent B), with a flow rate of 0.2 mL 
min-1 and the column held at 35ºC. After 10 µl injection, the gradient was kept at 98% 
solvent A for 5 minutes. Solvent A was then decreased to 70% and was held for 7 
minutes before increasing back to 98% over 30 seconds. The column was reequilibriated 
for 3.5 minutes. A column wash in 100% acetonitrile was carried out between each 
sample injection. The LC eluent was directly infused into the MS, with a backing pressure 
of 35psi, electrospray desolvatation temperature of 150ºC and 9 l min-1. The lockspray 




Figure 2.4: Chromatograms and calibration curves for target analyte standards (100 ng ml-1 in 
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Abstract 
Only a small proportion of pharmaceuticals available for commercial use have been 
monitored in the aquatic environment, and even less is known about the effects on 
organisms. With thousands of pharmaceuticals in use, it is not feasible to monitor or 
assess the effects of all of these compounds. Prioritisation schemes allow the ranking of 
pharmaceuticals based on their potential as environmental contaminants, allowing 
resources to be appropriately used on those which are most likely to enter the 
environment and cause greatest harm. Many different types of prioritisation scheme exist 
in the literature and those utilising predicted environmental concentrations (PECs), the 
fish plasma model (FPM), critical environmental concentrations (CECs) and acute 
ecotoxicological data were assessed in the current study using the fifty most prescribed 
drugs in the United Kingdom. PECs were found to be overestimates of mean measured 
environmental concentrations but mainly underestimations of maximum concentrations. 
Acute ecological data identified different compounds of concern to the other effects 
assessments although the FPM and CECs methods were more conservative. These 
schemes highlighted antidepressants, lipid regulators, antibiotics, antihypertensive 
compounds and ibuprofen as priority compounds for further study and regulation.  
 
3.1 Introduction 
Concern over the presence of pharmaceuticals in the environment and the subsequent 
development of environmental risk assessments (ERAs) for these compounds began in 
the 1990s (Küster and Adler 2014). Currently, only Europe and the USA have specific 
ERA protocols for the assessment of pharmaceuticals, which are required to be 
completed in order to register them for commercial use (Adler et al. 2008). In 2006, an 
EU regulation on the Registration, Evaluation, Authorisation and Restriction of chemicals 
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(REACH) came into effect, and now all chemicals being manufactured in or imported to 
the EU must be assessed following ECHA guidelines, including information on potential 
risks and hazards to the environment (Ehrlich et al. 2011). However, prior to the 
implementation of such legislation, pharmaceuticals have been released into the 
environment unregulated for years. The number of human pharmaceuticals in use has 
been reported as being between 1,500 and 10,000 (Guo et al. 2016; Dong et al. 2013). 
Only a little over 200 of these have been monitored in freshwaters and fewer in marine 
waters, and even less is known about their impacts once they enter the aquatic 
environment (Fabbri and Franzellitti 2016; Hughes et al. 2013). This has left continuing 
uncertainty surrounding the environmental impacts of pharmaceuticals in the aquatic 
environment. The use of a prioritisation scheme can help address this by identifying a 
smaller set of compounds which have the potential to enter the environment and pose a 
biological risk.  This can allow researchers and policy makers to direct resources towards 
further study; they can help decide which compounds need to be monitored in the 
environment and which require more information on their fate and biological effects 
(Mansour et al. 2016). 
Many prioritisation schemes are based on existing ERAs, which include the calculation 
of predicted environmental concentrations (PECs) and an assessment of the risk to biota. 
PECs are usually derived from usage data on the volume of drugs produced per year, or 
number of prescriptions filled, which may be further refined based on processes which 
affect the compounds between production and entering the environment, such as 
metabolism, wastewater treatment, and dilution (Besse and Garric 2008).  Often, where 
experimental data is missing or chemical properties are not known, simplified PECs, 
where little or no fate criteria are applied, may be calculated to facilitate quick 
assessment of a large number of chemicals (Ashton et al. 2004; Besse and Garric 2008; 
Kostich and Lazorchak 2008). As a result, the PECs calculated in such schemes give 
broad predictions for a country or large area and are not refined enough to give 
predictions at different spatial or temporal scales.  
PECs are usually paired with assessments of hazards to biological organisms inhabiting 
the receiving environments. One such method is through the use of risk quotients, which 
determine if the predicted no effect concentrations (PNECs) of a compound exceed 
PECs. If the result is greater than 1 then the study compound is deemed to pose a threat 
(Hoyett et al. 2016). PNECs are usually calculated by selecting the most sensitive LC50 
and applying an assessment factor (Backhaus and Faust 2012). Such experimental data 
is often unavailable in the literature, however, and it is time consuming to generate such 
data for a prioritisation scheme. Ecotoxicological structure-activity relationships 
82 
 
(ECOSAR) can be used to calculate chronic and acute LC50 values and are allowed 
under REACH guidelines (Sanderson et al. 2004, Ortiz de García et al. 2013) 
Pharmaceuticals are unique contaminants as they are designed to be biologically active 
and, unlike many other environmental contaminants, information from the medical 
literature on the pathways and effects of pharmaceuticals in vertebrates is abundant. 
This information has been utilised to produce alternative methods of assessing the 
hazard of pharmaceuticals to biota. Fish are not biochemically different from vertebrates 
and share many of the same drug targets (Huggett et al. 2003). The fish plasma model 
utilises this information and compares the human therapeutic concentration to a 
calculated fish plasma concentration. Vertebrates are usually more sensitive to 
chemicals than invertebrates, due to shared targets. It is thought that this model is a 
scheme sufficient to predict the environmental hazard of chemicals (LaLone et al. 2014).  
Despite their extensive development, the prioritisation schemes which exist in the 
literature are varied and often highlight different compounds of concern (Besse and 
Garric 2008; Donnachie et al. 2016; Roos et al. 2012).  Moreover, it can be difficult to 
compare them as they are applied to different data sets and scenarios which can make 
it hard to understand which compounds really are of most concern or to select a scheme 
for use in research and management. The aim of this paper was, therefore, to use a 
range of common prioritisation schemes to assess the environmental risk of the fifty most 
prescribed pharmaceuticals in the UK, highlight compounds of concern, and make 
suggestions as to the efficacy of the different schemes.  
3.2 Methods 
3.2.1 Predicted Environmental Concentrations 
3.2.1.1 Calculations 
Information on the quantity of pharmaceuticals prescribed was obtained from data 
released monthly by the National Health Service England for 2014 (NHS, 2014). The 50 
most prescribed compounds during this period were used for this assessment.  For each 
compound, the monthly and annual mass of prescriptions was calculated (Appendix 3.1).  
PECA was calculated using (Eq. 3.1), where A is the amount of pharmaceuticals 
dispensed (kg year-1), E is the fraction of the compound excreted unchanged, V is the 
volume of waste water per capita per day (assumed to be 200 litres), P is the population 
of England in 2014, and D is the dilution of waste water (assumed to be 10 times; EMEA 
2006). This method was derived from the approach detailed in the EU technical guidance 
for risk assessment of human pharmaceuticals (EU 2003). Excretion rates were obtained 
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from peer reviewed literature or online databases and the highest excretion rate was 
used in the calculation (Appendix 3.2). PECB further refined this equation by applying the 
removal rate for pharmaceuticals in wastewater treatment plants (WWTPs ;Eq. 3.2), 
where R is the removal rate. Removal rates were obtained from peer reviewed literature 
and where multiple removal rates were published for the same compound, the lowest 
was chosen in order to create a more conservative estimate (Appendix 3.2). If no removal 
rate, or a negative one, was found then it was assumed to be 0. PECC included further 
refinement; taking into account metabolism and removal in wastewater (Eq. 3.3). 
PECA =
A ∗ E






A ∗ (1 − R)






A ∗ E ∗ (1 − R)




PECD (Eq. 3.4) is derived from the EMEA guidelines and does not require prescription 
data to be calculated. Instead, it includes the proportion of the population being treated 
with a particular drug (Fpen), where a suggested value of 1% is used (EMEA 2006). 
Dose is the maximum dosage per person and Capstp is the capacity of the local WWTP 
(assumed to be 10,000; EMEA 2006). The EMEA guidelines also suggest the inclusion 
of information on the fraction of the compound absorbed to suspended matter. Due to 
the unavailability of this data for most compounds this was not included  (Besse et al. 
2008).  
PECD =
Elocalwater ∗ (1 − R)




Elocalwater =  Dose ∗ E ∗ Fpen ∗  Capstp (Eq. 3.5) 
 
  
Each compound was ranked by each of the PEC calculations (Appendix 3.3) and the 
mass prescribed annually in order to compare how the different schemes altered the 
predicted relative environmental risk.  
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3.2.1.2 Comparison with Environmental Concentrations 
In order to compare the PECs to measured environmental concentrations (MECs) data 
were taken from monitoring studies carried out in the United Kingdom (Baker and 
Kasprzyk-Hordern 2013; Bound and Voulvoulis 2006; Burns et al. 2017; Burns et al. 
2018a; Kasprzyk-Hordern et al. 2008; Kasprzyk-Hordern et al. 2009; Kay et al. 2017; 
Nakada et al. 2017; Roberts and Thomas 2006; Ashton et al. 2004). Only monitoring 
studies from surface water were included, measurements from influent and effluent were 
omitted. The mean MEC across all studies was calculated and compared to each of the 
PECs along with the maximum MEC.  
3.2.2 Effect Data 
3.2.2.1 Fish Plasma Model  
The FPM was calculated according to Huggett et al. (2003). This model compares the 
human therapeutic plasma concentration (HTPC) and the fish steady state concentration 
(FssPC) to give an effective ratio (ER), a measure of risk (Eq. 3.6).  FssPC was estimated 
for each of the PEC values calculated in 2.1.1 (Eq. 3.7) and the HTPC was obtained by 
using the peak serum concentration that is reached in humans after the drug has been 
administered (cmax). Where multiple cmax values were found, the higher value was 
used in this assessment (Appendix 3.4).  
 






FssPC = PEC x PBlood:Water (Eq. 3.7) 
 




The compounds were ranked from lowest to highest by ER. Huggett et al. (2003) 
suggested that compounds with an ER<1000 may warrant further assessment. 
3.2.2.2 Critical Environmental Concentrations  
Critical environmental concentrations (CECs) were proposed by Fick et al. (2010) and 
utilise the concept of the FPM but are independent of environmental concentrations. 










3.2.2.3 Risk Quotients 
Information on the acute toxicity of each of the compounds was obtained from reviews 
containing comprehensive experimental ecotoxicological data or studies containing such 
data provided by pharmaceutical companies  (Sanderson and Thomsen 2009, Sangion 
and Gramatica 2016a, Vestel et al. 2016). For compounds not included in these studies, 
LC50 values were obtained from risk assessments or scientific literature (Appendix 3.4). 
Values were only included if they followed standard protocols (for example, OECD, US 
EPA), used at least five concentrations in the exposures and at least three replicates per 
treatment. This data was unavailable for 12 compounds, so ECOSAR (v 1.11) was used 
to estimate LC50 values although the model was unable to estimate these for 7 of the 
compounds. A relative ranking, where the ranking was divided by the number of 
compounds in the scheme, was used in order to compare rankings across all effect 
schemes. 
Risk quotients (RQ) were calculated by dividing the lowest LC50 value for fish, algae or 
daphnia by each of the PECs calculated in 2.1.1. An assessment factor of 1000 was 
applied in order to account for any uncertainties and provide a more conservative 
assessment.  Those compounds with a RQ > 1 deemed to be hazardous to the 
environment.  
3.3 Results 
3.3.1 Exposure Criteria 
3.3.1.1 Comparison of predicted environmental concentrations between schemes 
Metformin, gabapentin, flucloxacillin, amoxicillin, naproxen and ibuprofen were ranked in 
the top 10 across all PEC schemes, whereas tamsulosin, ethinylestradiol, fluticasone, 
budesonide, beclomethasone, felodipine, and tiotropium were ranked in the bottom 10 
(Figure 3.1). These compounds were in the top 10 and bottom 10 respectively when 
ranked by the amount dispensed annually. For most compounds, there was less than a 
10 place difference between schemes (Appendix 3.3). Where larger differences occurred 
it can mostly be attributed to different results between schemes which utilised usage data 
(PECA, PECB and PECC) and PECD which did not. However, the PEC values for individual 





Figure 3.1 Comparison of the ranking of pharmaceuticals by compound class between predicted 




3.3.1.2 Comparison with measured environmental concentrations 
MECs in the UK were available for 24 out of the 50 study compounds. Of these, warfarin 
sodium, sertraline prednisolone and fluticasone propionate were below the method 
detection limit (MDL) in all studies. All of the schemes underestimated the maximum 
concentrations for tramadol, salbutamol, paracetamol, ibuprofen and ethinylestradiol 
(Figure 3.2). Maximum MECs were overestimated for amoxicillin, diltiazem, gabapentin 
and naproxen by all schemes. For the other compounds, PECB overestimated maximum 
concentrations more than the other schemes.  
 
Figure 3.2 Ratio of PEC: maximum MEC for each of the schemes. The line denotes a ratio of 1.  
All PECs were overestimates of mean MECs for all of the compounds, with the exception 
of ethinylestradiol and salbutamol (Figure 3.3). PECA, PECC and PECD also 
underestimated the MECs of propranolol and tramadol. Further to this PECC and PECD 
underestimated the MECs for paracetamol and codeine respectively. The ratio for mean 
MECs was much higher than those for maximum MECs for all compounds. PECD 
overestimated MECs to a greater degree than the other schemes, and PECC more 




Figure 3.3 Ratios of PEC: mean MEC for each of the schemes. The line denotes a ratio of 1 
3.3.2 Effect Criteria 
For many of the compounds, LC50 values resulted in the opposite ranking to the other 
schemes (Appendix 3.5). The FPM, LOGKOW and CEC schemes resulted in simvastatin, 
atorvastatin, candesartan, ibuprofen and losartan being ranked in the top 25%, however, 
the LC50 ranked these compounds as lower priority (Figure 3.4). The opposite was true 
for allopurinol, alendronic acid, beclomethasone and amoxicillin. Pregabalin, gabapentin, 
isosorbide mononitrate and tiotropium were ranked in the bottom 25% across all 
schemes. CECs highlighted some compounds as priority that the other schemes did not; 
ethinylestradiol, fluticasone propionate and beclomethasone diproprionate had a higher 
relative ranking before the inclusion of PEC values. As a compound class, 
antidepressants and antibiotics were given a high priority ranking, whereas 
bronchodilators and mucosal protectants were not.  
All compounds had an ER ratio < 1000, with the exception of tiotropium and alendronic 
acid, where the ER exceeded this value with all PECs (Appendix 3.6).  Isosorbide 
mononitrate also had an ER < 1000 for FPMA, and FPMC. Less compounds exceeded 
the RQ value of 1; all PECs resulted in an RQ > 1 for amoxicillin (Appendix 3.6). PECB 
resulted in the RQ being exceeded for the allopurinol and fluoxetine and PECD for 









3.4.1 Comparison of schemes for predicted environmental concentrations 
For many of the compounds in this assessment, the ranking within each PEC scheme 
was correlated with the amount dispensed, which has also been found in other 
prioritisation studies (Ashton et al. 2004; Roos et al. 2012). Of the compounds which 
were ranked in the top ten across all schemes, metformin, amoxicillin, naproxen and 
ibuprofen have previously occurred on many priority lists (Burns et al. 2018b). 
Gabapentin and flucloxacillin have only been listed of concern in one prioritisation 
exercise each (Helwig et al. 2013; Ortiz de Garcia et al. 2013) and, as a result, fewer 
monitoring studies include these compounds. PECD results were less closely related with 
the amount of compound dispensed, as this was not included in the calculation. Instead, 
PECD used the maximum dosage and assumed 1% of the population was taking the 
compound. It is unsurprising that compounds which have a higher dosage are also 
prescribed at higher masses. However, for many compounds, the usage has been found 
to surpass 1% (Pereira et al. 2017). As a result, the inclusion of usage data in risk 
assessments is very important and, where this is not available (e.g. many developing 
countries), its production should be seen as a high priority by governments. As over the 
counter (OTC) sales of some products have been attributed to up to 50% of this, it is 
very important that these figures are available for risk assessment purposes (Guo et al. 
2016). Of the compounds assessed in the current study, paracetamol, ibuprofen, 
diclofenac, omeprazole and naproxen are available OTC in the United Kingdom. Even 
though OTC data were not available, omeprazole was ranked between 10 and 20 across 
all schemes and if OTC sales were also included, it could be much more important in 
terms of environmental impact. Furthermore, many pharmaceuticals are also used for 
veterinary purposes and these data are needed for more accurate PEC calculations.  
Although, for the majority of compounds, ranking by the amount of pharmaceutical 
dispensed may be sufficient to estimate relative environmental exposure, some 
compounds undergo extensive metabolism or removal in WWTPs, making some 
refinement necessary. Amoxicillin, metformin, gabapentin, ibuprofen and naproxen are 
prescribed in such high numbers that the application of removal and excretion data has 
little impact on their relative ranking. Gliclazide, on the other hand, had a 20 place ranking 
difference between the amount dispensed and PECA due to its extensive excretion. 
Those which were ranked between 20 and 40 showed more variability in their ranking 
between schemes than those at the top and bottom end, as they were dispensed in 
similar amount to other compounds. Information on the metabolism of pharmaceuticals 
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was available in the scientific literature and pharmaceutical databases, with little variation 
in reported values.  
Removal rates during wastewater treatment had less of an effect on the ranking of 
compounds than excretion rate. It is possible that this is the result of the overall lack of 
information of this process or variability within the data, depending on external factors 
such as temperature and WWTP efficiency (Golovko et al. 2014). For example, removal 
of metformin has been reported to be as low 0% and as high as 99% (Santos et al. 2013). 
Variability such as this can have a great impact on the ranking of compounds; PECB 
included the lower rate of removal of 0% which resulted in a ranking of 1, however, using 
the higher removal rate of 99% would have resulted in the lower ranking of 23. 
Furthermore, in some cases, an increase in the compound concentration has been seen 
in effluent as the result of conversion back to the parent compound in WWTPs and so a 
negative removal rate would have to be used in a PEC scheme to accurately take this 
occurrence into account (Paíga et al. 2016).  
3.4.2 Comparison of predicted environmental concentrations with measured 
environmental concentrations 
In the majority of cases, the PECs failed to accurately represent the MECs; mean MECs 
were mostly overestimated, and half of the maximum MECs were underestimated by all 
schemes. PECA, PECB and PECC were most accurate in estimating mean MECs, despite 
overestimations. The MECs of naproxen were the least accurately identified, with PECs 
overestimating maximum concentrations by a factor of 6-10, and mean concentrations 
by a factor of 106 to 163. Nevertheless, these afford a degree of environmental safety. 
When interpreting these results, the lack of available monitoring data needs to be taken 
into consideration and many compounds were only measured at one time point and at 
one or two sites. Concentrations of some pharmaceuticals have been shown to fluctuate 
depending on seasonal and environmental conditions, so more thorough monitoring 
studies are needed to further validate methods for producing PECs (Moreno-Gonzalez 
et al. 2015). Ferrari et al. (2004) compared PECB and the highest MECs for five 
pharmaceuticals in wastewater effluent and rivers in France and Germany. In German 
effluents, these concentrations were accurately predicted for carbamazepine and 
diclofenac, but were underestimated (although by less than a factor of 10) for 
propranolol, clofibric acid and sulfamethoxazole, and overestimated for oflaxin. However, 
in French effluents, MECs were overestimated for all compounds showing that the 
scenario being assessed is important when choosing a PEC model and that local factors 
which could affect concentrations are considered. Burns et al. (2017) also compared 
MECs and PECs which were calculated using local hydrological information alongside 
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lowest removal and highest excretion rates. MECs were accurately predicted in one river 
but not another, which was attributed to missing inputs. The inclusion of local 
hydrological information such as this may help to produce more accurate PECs.  
PECA, PECB and PECC rely upon the accuracy of usage data to form reliable estimates. 
Besides the compounds available OTC, prescription data may not always be an accurate 
representation of the usage of compounds. It is unlikely that all pharmaceuticals 
prescribed will be consumed, and a survey of 400 people in South-Eastern England 
showed that only 53% of people finish their medication (Bound and Voulvouslis 2005), 
and another survey in the United States showed that more than 98% of people disposed 
of their unused medication in household waste or down the sink and toilets (Kupis and 
Krenzelok 1996). Kostich and Lazorchak (2008) tried to add estimates of unconsumed 
pharmaceuticals into their PEC calculations assuming that approximately 5% of drugs 
prescribed for long-term therapy were wasted compared to 15% prescribed for short term 
therapy and 33% for topical use. Whilst naproxen is a prescription only NSAID, it is often 
prescribed short-term or on an as needed basis for pain management, and as a result 
could help explain the over-estimate of its concentrations.   
3.4.3 Comparison of effect based methods 
FPM, LogKOW and CEC schemes resulted in different rankings to acute LC50 and 
triggered different compounds for further assessment, which is concurrent with other 
recent studies, showing that LogKOW has a strong influence on these calculations (Roos 
et al. 2012). Additionally, FPMs were more conservative than RQs, triggering more 
compounds for further assessment. Thus, simply ranking compounds by logKOW could be 
a useful approach for determining the relative hazard pharmaceuticals pose to biota. 
Nevertheless, although logKOW is used in FPM and CEC models, it does not necessarily 
indicate the compound will be toxic, but instead that it is likely to be taken up by fish at a 
level sufficient to have a biological effect (Schrieber et al. 2011). Instead, it is suggested 
that those with an ER less than 1000 warrant further assessment (Huggett et al. 2003). 
LogKOW values have been used as predictors for bioconcentration however this 
measurement was originally developed for non-polar chemicals, and as a result does not 
work for many chemicals (Schrieber et al. 2011).  
The use of acute LC50 and QSAR in order to assess the potential hazard of 
pharmaceuticals has been debated. Although LC50 values are derived from experimental 
work, they can be influenced by variables such as the number of concentrations 
assessed (Hoyett et al. 2016). The primary concern relating to pharmaceuticals in the 
environment is the potential chronic exposure to low levels, and not acute toxicity. As a 
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result, they may affect endpoints which are not covered by traditional risk assessments 
(Johnson et al. 2017). QSARs have been used to model the potential toxicity of 
contaminants to fish, daphnia and algae. There are several QSAR models which have 
been proposed for use in predicting ecotoxicity of pharmaceuticals which have found to 
vary in accuracy (for example, de Roode et al. 2006; Sangion and Gramatica, 2016a).  
There is evidence that fish are more sensitive than algae or invertebrates as they retain 
many of the same drug targets as humans (Donnachie et al. 2016). The FPM was 
developed in order to utilise this information. A read-across approach can be used in 
assessing the potential risk of pharmaceuticals to invertebrates and algae. Fish share 
86% of targets with humans, 61% have been found to be conserved in daphnia and 35% 
in algae (Gunnarsson et al. 2008).  There is particular concern surrounding the toxicity 
of antibiotics and statins to algae, in part due to conserved pathways, but also due to the 
inhibition of symbiotic bacteria (Guo et al. 2015). CEC resulted in a higher ranking for 
statins and two of the antibiotics than LC50 values. Amoxicillin, on the other hand, was 
highlighted by its acute toxicity and not by the FPM. Only the RQ which included PECA 
exceeded 1 for amoxicillin, whereas this was exceeded by all of the FPM schemes.  As 
a result, the FPM and CEC will add a degree of protection for organisms besides fish.  
For many compounds, FPM and CECs resulted in similar rankings. The minor influence 
PEC has on FPM confirms what has been found in other comparisons between 
prioritisation schemes (Roos et al. 2012). However, ethinylestradiol, fluticasone 
propionate and beclomethasone were highlighted by CECs, but not by FPMs as the PEC 
values for these compounds were small. In this case, ethinylestradiol had a low PEC, 
however MECs were much higher than this. Ethinylestradiol is a compound on the EU’s 
priority watch list due to concern over its potential effects at environmentally relevant 
concentrations. Johnson et al. (2017) ranked chemicals based on their measured 
environmental concentrations in UK Rivers and measured ecotoxicity concentrations, 
and found that ethinylestradiol was highlighted as posing the greatest risk.  As a result it 
is important that PEC results are accurate if FPM is going to be used. The use of an 
assessment factor or ER value of 1000 allows for the most conservative estimate of risk 
whilst accounting for uncertainty in the PEC values.  
3.4.4 Selecting a prioritisation scheme 
It is important to consider the inclusion of compounds into a scheme to begin with. 
Metoprolol, carbamazepine, aspirin and sulfamethoxazole were four of the most cited 
pharmaceuticals of concern in the prioritisation literature but were not in the 50 most 
prescribed compounds (Donnachie et al. 2016). The high number of prescriptions does 
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not necessarily translate into a large mass of the compound; bronchodilators, for 
example, were prescribed in high numbers, but at a very low mass. As a result, certain 
compounds may be overlooked and it may be necessary to select compounds based on 
their mass as well as prescription numbers.  
Of the PEC schemes used in this assessment, PECA is the most suitable for assessing 
the relative exposure risk as it requires limited data, but also conservatively estimates 
the likelihood of pharmaceuticals entering the environment. It can be used to select 
pharmaceuticals for which to further refine PECs based on local criteria before selection 
of compounds for monitoring in the environment. Where information on the number of 
prescriptions is not available, PECD is a better alternative as it can work within the 
confines of available data.  
Assessment of the potential effects of pharmaceuticals should be used alongside PEC 
evaluations. LogKOW offers a quick and easy method for assessing the relative risk, based 
on potential bioaccumulation. The use of CECs and FPM add an extra level of 
refinement, based on utilising information on mammalian effects. FPM appears to give a 
conservative approach to prioritising pharmaceuticals in comparison to acute RQs. As a 
result, those compounds which exceed the RQ threshold should be of priority. The use 
of CECs over FPMs allows the ranking of compounds independent of PECs. However, 
both exposure risk and potential effects should be included, as compounds found at 
small concentrations could still be enough to warrant an effect. For example 
ethinylestradiol was ranked as a low priority by the PEC schemes, but inclusion of effect 
information increased its ranking. 
When prioritising pharmaceuticals, it is essential to take a holistic approach which 
conservatively highlights potential compounds of concern which warrant further 
assessment. It is important to consider why the exercise is being carried out and the 
question it is trying to address. There will not be a one size fits all approach, and not all 
schemes will be appropriate in all situations. As a result, the limitations to each of these 
schemes needs to be kept in mind.  
3.4.5 Compounds of concern 
The combination of PEC and effect criteria clearly highlight groups which should be a 
priority for further research. Some assessments have only added one compound from 
each class to the priority list, assuming that each class will have a similar mode of action 
and similar effect (Besse and Garric, 2008). Antidepressants were ranked high across 
all of the effect schemes, and moderately for PECs too. Overall ranking between 
compounds does not differ much, however, fluoxetine may be of most of concern due to 
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exceeding the RQ threshold values when none of the others did. Fluoxetine is commonly 
present on priority lists, however some rankings have pointed towards sertraline, 
citalopram and amitriptyline as representing a greater hazard (Besse and Garric 2008; 
Roos et al. 2012; Sangion and Gramatica 2016b). Many of these antidepressants have 
been found to have an effect on biota at environmentally relevant concentrations and the 
use of FPM also highlights this (Silva et al. 2015). To the authors’ knowledge, this is the 
first prioritisation exercise which has highlighted mirtazapine and venlafaxine to be a 
potential concern.  
Similarly to antidepressants, candesartan and losartan had moderate PEC rankings but 
high effect rankings for FPM, CEC and LC50, whilst other anti-hypertensives had a low 
ranking across both PEC and effect schemes. These compounds are not commonly 
included in prioritisation exercises, however, losartan has been present on priority lists 
previously (Besse and Garric 2008). Candesartan had a higher ranking across schemes 
and as a result may be more of a concern. The lipid regulators, atorvastatin and 
simvastatin also had moderate to low PECs. However, their high ranking among CECs 
and FPM means they warrant further investigation. 
Amoxicillin and flucloxacillin were two of four compounds to exceed a RQ value of 1. 
Both of these compounds were ranked highly as the result of PEC values. The effect 
rankings of flucloxacillin were much higher than those of amoxicillin. Flucloxacillin is not 
commonly present in monitoring or effects studies and there is still uncertainty about its 
occurrence and impacts so it could be seen as a priority compound.  
Ibuprofen was ranked in the top 10 of all of schemes, with the exception of acute LC50. 
Ibuprofen is the fifth most prioritised compound in the prioritisation literature (Burns et al. 
2018b). The environmental impact of ibuprofen pollution has been the focus of many 
studies and its repeat presence on priority lists and high rankings in the current study 
indicate the importance in understanding its fate and effects.   
Allopurinol may also warrant further assessment due to its high exposure ranking and 
RQ value. Whilst it had a low ranking for FPM, CEC and LogKOW values it had an ER < 
1000. Allopurinol has been stated to be a highly prescribed drug in other EU countries 
(Küster and Adler, 2014; Roos et al. 2012) although Roos et al. (2012) carried out a 
comparison of first-tier prioritisation schemes, including FPM, on 582 pharmaceuticals in 
Sweden, and did not find it to be a high priority. However, it has been highlighted on 
other priority lists based on exposure and effect criteria (Besse and Garric, 2008; Linert 
et al. 2007). Despite this, it is not present in the monitoring or ecotoxicity literature and it 
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has only been monitored in coastal waters in Spain, where it was not detected 
(Rodriguez-Navas et al. 2013).   
Other compounds such as metformin and gabapentin are ranked in the top by PEC 
schemes, but inclusion of effect criteria decreased their ranking. However, due their high 
PECs, moderate effect rankings across FPM and acute LC50 values, they may still 
warrant further assessment. It is particularly important to understand their occurrence 
and fate. Metformin in particular may be of concern as it now a widely used drug, and its 
usage has increased rapidly over the last decade (Oosterhuis et al. 2013).  
This assessment also clearly highlights compounds which are not of concern. 
Bronchodilators were ranked in the bottom of all schemes and corticosteroids were 
ranked at the bottom across all PEC schemes. This is concurrent with other prioritisation 
exercises. As a result, these compounds are not commonly featured in monitoring 
campaigns or experimental effects work. Although the priority ranking increased with the 
application of effect criteria, it was still low.  
3.4.6 Future direction for the management of pharmaceuticals in the environment 
There is some evidence that EU policy has not used risk assessment approaches to 
accurately identify compounds of concern. In the present study, ibuprofen and naproxen 
had a higher PEC and effect ranking than diclofenac even though the latter has been 
placed on the EU priority watch list. This could perhaps be attributed to the fall in 
diclofenac’s usage over the past few years though (Mavragani et al. 2016). 
Ethinylestradiol is another compound included on the EU priority watch list even though 
it had a low PEC ranking and similar effect ranking; only CECs ranked it as a priority. 
Similar results were seen in comparison of first-tier risk assessments by Roos et al. 
(2012), where FPM did not result in a high ranking for ethinylestradiol but CEC and three 
other schemes did. As pharmaceuticals are designed to be biologically active, it is 
important that there is an understanding of these pathways in non-target organisms in 
order to create better risk assessments.  
There has been an increasing interest in the occurrence of pharmaceuticals in 
environmental compartments other than effluent and water such as sediment and marine 
environments. Comparatively little is known about the occurrence of pharmaceuticals in 
these areas (Fabbri and Franzellitti 2016; Gaw et al. 2014) and use of the PEC schemes 
employed here may not appropriately predict presence in these compartments. Other 
properties, such as lipophilicity, pH and sediment type may be more relevant in predicting 
the presence of pharmaceuticals in sediments, and in turn the potential risks to biota 
which live within these systems (Al-Khazrajy and Boxall 2016). Salinity is also a defining 
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factor of marine waters and it is hypothesised that the physical-chemical characteristics 
of some compounds may change in marine waters. For example, the partition coefficient 
between sediment and water for estrone increases with increasing salinity, meaning 
concentrations will be lower (Pal et al. 2010). 
All pharmaceuticals are metabolised to a different degree, yet only two prioritisation 
schemes have included metabolites (Besse and Garric 2008; Capleton et al. 2006). If 
metabolism and degradation play a significant role in the fate of pharmaceuticals then 
metabolites will be present in the environment. Few studies have covered the occurrence 
and effects of metabolites, many of which are inert, but some of which have been found 
to be pharmacologically active and even toxic (García-Cambero et al. 2015).  
3.5 Conclusion 
Prioritisation schemes should include assessments of the potential of a compound to 
enter the environment as well its potential toxicity. Excretion of pharmaceuticals had a 
large influence on the ranking of PECs for different compounds, and as a result should 
be included in these calculations. CECs should be used alongside PECs in order to 
assess potential hazard; both of these schemes result in a conservative estimate of risk, 
and highlight compounds which warrant further assessment. Antidepressants, statins, 
antibiotics candesartan, losartan and ibuprofen were highlighted as the substances of 
greatest environmental concern.  
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Abstract 
There is a lack of data on the occurrence of pharmaceuticals in estuaries worldwide, with 
little understanding of their temporal and spatial variations globally. Ibuprofen, 
paracetamol, diclofenac, trimethoprim and citalopram were measured in twelve estuaries 
in the UK.  Initially, these compounds were monitored in the Humber Estuary, where 
samples were taken every two months over a twelve month period in order to assess 
their spatial and temporal variations. Ibuprofen was found at some of the highest 
concentrations ever measured in an estuary globally (18 – 6297ng l-1), with paracetamol 
also measured at relatively high concentrations (4 – 917 ng l-1) in comparison to the other 
compounds. In terms of spatial distribution, a pattern was observed, where highest 
concentrations were found at a site where wastewater is discharged, whilst compound 
concentrations were often lower upstream and downstream of this site. The downstream 
profile of pharmaceuticals differed temporally with concentrations highest downstream 
when input from wastewater effluent was highest. Eleven further estuaries were sampled 
around the UK in order to put the occurrence of pharmaceuticals seen in the Humber 
Estuary into a wider context. Pharmaceutical concentrations in the other estuaries 
sampled were less than 210 ng l-1,  but, again, ibuprofen and paracetamol were found at 
concentrations higher than other compounds, whereas diclofenac and citalopram were 
absent from many estuaries. The Humber, which is the receiving environment for the 
sewage effluent for approximately 20% (13.6 million people) of the population of 
England, was observed to have the highest overall concentration of pharmaceuticals in 
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contrast to the other estuaries sampled, thereby representing a worst case scenario for 
pharmaceutical pollution.  
4.1 Introduction 
Despite the extensive and long-term use of pharmaceuticals, it has only been in the past 
few decades that interest in pharmaceutical pollution has gained popularity and now 
hundreds of pharmaceuticals have been detected in the aquatic environment (Hughes 
et al. 2013; Gaw et al. 2014). Their presence in the aquatic environment is sustained 
through continuous input from wastewater treatment plants (WWTPs), as well as from 
improper disposal, agriculture and aquaculture (Godoy et al. 2015). Pharmaceuticals are 
designed to be biologically active, often at low levels, and their presence in surface water 
has led to concern over their potential biological effect (Santos et al. 2010). Many 
pharmaceuticals (e.g. diclofenac and fluoxetine) have been found to illicit a negative 
response on biota in laboratory exposures at concentrations similar to those found in the 
aquatic environment (Eades and Waring 2010; Franzellitti et al. 2013; Minguez et al. 
2016).  
The fate of pharmaceuticals is best understood in the freshwater environment, with input, 
environmental conditions, biological degradation and sediment-related processes 
playing a prominent role in their spatial and temporal distribution (Li 2014). 
Pharmaceuticals often show a decline in concentration downstream from input sources 
as the result of dilution, degradation and partitioning to sediment (Kunkel and Radkle 
2012). However, due to the prevalence of WWTPs, this leads to the continuous input of 
pharmaceuticals into the environment. As a result, these processes are not enough to 
sufficiently remove compounds leading to their high detection in the aquatic environment 
and potentially, transportation into estuaries and coastal waters (Ebele et al. 2017).  
Estuaries are receiving waters, often for many rivers, acting as a confluence for 
contaminants, therefore increasing the potential risk of pharmaceutical pollution in these 
environments (Ridgway and Shimmield 2002). Estuaries are ecologically important to 
ecosystem services, providing habitat for many species and acting as an area for 
recreation and transport (Ridgway and Shimmield 2002). Despite this, few studies have 
measured the occurrence of pharmaceuticals in estuaries, and those that do, exist 
typically lack the resolution to determine spatial and temporal patterns (Table 4.1). 
Studies which have investigated the spatial and temporal patterns of pharmaceuticals 
are often locally focused, monitoring only one estuary (for example Tamtam et al., 2012; 
Hedgespeth et al. 2012; Cantwell et al. 2017) and it is important to determine if any 
patterns seen are relevant at a wider scale. It is important to examine the fate of these 
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compounds across a wider spatial scale in order to determine whether they pose a risk 
to the environment. 
Table 4.1: Maximum concentrations of ibuprofen, paracetamol, diclofenac and trimethoprim 
detected in estuaries globally (ng l-1) Citalopram has not previously been monitored in any 
estuaries.  
 
This study aimed to further contribute to the overall picture of pharmaceutical 
contamination in estuaries. Five target compounds — ibuprofen, paracetamol, 
diclofenac, trimethoprim and citalopram were chosen for the present study, based on 
their prevalent usage and predicted risk to the aquatic environment (National Health 
Service 2017; Roos et al. 2012). To the author’s knowledge, citalopram has not 
previously been monitored in the estuarine environment (Table 4.1). Moreover, 
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monitoring of the aforementioned compounds is limited, with some of these 
measurements dating back almost 15 years. The target compounds were measured 
every other month over a twelve month period at various sites in the Humber Estuary to 
determine their spatial and temporal occurrence. In addition, eleven further estuaries, 
located in other parts of the UK, were selected in order to determine whether 
concentrations observed in the Humber were representative of other estuaries.  
4.2 Methods 
4.2.1 Study Area 
The Humber Estuary is a macrotidal estuary located in Yorkshire, on the East Coast of 
England, UK (Figure 4.1). It is 303 km2, has an average depth of 6.5 m and is the 
confluence for the Rivers Ouse, Trent and Hull which pass through some of the largest 
urban areas in the UK, thus it is the receiving water for approximately 20% of UK effluent 
(European Environment Agency, 2017; Table 4.2). Samples were collected from nine 
sites along a 65 km stretch on the North side of the estuary (Figure 4.1). Two of these 
were located in the River Ouse: A1 (20 km from Humber) was the furthest upstream and 
A2 was located less that 1km upstream from the confluence with the Humber Estuary. 
The furthest site upstream in the Humber Estuary (R1) was the receiving site for effluent 
from Melton WWTP, which serves a population equivalent (PE) of 12,255 (European 
Environment Agency, 2017). Three sites (R2-R4) were positioned every 2 km 
downstream from R1. Three final sites (A3-A5) were located 20km from R1 in the lower 
estuary and 15 km from the mouth. Further information on site location can be found in 
Appendix 4.1. The Humber Estuary is an important site for conservation and has been 
designated as a Special Protection Area (SPA), also containing a Special Area of 
Conservation (SAC). It is also a vital habitat for many species of international importance, 
providing habitat for 4.1% of the red knot (Calidris canutus) and 5.7% of the common 
redshank (Tringa tetanus) international populations, and as a result has also been 
designated as a RAMSAR site (Buck et al. 1997) 
Samples were also collected from eleven further estuaries which encompassed a range 
of estuary types, tidal ranges and sizes (Table 4.2). The total PE was calculated for the 
WWTPs in the catchment area of each estuary (Table 4.2); further information on the 
proximity of WWTPs to the sampling sites in each estuary can be found in Appendix 4.2.  
Many of these estuaries have been designated as SACs, SPAs and RAMSAR sites as 
the result of the sensitive and important species resident to them. 
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Table 4.2: Information on the type and size of estuaries sampled (Davidson et al.1991). 
Information on the number of WWTPs and the population equivalent served in 2014 was 
calculated from an interactive wastewater treatment map (European Environment Agency 2017).  
  
4.2.2 Sampling 
4.2.2.1 Seasonal monitoring 
Sampling was carried out in the Humber Estuary, UK, every two months from October 
2016 to August 2017 at sites R1-R4 (Figure 4.1).  Samples were also collected from four 
additional sites (A1-A2 and A4-A5) in October, February and June, and a further site (A3) 
in February and June (Figure 4.1). Sampling was carried out during a high neap tide (± 
3 hours) to minimise differences in diurnal concentrations as the result of tides (Lara-
Martin et al. 2014).  At each site, 3 x 1 L of surface seawater were collected in amber 
glass bottles and temperature, pH and dissolved oxygen were determined using a HACH 
meter and salinity (0 – 27 ppt) measured with a refractometer (Appendix 4.1).  Water 
samples were kept on ice or in the fridge at 4 °C and extracted within 48 hours for 




4.2.2.2 UK wide monitoring 
Sampling was carried out in eleven additional UK estuaries in order to provide a wider 
context for the concentrations of pharmaceuticals seen in the Humber Estuary (Figure 
4.1). Sampling was carried out in August and September 2017 and samples were also 
collected during high tides (± 3 hours). Within each estuary, sites were chosen in the 
upper, middle and lower parts of the estuary and 1 L of water was collected at each of 
these in amber glass bottles. (Appendix 4.2). Temperature, pH, dissolved oxygen and 
salinity (0-34 ppt) were determined as above and samples were stored and extracted in 









































































































































































4.2.3 Chemical Analysis 
4.2.3.1 Study Compounds 
Five study compounds — ibuprofen, paracetamol, diclofenac, trimethoprim and 
citalopram, were chosen for monitoring (Table 4.3). Standards of diclofenac sodium 
(≥98.5), acetaminophen (≥99%), citalopram (≥98), ibuprofen (≥98%), and trimethoprim 
(≥98%) were supplied by Sigma-Aldrich Ltd. (Dorset, UK). 
 
Table 4.3: Physico-chemical characteristics of the study compounds. Physico-chemical data 
obtained from USEPA (2019). Prescription data obtained from (National Health Service 2019; 
Appendix 4.3). 
 
4.2.3.2 Solid Phase Extraction 
A composite sample was made, by combining the 3 x 1L surface water samples collected 
from each site during seasonal monitoring, or from each of the estuaries during the UK-
wide survey; they were added together in a 5 L beaker and stirred vigorously for two 
minutes. A 500 mL subsample was taken and filtered through a 0.45 µm cellulose filter 
(Scientific Laboratory Supplies, Hessle, UK) under vacuum. Solid phase extraction was 
performed on the filtered water samples using Oasis HLB cartridges (Waters 
Corporation, Massachusetts, USA), which were conditioned with 5 mL 100% methanol 
followed by 5 mL deionised water at a rate of 1 mL min-1. The sample was loaded on to 
112 
 
the cartridge at a rate of 10 mL min-1, during which care was taken not to let the sorbent 
material dry out. The cartridges were then rinsed with 5 mL deionised water. The sorbent 
was dried under vacuum for 15 minutes to remove excess water prior to elution. Elution 
was performed with 5 mL 0.1% TFA in methanol, followed by a further 5 mL. The eluent 
was evaporated to dryness using a rotary evaporator (40ºC, speed 7) and reconstituted 
with methanol: water (10:90).  
SPE recovery was evaluated by spiking known concentrations (100, 200, and 1000 ng l-
1) of all study compounds into three replicates each of artificial seawater made up to 20 
ppt in deionised water (Appendix 4.4). The mean recovery across all concentrations was 
used to correct the measured environmental concentration (Table 4.4). 
 
Table 4.4: Mean method detection limits (± standard deviation), mean method quantification 
levels (± standard deviation) and mean recovery (± standard deviation) of target compounds.  
 
4.2.3.3 UltraperformanceTM-ESI-(QqLIT) MS/MS analysis 
Analysis was carried out according to Gros et al. (2012). Briefly, chromatographic 
separations were performed with a Waters Acquity Ultra-Performance liquid 
chromatograph system equipped with two binary pumps systems (Milford, 
Massachusetts, USA), and coupled to a 5500 QTRAP hybrid quadrupole-linear ion trap 
mass spectrometer with a turbo ion spray source (Applied Biosystems, Foster Systems, 
Foster City, CA, USA). Citalopram and trimethoprim were analysed under positive 
electrospray ionisation (PI) using an Acquity HSS T3 column (50 mm x 2.1 mm, 1.8µm 
particle size) and ibuprofen, paracetamol and diclofenac were analysed under negative 
ion (NI) electrospray using an Acquity BEH C18 column (5 mm x 2.1 mm, 1.7 µm particle 
size), both from Waters Corporation. 
All data acquisition was performed in Analyst 2.1 software.  Quantification of analytes 
was performed by selective reaction monitoring (SRM), monitoring two transitions for 
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each compound as described in Gros et al. (2012).  Method detection limits (MDL) and 
Quantification levels (MQL) were determined for each of the compounds based on a 
signal-to-noise ratio of 3 and 10, respectively (Table 4.4).  
4.2.4 Statistical Analysis 
Statistical analysis was performed in R 3.3.1. In order to determine if there was a 
difference in the occurrence of pharmaceutical between sampling months, 
concentrations from Melton, North Ferriby, Hessle East and Hessle West were grouped 
together, as these sites were sampled during all of the sampling periods. A Friedman’s 
Test followed by a Nemenyi post-hoc test were conducted using the PMCMR package 
(Pohlert 2014). Relationships between pharmaceutical concentrations and site-specific 
physico-chemical properties (Salinity, pH and dissolved oxygen) were investigated using 
a linear model. All data is presented in graphs created by the ggplot2 package (Wickham 
2016).  
4.3 Results 
4.3.1 Humber Estuary 
Pharmaceuticals were frequently detected (58 - 97% of samples for individual study 
compounds) in the Humber Estuary (Table 4.5) and concentrations followed the order of 
ibuprofen>paracetamol>diclofenac>trimethoprim>citalopram. Whilst mean 
concentrations were in the order of 100 ng l-1 or below, maximum concentrations were 
approximately 5 to 10 times higher (Table 4.5; Appendix 4.5). Maximum levels of 
ibuprofen and paracetamol detected in the Humber are the highest concentrations 
reported in estuaries to date (Table 4.1). Furthermore, this is the first study to detect 












Table 4.5: Pharmaceutical concentrations (ng l-1) in surface water in the Humber Estuary (n=38) 
during a 12 month sampling campaign. Values were corrected based on mean recovery values 
(Table 3).  Max = maximum concentration, SD = standard deviation. Detection rate is the amount 
of samples above the method quantification limit (MQL).  
 
A general pattern was observed in the occurrence of pharmaceuticals in the Humber 
surface water, with pharmaceutical concentrations peaking at sampling site R1 (Figures 
4.2) and concentrations upstream (sampling sites A1-A2) and downstream (sampling 
sites R2-A5) of this site were similar to each other. Conversely, this pattern was not 
consistent in that the chemical concentrations at some of the sampling periods (for 
instance: paracetamol and diclofenac in June), displayed a reduction in levels 
downstream (A3-A5). Maximum concentrations were generally seen at sampling site R1 
although during some of the sampling periods, they also occurred at sites R2-R4.  
Salinity in the Humber Estuary ranged between 0 ppt (sites A1 and A2) to 27 ppt (site 
A5). Although salinity differed during each sampling period, a general downstream 
decline was observed (Appendix 4.1). There was not a clear pattern in the pH and 
dissolved oxygen measurements. The linear regression analysis indicated that there was 
significant relationship between dissolved oxygen and concentrations of paracetamol (R2 
= 0.15, P = 0.03), diclofenac (R2 = 0.29, P = 0.001) and trimethoprim (R2 = 0.22, P = 
0.007), with lower dissolved oxygen corresponding with higher concentrations (Figure 
4.3). There was also a significant relationship between pH and dissolved oxygen (R2 = 
0.12, P = 0.03). However, this was a very weak relationship with R2 values less than 0.3 
for all compounds. No statistically significant relationship was seen between salinity and 
any of the compound concentrations (Figure 4.3).  
Of the three months where all sites were sampled, February had the highest detection 
rates and concentrations of pharmaceuticals at downstream sites (A3-A5), whilst many 
of the compounds were absent at these sites in October and June (Figure 4.2). In 
contrast, ibuprofen was an exception to this with compounds found at these sites during 
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all of the sampling periods. Citalopram also showed little decline in downstream 
concentrations in June, and was present at A3-A5, at concentrations similar to or higher 
than many of the sites further upstream (Figure 4.2). There appeared to be a relationship 
between the concentration of pharmaceuticals at R1 and those seen at the other sites; 
typically, a higher concentration at R1 resulted in a higher presence at sites further 





Figure 4.2 Concentrations of target analytes at nine sites in the Humber Estuary. Values were 
corrected based on mean recovery values (Table 4.3). Sites are listed from furthest upstream 
(A1) to furthest downstream (A5). R1-R4 were sampled every sampling event, whilst the other 





Figure 4.3: Linear regressions of salinity, pH and dissolved oxygen and concentrations of (A) 
ibuprofen (B) Paracetamol, (C) Diclofenac, (D) Trimethoprim and (E) Citalopram.   
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Sites R1-R4 were sampled more frequently than the other sites, and trimethoprim was 
the only compound to show a statistically significant difference between sampling months 
(Friedman’s Test, chi-squared = 14.71, p < 0.05) with concentrations, significantly higher 
in winter (December and February; 3.29 – 166.54 ng l-1), compared to October and the 
summer months (June and August; 0 – 142 ng l-1; Figure 4.4). Nevertheless, the 
difference was almost significant for ibuprofen (p = 0.054) and citalopram (p = 0.051). 
For citalopram, February had the highest concentrations (3.74 – 42.93 ng l-1), whereas 
ibuprofen concentrations were higher in April and June (186.37 – 6297.14 ng l-1; Figure 
4.3) in comparison to the other sampling periods. All compounds had lowest mean 
concentrations in August (Figure 4.4), with no peaks seen at sampling site R1 (Figure 
4.2).  
 
Figure 4.4 Mean bi-monthly concentrations (± one standard deviation) of (A) Ibuprofen (B) 
Paracetamol (C) Diclofenac (D) Trimethoprim and (E) Citalopram at the four sites monitored most 
frequently (R1-R4). Values were corrected based on mean recovery values (Table 4.3). Letters 




4.3.2 UK-wide Sampling 
Pharmaceuticals were detected in all of the estuaries sampled around the UK but only 
at concentrations in the low ng l-1 range and were generally present at concentrations 
lower than those detected in the Humber Estuary (Figure 4.5). The order of 
pharmaceuticals were similar to that found in the Humber 
(ibuprofen>paracetamol>diclofenac>citalopram>trimethoprim), except trimethoprim was 
found at lowest concentrations (Appendix 4.6). Ibuprofen and trimethoprim were present 
in all of the estuaries sampled, whereas diclofenac was only detected in two of the other 
estuaries, the Cromarty and Thames (Figure 4.5). The Thames and Humber were the 
only estuaries to contain all of the compounds. The Humber had the overall highest 
concentration of pharmaceuticals, and the Cromarty and Tay were the only other 
estuaries which had a total concentration of pharmaceuticals over 200 ng l-1 (Figure 4.5). 
 
 
Figure 4.5 Concentrations of citalopram, diclofenac, ibuprofen, paracetamol and trimethoprim 
across eleven estuaries in the UK. Concentrations have been corrected for recovery (Table 4.3). 
Concentrations reported for the Humber are maximum concentrations measured in August, when 






Most monitoring studies to date have been carried out in freshwater systems as it was 
originally thought that estuaries and coastal waters would dilute compounds so that they 
would be undetectable (Fabbri and Franzellitti 2016). Despite this hypothesis, 
pharmaceutical contamination was found to be widespread as all of the estuaries 
monitored contained at least three of the target analytes at levels of a similar magnitude 
to those found in the freshwater environment, and higher than those measured in many 
other estuaries (Hughes et al. 2013; Table 4.1). The levels of pharmaceuticals detected 
in this study, contribute to the overall picture on pharmaceutical pollution and add to the 
growing evidence that it is a global issue (aus der Beek et al. 2016). Our work indicates 
that the limited monitoring carried out to date may not have captured peak concentrations 
that occur in these environment and clearly highlights that further work is needed. 
Ibuprofen was detected at the highest concentrations and in all of the estuaries sampled, 
with its occurrence not only exceeding levels detected in other estuaries (Table 4.1), but 
also those seen in river water both in the UK (Barbara Kasprzyk-Hordern et al. 2008; 
Kay et al. 2017; Burns et al. 2017, 2018), as well as globally (Hughes et al. 2013). 
Ibuprofen has only been measured in 7 estuaries previously, with maximum 
concentrations all under 100 ng l-1 (Table 4.1). Further monitoring studies should include 
ibuprofen as a priority to determine if high concentrations seen in the UK are similar to 
those elsewhere.  
Concentrations of paracetamol, diclofenac and trimethoprim were similar to those seen 
in other global estuaries, with mean concentrations less than 100 ng l-1 (Table 4.1). Whilst 
maximum concentrations of paracetamol were similar to those detected in rivers 
(Barbara Kasprzyk-Hordern et al. 2008; Burns et al. 2017), concentrations of diclofenac 
and trimethoprim were considerably lower (Hughes et al. 2013; Nakada et al. 2017). In 
the present study, water samples were collected at high tide, when concentrations would 
be expected to be lowest, so it is possible that these levels could be higher at other points 
in the tidal cycle (Yang et al. 2016). This is the first study to measure the occurrence of 
citalopram, however concentrations were low and did not exceed 50 ng l-1. These low 
concentrations are in agreement with previous studies which have monitored citalopram 
in rivers (Hughes et al. 2013). Despite these low concentrations, PNECs for citalopram 
are below this (Minguez et al. 2016).  
Whilst an overall widespread occurrence of pharmaceuticals was seen in the UK, 




4.4.1 Humber Estuary 
4.4.1.1 Spatial Variation 
It is generally expected that pharmaceutical concentrations will decrease downstream 
due to physical processes in an estuary leading to their breakdown and removal 
(Daughton 2016). The spatial pattern of pharmaceutical occurrence in the Humber 
Estuary followed this pattern to a degree; peak concentrations were found in the middle 
of the estuary, particularly at R1, where samples were collected next to an outlet from a 
WWTP, indicating that they could be a significant source of pharmaceuticals in the 
Humber Estuary. Input from WWTPs has been attributed as the largest source of 
pharmaceutical pollution in the aquatic environment (Caldwell 2016). Dissolved oxygen 
was often lowest at R1, and can explain the relationship observed between diclofenac, 
paracetamol and trimethoprim. Dissolved oxygen is often lowest at sites where 
wastewater effluent is discharged, as the result of increased microbial activity and 
decreased water quality (Igbinosa and Okoh 2009). However, the overall relationship 
between these variables was weak and could be explained by maximum concentrations 
seen outside of this site or difference in dissolved oxygen between sampling periods and 
indicates that other variables are important in determining the concentrations of these 
compounds.  In some cases maximum concentrations were detected outside of this site; 
in April and June, maximum concentrations for paracetamol and ibuprofen occurred at 
sites R2-4. It is difficult to determine what caused these peaks as composite sampling 
can lead to uncertainty in the representativeness of samples in cases such as this, 
however these sites are within 6km from R1, so it is possible that the large increases 
seen at these sites are still due to input at R1, and fluctuations of concentrations between 
these sites are the result of sampling timing or within sample variation (Ort et al. 2010). 
The site R4, which showed the highest levels (6.2 µg l-1) of ibuprofen was also 7km 
upstream from the confluence of the River Hull. Transport of pharmaceuticals from this 
tributary upstream during high tide could also account for the increases seen. The River 
Trent, located near the confluence with the Ouse (Figure 4.1), will also account for the 
addition of further pharmaceuticals. Inputs of pharmaceuticals in other studies have also 
been attributed to other sources such as improper disposal, leaching from landfills or 
through veterinary usage and subsequent runoff of these compounds into the aquatic 
environment, which could account for these differences.  (Bound and Voulvoulis 2005; 
Ebele et al. 2017). 
Dilution plays a key role in the fate of pharmaceuticals in the aquatic environment and 
the decrease in concentrations after R1 is presumably caused by dilution away from the 
input source (Baker and Kasprzyk-Hordern 2013). Decline of pharmaceutical 
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concentrations downstream the estuary was observed more in some compounds than 
others, and as a result, is unlikely to be fully explained by dilution. Other studies have 
seen a negative correlation between pharmaceutical concentrations and salinity, which 
was not seen in this study, and could partially be explained by the input of 
pharmaceuticals throughout the estuary or other factors leading to their removal from 
surface water (Cantwell et al. 2017). Degradation of pharmaceuticals has been found to 
be a significant factor affecting the fate of pharmaceuticals and could account for these 
differences (Caracciolo et al. 2015).  Citalopram experienced the lowest decrease in 
concentration downstream, and was typically the same concentration, or higher at A5 
than A1, which could be explained by the low degradation which has been observed in 
other studies  (Metcalfe et al. 2010; Styrishave et al. 2011). Ibuprofen, paracetamol and 
trimethoprim also showed little decline in concentration beyond initial dilution after R1, 
which is consistent with what has been seen in other studies. These compounds have 
been found up to 10 km downstream from a WWTP (Bendz et al. 2005, Kay et al. 2017, 
Burns et al. 2018), and trimethoprim has even been found 200 km downstream from an 
WWTP (Tamtam et al. 2008). Further WWTPs are located within the estuary (European 
Environment Agency, 2017) which could also account for this lack in decline. Diclofenac 
on the other hand, was not detected at A3 or A5 during any of the sampling periods, but 
was found at A4.  The downstream decline of diclofenac has been found to be variable, 
with some studies finding it to be more persistent than others (Bendz et al. 2005; 
Wilkinson et al. 2017). Removal of compounds through degradation and sorption to 
sediment has been found to be highly dependent on environmental conditions, 
compound properties and sediment type. Linear regressions indicated there was a weak 
negative relationship between diclofenac concentrations and pH. Diclofenac is an acidic 
compound (pKa 4.2), and it would be expected that removal as the result of sorption to 
sediment and uptake by organisms would be higher at lower pH as the result of ionisation 
(Oh et al. 2016). The pH in the Humber ranged between 7.5 and 8.9, and as a result 
diclofenac would not be fully protonated at any of the sites. In estuaries, a positive 
correlation is often seen between pH and salinity, but not in the Humber. However, pH 
can also fluctuate as the result of mixing, biological activity, water quality and presence 
of other contaminants (Howland et al. 2000).  
4.4.1.2 Temporal Variation 
Seasonal differences of pharmaceuticals have been observed in a number of studies 
and these are often attributed to changes in usage and local environmental conditions 
(Golovko et al. 2014b; Moreno-González et al. 2014). Trimethoprim was the only 
compound to show significant temporal differences in concentrations (at sites R1-R4), 
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with average winter concentrations over double that of those during the summer months. 
Previous studies have explained the seasonal occurrence of antibiotics in winter due to 
their higher usage in those months to treat seasonal infections (Verlicchi and Zambello 
2016).  The temporal differences seen in the occurrence of trimethoprim in the Humber 
Estuary appeared to follow this pattern, as prescriptions were highest in October 2016 
to March 2017 and lowest in August 2017 (Appendix 4.4). Trimethoprim has been 
observed to have higher winter concentrations in some studies (Golovko et al. 2014b) 
but not in others (Burns et al. 2018). Burns et al. (2018) found higher levels of 
trimethoprim during spring in the Ouse (upstream from A1), which was attributed to 
hydrological differences seen between the seasons sampled. As a result, it is likely that 
the temporal differences in trimethoprim are the result of different site specific conditions 
or daily variations. Temporal variations in other studies have also been explained by 
lower temperatures, leading to lower degradation (Golovko et al. 2014a), however, input 
at R1 was highest in April. The other target compounds have exhibited temporal 
differences in other locations, but did not in the Humber. Paracetamol, for instance, has 
been detected at high concentrations in spring in some rivers but winter in others, whilst 
other studies found no temporal variations (Paíga et al. 2016; Ma et al. 2017; Burns et 
al. 2018).  
Temporal variations in the downstream pattern of pharmaceuticals were also observed, 
with the greatest variation seen at the sites furthest downstream (A3-A5). 
Pharmaceuticals were mostly absent from these sites in October, with the exception of 
ibuprofen, where concentrations were reduced. Sampling at high tide could account for 
the absence of these pharmaceuticals downstream as the result of increased dilution or 
transport of contaminants upstream (Munro et al. 2019). Pharmaceutical concentrations 
often fluctuate diurnally as the result of timing of effluent discharges from WWTPs and 
combined sewer overflows (CSOs), as well as variations in wastewater as the result of 
consumption patterns (Xu et al. 2007). To an extent, there was a pattern in the presence 
of compounds at R1 consistent with those seen downstream the estuary, so it is possible 
that the temporal variations could be the result of these daily variations, instead of 
conditions seen seasonally. The concentration of pharmaceuticals at R1 were lowest in 
October and the low input could, in part, account for the absence of compounds seen at 
sites furthest downstream (A3-A5).  Likewise, concentrations for the majority of 
compounds were highest at R1 during February where concentrations were highest at 
sites furthest downstream (A3-A5). This is further evidence that there is a difference in 
input from WWTPs. R1 is not the only site at which wastewater is discharged, but if these 
other sites exhibit the same temporal variations, then it could explain the differences 
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observed in concentrations at A3-A5. WWTP removal has been found to be less efficient 
during the winter time due to lower temperatures and decreased biodegradation, leading 
to higher concentrations in effluent (Vieno et al. 2005). At R1, concentrations for all 
compounds were lowest in August when temperatures were warmest (Appendix 4.1). 
4.4.3 UK Estuaries 
The Humber Estuary was shown to represent a worst case scenario in terms of 
pharmaceutical pollution, with all five pharmaceuticals present at relatively high 
concentrations. Of the estuaries sampled, it was the second highest impacted by 
WWTPs, with a PE of approximately 13.7 million people. The Thames, which was the 
most impacted, was the only other estuary to contain all five compounds. A higher 
presence of  pharmaceuticals is frequently seen in large urban areas due to their 
increased usage (Hong et al. 2018). With the exception of both the Humber and the 
Thames estuaries, there was no apparent relationship between the number of WWTP 
and concentrations (Table 2). The Cromarty Firth, which was the receiving water of only 
3 WWTPs (15,600 PE), exhibited similar levels of pharmaceuticals to the Humber. This 
could be explained by differences in WWTP efficiency, as technology used in WWTPs 
can greatly affect the removal of pharmaceuticals. For example, ibuprofen removal has 
been reported to be between 7% and 99% at different WWTPs (Radjenovic et al. 2007; 
Jelic et al. 2015). It is possible that the removal efficiency of WWTPs could differ between 
areas, with rural areas being less efficient as they are serving smaller populations. Rural 
areas are more likely to have a higher occurrence of septic tanks, which could contribute 
to the elevated levels seen in the Cromarty (Hanamoto et al. 2018). Whilst the Humber 
experienced the lowest concentration in August, it is possible that seasonal variations in 
population in areas like the Scottish Highlands (a tourist destination), where the Cromarty 
is located, could be responsible for these higher concentrations, increasing pressure on 
WWTPs. Pharmaceuticals in a Portuguese river have previously shown higher 
concentrations which was thought to be the result of increased summer populations 
(Rocha et al. 2014).  
The presence of pharmaceuticals is greatly influenced by environmental conditions and 
proximity of the sampling site to input sources, possibly accounting for some of the 
apparent differences in concentrations observed between estuaries. Water samples from 
different locations in the estuary were mixed together and a subsample was taken to 
obtain a snapshot of the presence of pharmaceuticals, and it is likely that these 
concentrations will vary depending on these factors. This could possibly explain the 
absence of diclofenac, which in the Humber study was frequently undetected in sites 
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downstream the estuary. Citalopram also had a low detection (50%) in estuaries, 
however, it was detected in estuaries which have the highest PE.  
There are also likely to be more complex interactions in play which further affect the 
occurrence of pharmaceuticals in estuaries and can help to explain the spatial 
differences seen. Differences in site specific conditions such as salinity profiles and 
hydrology can affect sorption processes, degradation and dilution. Undoubtedly, these 
processes, in conjunction with daily variations in rainfall and temperature, are likely to be 
responsible for differences in concentrations in estuaries between sampling periods, yet 
it is still clear that pharmaceutical pollution is a ubiquitous problem in estuaries (Tamtam 
et al. 2008). 
Ibuprofen, paracetamol, diclofenac and trimethoprim were previously monitored in the 
Mersey, Thames, Tees and Tyne estuaries (as well as Belfast Lough) in 2002 (Thomas 
and Hilton, 2004).  It was also found that ibuprofen was present at highest 
concentrations. Paracetamol, however, was not detected in any of the estuaries sampled 
in 2002, which indicates that the occurrence of this compound could be rising. A rise in 
pharmaceuticals would be consistent with what has been found in other areas. For 
example, analysis of sediment cores in the Bay of Jamaica showed an overall rise in 
pharmaceutical concentrations over time, with these concentrations doubling over the 
last decade (Lara-Martin et al. 2015). This highlights the importance of establishing 
baseline measurements of pharmaceuticals, in order to determine areas most at risk and 
therefore require continued monitoring. The Humber Estuary likely poses the greatest 
risk, particularly due to the high level concentrations of ibuprofen. Other large urban 
estuaries (such as the Thames and Severn) may also warrant a further detailed study. 
However, as seen with the Cromarty, focus on monitoring should be extended to rural 
areas as well.  
4.5 Conclusion 
All five target analytes — ibuprofen, paracetamol, diclofenac, trimethoprim and 
citalopram were detected in twelve estuaries in the UK. Diclofenac is a compound that 
has been highlighted as a potential concern, yet paracetamol and ibuprofen were 
consistently detected at higher concentrations and at levels which could be toxic to 
aquatic organisms (Vestel et al. 2016). In particular, the concentrations of ibuprofen 
measured indicates that the limited monitoring of pharmaceuticals in estuaries around 
the globe to date has not accurately quantified peak concentrations. Whilst trimethoprim 
was detected in every sample it was only present at concentrations in the low ng l-1 range. 
Citalopram was present at lowest concentrations, but also showed the least change in 
126 
 
concentration downstream the estuary. A more intensive monitoring regime of the 
Humber Estuary showed that pharmaceutical input from WWTPs is a significant source 
and could explain the overall higher concentrations of pharmaceuticals in large urban 
estuaries. Despite this, a rural estuary had the highest concentration of ibuprofen which 
may be due to lower removal at smaller rural sewage works. More detailed studies need 
to be undertaken in order to understand the complex interactions taking place in 
estuaries which could affect the fate of pharmaceuticals. 
Whilst there was little significant variation of pharmaceutical concentrations between 
sampling periods in the Humber Estuary, August typically had the lowest input from 
WWTPs and overall lowest concentrations, which is when samples were taken from 
estuaries throughout the UK. Consequently, it could be expected that pharmaceutical 
concentrations may exceed those measured. Additionally, samples were taken on a high 
tide when it would be expected that concentrations are lowest due to dilution. This study 
provides an important baseline of pharmaceutical measurements in the UK, and 
highlights ibuprofen as a compound which may warrant further assessment. This work 
provides further evidence to the growing problem of pharmaceutical pollution, 
highlighting that it is not only an urban and localised issue. 
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Abstract 
Diclofenac and metformin are two pharmaceuticals of particular environmental concern 
due to their widespread usage and presence in the aquatic environment at high 
concentrations. Estuaries have the potential to act as a sink for emerging contaminants 
such as these, putting resident and visiting biota at risk. Despite the ecological and 
commercial importance of the estuarine polychaete, Hediste diversicolor, little is known 
about the effects of pharmaceutical contamination on this species. This study 
investigates the effects of diclofenac and metformin on energy status, by evaluating 
mRNA expression of ATP synthase and c-amp activated protein kinase. H. diversicolor 
were exposed to either 100 ng l-1 or 1µg l-1 of either diclofenac or metformin for 7 days.  
ATP synthase expression was significantly higher in individuals exposed to the higher 
level of metformin than the other treatments. No other significant differences were seen 
in any of the other treatments. This study reveals that environmentally relevant 
waterborne concentrations (1 µg l-1) of metformin have the potential to induce 
environmental stress in H. diversicolor individuals and the requirement to sustain high 
energy levels could have long term consequences on physiological processes.  
5.1 Introduction 
Many compounds are bioavailable to aquatic organisms and some compounds (such as 
diclofenac and ibuprofen) have been found in the tissues of aquatic organisms, whilst 
others have not. Both of these compounds were present in the tissues of mussels 
(Mytilus galloprovincialis) sampled from the field and after exposure under laboratory 
conditions, whilst ketoprofen and paracetamol were not (Mezzelani et al. 2016). 
Pharmaceuticals may pose a risk to non-target organisms, as they are designed to be 
biologically active, and have the potential to illicit a response in non-target organisms 
which possess conserved drug targets (Gunnarsson et al. 2008). In some species, these 
targets may have a different physiological role, causing effects not seen in humans.  An 
example of this is diclofenac, which caused the decline of vultures (Gyps coprotheres) in 
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Pakistan as the result of renal toxicity, despite being used in veterinary medicine without 
the same effects (Oaks et al. 2004). This increased sensitivity is thought to be due to the 
differences in cytochrome P450 enzymic pathways (Naidoo et al. 2010). Diclofenac is a 
widely available over the counter (OTC) non-steroidal anti-inflammatory drug (NSAID), 
which is frequently detected in surface water at hundreds of ng l-1, with peak 
concentrations as high as 18 µg l-1 (Hughes et al. 2013). In vertebrates, diclofenac inhibits 
cyclooxygenase (COX), which is responsible for the formation of prostanoids (Gan 
2010). There are two isoforms in vertebrates, COX I which is responsible for the baseline 
levels of prostaglandins involved in processes such as thermoregulation, ovulation, 
sexual behaviour, homeostasis, ion transport and kidney filtration required for 
physiological processes, and COX II which produces prostaglandins at the point of an 
injury (Gan 2010). These isoforms are also present in invertebrates, and there is 
evidence that many of these functions are conserved (Ruggeri and Thoroughgood, 
1985).  
Metformin is among the top 10 drugs prescribed with annual prescriptions in the millions 
in USA and Europe (Marshall 2017). It is of environmental concern, because of the 
amount consumed, its increasing usage,  and the fact that it is not heavily metabolised 
and is excreted via urine relatively unchanged (Oosterhuis et al. 2013; Xu et al. 2018). 
As a result, it should be considered a priority substance. Recent studies have detected 
metformin at high concentrations in wastewater effluent (21 µg l-1; Scheurer et al. 2009) 
and surface water (2.5 µg l-1; Bradley et al. 2016; Burns et al. 2018).  Metformin is 
prescribed for type II diabetes, and is used to regulate glucose levels through the 
activation of c-AMP activated protein kinase (AMPK) leading to inhibition of hepatic 
glucogenesis and increased glucose uptake in muscles (Joshi 2005). 
H. diversicolor are polychaetes, which are a key species ubiquitously present in estuaries 
globally (Scaps 2002). They are one of the most important prey items in estuaries, 
providing food for a variety water birds, such as the grey plover (Pluvialis squatarola) 
and fish species such as sole (Solea solea; Cobra et al. 2000; Rosa et al. 2008). H. 
diversicolor are also of commercial interest and are harvested from estuarine sediment 
and sold as fishing bait (Virgilio and Abbiati 2004). To the authors’ knowledge, only two 
studies (Maranho et al. 2014, 2015) have previously studied the effects of 
pharmaceuticals on this species, however, they are well studied for other groups of 
substances such as metals (He et al. 2019), nanoparticles (Buffet et al. 2014)  and 
pesticides (Scaps et al. 1997). Additionally, they are easily maintained in the laboratory, 
and sensitive to contaminants, which could make them a useful bioindicator of sublethal 
pharmaceutical pollution in estuaries (Scaps et al. 2002; Maranho et al. 2014).  
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Few studies have looked at the effects of pharmaceuticals in estuarine or marine 
species, and studies are often limited to short exposures and standard endpoints (Gaw 
et al. 2014; Fabbri and Franzellitti 2016). The objective of this study was to assess the 
effects of diclofenac and metformin at environmentally relevant concentrations on H. 
diversicolor energy status, through the evaluation of ATP Synthase (ATPS) and AMPK 
mRNA expression.  
Energy status has previously been used an indicator of environmental stress and energy 
reserves have been found to be lower in H. diversicolor in contaminated estuaries (Durou 
et al. 2007). Energy levels have been found to naturally vary in this species as they often 
live at the edge of their tolerance zone, and lower temperatures, pH and salinity can lead 
to increased metabolic rate (Barrick et al. 2016; Freitas et al. 2016). ATP is an important 
source for normal physiological functions such as growth and reproduction, and as a 
result, energy stores are often high in mature individuals, particularly close to spawning 
(Durou and Mouneyrac, 2007). As a result, exposure to environmental stressors which 
lead to increased ATP expenditure can lead to a reduction in these processes, which are 
essential for survival. It is therefore an important endpoint for assessment as exposure 
to pharmaceuticals could potentially impact H. diversicolor physiology.   
5.2. Materials and Methods 
5.2.1 Sample collection and maintenance 
H. diversicolor individuals were collected during low tide at Paull, East Riding of 
Yorkshire, U.K. (53°43’ North, 0°14’ West) in October 2016. Worms were kept in 
sediment until return to the lab, where individuals were rinsed and placed in aquaria 
containing 2.5 litres artificial seawater (20 ppt; Tropic Marin Synthetic Sea Salt) and coral 
sand. Coral sand was chosen as a substrate for H. diversicolor as it allows them to 
burrow, whist also ensuring that it is free from environmental contaminants. No more 
than 15 individuals were placed in each container in order to allow sufficient space and 
were left for 4 weeks to acclimate. Worms were maintained at a photoperiod 12:12 hours 
(light: dark), constant temperature (13°C ± 0.6), pH (7.9 ± 0.1), salinity (22 ppt ± 1) and 
oxygenation level (>89% saturation) under constant aeration. A photoperiod of 12:12 
was chosen, as H. diversicolor were collected in early October when there is between 
11 and 12 hours of daylight (UK Hydrographic Office, 2019).  Feeding and water changes 
were carried out on alternate days; individuals were fed with ZM flake fish food, feeding 




5.2.2 Exposure assays 
Exposure assays were conducted under semi-static conditions for 7 days. Ten 
individuals (mean length 40.11 mm ± 17.90 SD, mean mass 90.46 mg ± 42.82 SD; no 
statistically significant difference between treatment) were placed in each treatment: 
either control, low concentration of metformin or diclofenac (100 ng l-1), or high 
concentration of metformin or diclofenac (1 µg l-1). These concentrations were chosen 
as they reflect median and peak concentrations of these compounds measured in 
surface waters (Yang et al. 2011; Hughes et al. 2013; Meador et al. 2016; Burns et al. 
2018). Four replicates of each treatment were maintained at each exposure. A standard 
solution of metformin hydrochloride (≥98%; Sigma-Aldrich, Dorset, UK) or diclofenac 
sodium (≥98.5%; Sigma-Aldrich, Dorset, UK) were made up at the beginning of the 
exposure. Water changes were carried out on days 3 and 5, where 2.5 litres of water 
from each treatment was renewed with 20 ppt seawater and with the relevant 
pharmaceutical added to each treatment after each water change. Water quality 
measurements were carried out daily to ensure temperature, salinity, pH and 
oxygenation level remained constant. The assays were terminated after 7 days and 
individuals were removed from the treatments and placed at -80°C to euthanise them. 
Each individual was divided into thirds; one third was reserved for tissue chemical 
analysis and two thirds for mRNA expression placed in 0.4 mL RNAlater® Stabilisation 
Solution (Thermo Fisher Scientific, Loughborough, UK) prior to storage at -20°C. 
5.2.3 mRNA isolation and characterisation 
The total RNA was extracted from 10 mg H. diversicolor tissue using the High Pure RNA 
Tissue Kit (Roche, Burgess Hill, UK) including DNase I treatment (180 U per sample) 
according to manufacturer’s instructions. Total RNA was quantified using a Qubit 1.0 
Fluorometer (Life Technologies, UK). cDNA synthesis utilised the Transcriptor High 
Fidelity cDNA Synthesis Kit reagents (Roche, Burgess Hill, UK) and was carried out 
according to manufacturer’s instructions. A total of 20 ng RNA was used in each reaction 
with 2 µl random hexamer primers (6 µM); following pre-incubation, Transcriptor high 
fidelity reaction buffer (containing RT reaction buffer, 250 mM Tris/HCl, 150 mM KCl, 40 
mM MgCl2), RNase inhibitor (0.02 U) and dNTP mix (100 µM) were added to create a 
final volume of 20 µl. Conditions for cDNA synthesis were as follows: pre-incubation for 
10 min at 65ºC followed by the cDNA reaction for 10 min at 25 °C and 60 min at 50 °C. 





5.2.4 Primer design 
Primers were designed for the 18S mRNA gene, to act as a housekeeping gene, from 
H. diversicolor (KC686629.1) using the Primer-Blast tool 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/). Degenerate primers were then 
designed for the housekeeping gene, elongation factor 1 (EF1), and the targeted genes 
of interest: AMPK and ATPS from a nucleotide alignment using Clustal Omega 
(http://www.ebi.ac.uk/Tools/msa/clustalo/; Appendix, 5.1). Primer details for all genes 
can be seen in Table 5.1.  
Table 5.1: Primers used for gene isolation of 18S, EF1, AMPK and ATPS from H. diversicolor 
 
5.2.5 PCR Amplification 
All PCR reactions contained 17.25 µl molecular grade water, 0.5 µl 40mM dNTP mix, 
0.25 µl (0.005 U) Q5® High Fidelity DNA polymerase (New England BioLabs, 
Massachusetts, USA), and 5 µl  Q5®  buffer (containing 2 mM Mg) (New England 
BioLabs, Massachusetts, USA). Thermal cycling conditions were as follow: 94°C for 30 
sec, followed by 35 cycles of denaturation at 94°C for 30 sec, annealing at 55°C for 30 
sec and extension at 72°C for 2 min.  PCR products were separated and visualised by 
agarose gel electrophoresis. EZ Seq Sanger sequencing service (Macrogen Europe, 
Amsterdam, The Netherlands) was used for DNA sequencing. 
Sequence data were edited, aligned and formed into sequences using BioEdit (Version 
7.0.9.0). Sequence identities were investigated using BLAST searches 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi) to perform nucleotide sequence comparison 
(blastn) and to compare the translated nucleotide sequences against the protein 
database (blastx) to identify protein domains. Sequences were aligned and used to 
perform phylogenetic analysis of amino acid sequences in Mega 5.2. Phylogenetic 
analysis consisted of Maximum Likelihood Analysis with the Nearest Neighbour 




5.2.6 Total quantitative real-time PCR analysis 
5.2.6.1 Amplification using quantitative real-time PCR analysis 
The total RNA was extracted from 10 mg H. diversicolor tissue from each of the 
treatments as previously described. RNA concentrations were quantified using a Qubit 
1.0 Fluorometer (Life Technologies, UK) and cDNA was generated using 20 ng RNA with 
Transcriptor High Fidelity cDNA Synthesis Kit reagents (Roche, UK) as previously 
described. Reactions were performed on a CFX96 Real Time PCR Detection System  
(BioRad, Hemel Hempstead, UK) and contained 10 µl FastStart Universal SYBR Green 
Master Mix (PrimerDesign, Camberley, UK), 7 µl of molecular-grade water,  2 µl each 
primer (Table 5.2) and 1 µl cDNA. All samples were analysed in duplicate and template 
negative reactions were carried out for each of the reactions.  
5.2.6.2 Primer optimisation and assay performance 
The optimisation of qPCR assays is required to ensure the validity and accuracy of gene 
expression evaluation. Primers were designed from the sequences isolated from H. 
diversicolor individuals outlined in section 5.2.5 using the NCBI primer-blast tool, and 
optimised for qPCR assays as described below. qPCR products were separated and 
visualised using gel electrophoresis (Figure 5.1) and sent to EZ Seq Sanger sequencing 
services.  Identity of isolated sequences were confirmed through alignment with 
previously aligned sequences and BLAST searches as described previously.  
 
Figure 5.1: Image of a 1% agarose gel electrophoresis of qPCR products. Lane 1, EF1 
housekeeping gene; Lane 2, 18S housekeeping gene; Lane 3, ATPS; Lane 4, AMPK; Lane 5, 
100 bp ladder. Negative controls were run on a separate agarose gel (Appendix 5.2). 
Primer specificity was determined by the melt peaks generated by the reaction, and the 
absence of other products. Firstly, five different primer concentrations were investigated: 
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100 nM, 200 nM, 300 nM, 400 nM and 500 nM with the conditions described previously. 
The primer pair with the lowest Ct (threshold value) and a melt curve only showing a 
single distinct product was chosen for subsequent qPCR assays (Table 5.2). Ct values 
greater than 40 were assumed to be due to low efficiency.  
To test the efficiency, accuracy and sensitivity of qPCR reactions, a standard curve was 
performed using a 1:10, 1:5 or 1:2 serial dilution of cDNA, subjected to the same 
conditions as previously described. To obtain a standard curve, the Ct values of each 
dilution were plotted against cDNA dilution. Primer efficiencies, assessed from these 
standard curves and those which had a value between 90–110% were chosen for qPCR 
assays in accordance with the MIQE guidelines (Bustin et al. 2009). The primers which 
met these guidelines are outlined in Table 5.2 and were used in qPCR based assays to 
determine expression of ATPS and AMPK of H. diversicolor exposed to pharmaceuticals. 
 
Table 5.2: Primers used for qPCR amplification of housekeeping genes and genes of interest 
from H. diversicolor 
 
5.2.7 Statistical Analysis 
Statistical analysis was carried out in R studio (1.0.136), using packages PMCMR and 
ggplot2 (Pohlert 2014; Wickham 2016). In order to determine if there was a statistically 
significant difference between the size and mass of H. diversicolor individuals between 
treatments, a one-way ANOVA test was used. The stability of housekeeping genes was 
checked by carrying out ANOVAs, with 18S selected as a housekeeping gene for data 
analysis.  To evaluate the relative gene expression, the 2-ΔΔCt method was used 
(Schmittgen and Livak 2008). Normalised values were expressed as fold difference 
compared to normalised control values, and used to calculate the degree of induction or 
inhibition. This method was chosen as normalisation to the reference genes can correct 
and compensate for sample to sample variation of the RNA input. Statistical analysis 
was carried out on 2-ΔCt values to determine if there was statistically significant difference 
in expression between treatments according to Livak and Schmittgen (2001) using 
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Kruskall-Wallis. A post-hoc Nemenyi test was conducted to determine differences 
between treatments.  
 
5.3 Results 
5.3.1 Isolation and characterisation of genes 
5.3.1.1 Target Genes 
A partial 199 bp ATPS sequence was isolated, sharing 91% similarity with Nereis 
vexillosa ATPS (DQ087492.1) sequence. The translated nucleotide sequence showed 
similarity with protein sequences from other species (Figure 5.2a). Comparison did not 
identify any specific conserved domain, but comparison of N. vexillosa protein sequence 
identified the ATPase beta subunit binding domain and conserved Walker A and Walker 
B motifs (Figure 5.2a). Phylogenetic analysis revealed that H. diversicolor was clustered 
with other annelids, N. vexillosa (AAZ30692.1) and Nephasoma pellucidum 
(ADW27397; Figure 5.3a).  
A partial 205 bp AMPK sequence was isolated, sharing 86% similarity with Schistosoma 
japonica AMPK (GU130533.1), and the translated nucleotide showed similarity with 
protein sequences from other species (Figure 5.2b). A comparison of H. diversicolor 
translated nucleotide sequence identified the serine/threonine protein kinase domain, as 
well as protein domains of the protein kinase superfamily, of which AMPK is a member. 
Phylogenetic analysis revealed that H. diversicolor was clustered with another annelid 
Hydroides elegans (BAE19914.1; Figure 5.3b). It is also closely related to vertebrates 
and arthropod species.  
5.3.1.2 Housekeeping Gene 
 A 511 bp partial EF1 sequence was isolated, sharing 97% similarity with Hediste 
japonica EF1 sequence (AB003702.1). The translated nucleotide showed similarity with 
protein sequences from other species, and elongation factor Tu GTP binding domains 
(GTP_EFTU) were identified (Figure 5.2c). Protein domains characteristic of EF1 alpha 
were also identified. Phylogenetic analysis revealed that the isolated partial H. 
diversicolor EF1 amino acid sequence was clustered with another annelid from the same 
genus H. japonica (BAA25731.1), but was more distantly related to another annelid, N. 










Figure 5.2: Alignment of H. diversicolor translated nucleotide sequence with multiple species. 
Dashes represent gaps in the alignment and asterisks represent homology. Shaded boxes show 
conserved domains and grey boxes show other conserved features. Alignments were cropped 
and are not shown in full. (a) EF1 alignments with A. aurita, O. mykiss and H. japonica 
(BAA25731.1) (b) ATPS alignments with N. vexillosa (AAZ306902.1), N. pellucidum 





Figure 5.3: Phylogenies of full and partial amino acid sequences for (a) ATPS (b) AMPK  and (c) 
EF1 rooted with Alitta virens elongation factor 2. Shaded boxes represent species groups: green 




5.3.2 Quantitative real-time PCR optimisation 
Five primer concentrations were tested in order to determine the optimal primer 
concentrations. 100 nM 18S and AMPK, 200 nM ATPS, and 300 nM EF1 resulted in the 
lowest Ct value and unique dissociation temperature peak according to melt curves 
(Figure 5.4ii). PCR amplification efficiency for reference and target genes ranged from 
90% (18S) to 110% (EF1), indicating that all of the primers had high specificity (Figure 
5.4iii). The serial dilution of these genes resulted in an R2 > 0.96 for all genes, showing 
that non-diluted cDNA used in qPCR assays were within this range (Figure 5.4i).  
 
Figure 5.4: (i) Standard curves (ii) melt peaks and (iii) qPCR amplification generated from 




5.3.3 Expression of ATPS 
After 7 days of exposure, only H. diversicolor exposed to the metformin treatment with a 
nominal concentration of 1 µg l-1 showed a significant difference from the control in the 
expression of ATPS (Kruskal-Wallis, χ2 = 19.271, p < 0.001), which led to an increase in 
expression (Figure 5.4). The relative expression of ATPS was also significantly higher in 
this treatment than the diclofenac treatments, however there was no statistically 
significant difference between metformin treatments (Figure 5.5).  
 
Figure 5.5: Fold change (2-ΔΔCt) in expression of ATPS in H. diversicolor exposed to  diclofenac 
high (1 µg l-1 nominal concentration; n = 22), diclofenac low (100 ng l-1; n = 28), metformin high 
(1µg l-1 nominal concentration; n = 28) or metformin low (100ng l-1 nominal concentration; n = 23) 
relative to control control (n = 28). Error bars represent standard deviation calculated as outlined 
in Livak and Schmittgen (2001). Different letters denote exposure groups that are significantly 








5.3.4 Expression of AMPK 
After 7 days of exposure, there was no significant difference in the expression of AMPK 
between any of the treatments (Kruskal-Wallis χ2 = 2.0641, p > 0.05; Figure 5.6). 
 
Figure 5.6 Fold change (2-ΔΔCt) in expression of AMPK of H. diversicolor exposed to either 
diclofenac high (1 µg l-1 nominal concentration; n = 22), diclofenac low (100 ng l-1 nominal 
concentration; n = 23), metformin high (1µg l-1 nominal concentration; n = 27) or metformin low 
(100ng l-1 nominal concentration; n =23) relative to control (n = 21). Error bars represent standard 
deviation calculated as outlined in Livak and Schmittgen (2001). 
5.4 Discussion 
5.4.1 RNA isolation and assay optimisation 
One partial housekeeping sequence (EF1) and two target sequences (ATPS and AMPK) 
were isolated from H. diversicolor as demonstrated by GenBank database comparisons, 
multiple species amino acid alignments (Figure 2) and phylogenetic trees (Figure 3). The 
target genes, ATPS and AMPK were 91% and 86% similar to other related genes and 
the phylogenetic analysis showed clustering of the target genes with other annelid 




Primer efficiencies for 18S, EF1, ATPS and AMPK were 90 – 110% efficient and 
concentrations of cDNA fell within the standard curves generated. Analysis of gene 
transcripts was calculated based on relative change in mRNA expression of a reference 
and target gene, so it is essential that these are consistent and reliable. RNA quality was 
not measured and partially degraded RNA could have resulted in poor reactions and 
unreliable expression results (Vermeulen et al. 2011). However, steps were taken to limit 
RNA degradation such as appropriate storage of samples in RNA later and storage of 
RNA at -80ºC. Additionally, two technical replicates were conducted for each of the 
sample reactions, and those which had a difference in Ct value greater than 0.5 were 
not included in the final analysis. Ct values of EF1 differed significantly between 
treatments and as a result was not a suitable housekeeping gene, and ΔCt values were 
calculated as relative expression between target gene and 18S.  
5.4.2 Pharmaceutical exposures  
The effects of metformin and diclofenac at low nominal (100 ng l-1) and high nominal (1 
µg l-1) concentrations on mRNA expression after 7 days of exposure were investigated 
in the polychaete H. diversicolor.  Following controlled exposure for 7 days, the high 
nominal dose (1 µg l-1) of metformin was the only treatment to alter expression of ATPS, 
and none of the treatments had a significant effect on AMPK. No mortalities were 
observed in these exposures, indicating that these compounds only have the potential 
for sub-lethal toxicity. It was not possible to analyse water samples from exposures for 
pharmaceutical concentrations, and as a result, it is only possible to express treatment 
doses as nominal concentrations. It would have been beneficial to take these 
measurements in order to confirm actual exposure concentrations in order to better 
interpret the results (Harris et al. 2014). Semi-static exposures were conducted, which 
could result in a decrease in water concentration between dosing and replenishing water 
as the result of degradation or in the rise in concentrations as the result of repeated 
dosing. All exposure media was replenished every other day in order to minimise these 
effects and try to ensure stable exposure concentration for the duration of the 
experiment.  
Whilst there was no statistically significant difference in the size of H. diversicolor 
individuals between treatments, there was a difference within-treatments, which could 
account for the high variation seen in the expression of ATPS and AMPK (Harris et al. 
2014). The uptake of pharmaceuticals could differ between individuals of different sizes 
or maturity, which could lead to this variation in gene expression. Additionally, difference 
in size indicates differences in maturity which can lead to differences in energy status 
and can also account for variability (Durou and Mouneyrac 2007). At the end of the 
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exposures, H. diversicolor were divided into thirds, with two thirds reserved for qPCR 
analysis and one third for tissue analysis. The portion of the worm (i.e. head, middle or 
tail) was randomly divided for these analyses, which could account for some of the 
variability seen in gene expression. Different organs will have different metabolic 
requirements and energy is often partitioned to tissue and organs based on this need 
which can lead different expression between the anterior and posterior end. In fish, 
partitioning has of energy has been found to be allocated differently in mature and 
reproducing individuals, and will also differ between sex (Patterson et al. 2004). The 
uptake and accumulation of pharmaceuticals has also been found to be tissue-
dependent in fish, and if this is the same for H. diversicolor, it could help explain these 
variations. (Zhao et al. 2015) 
5.4.3 Metformin 
In vertebrates, the primary function of metformin is to reduce glucose output in the liver 
and secondarily to stimulate glucose uptake in the muscles (Joshi 2005). The primary 
target of metformin in humans has been debated (Viollet et al. 2012). It was originally 
thought AMPK was the primary target, but it has also been suggested that the activation 
of AMPK is the result of specific inhibition of respiratory chain complex I (Bridges et al. 
2014; Fontaine 2014). Metformin has been shown to activate AMPK and exert a similar 
therapeutic effect in non-target vertebrates as humans, causing the inhibition of hepatic 
glucogenesis in fish (Panserat et al. 2009) and the activation of glucose uptake into fish 
muscle (Magnoni et al. 2012).  
The pathway of metformin in invertebrates is not currently known but there is evidence 
that it still acts as an AMPK activator (Sheng et al. 2012). AMPK is highly conserved and 
has been found to maintain energy budgets in other invertebrates including crustaceans 
and molluscs (Sokolova et al. 2012). Metformin has also been found to activate AMPK 
in Daphnia (Sheng et al. 2012).  AMPK is responsible for regulating energy budgets in 
response to environmental or nutritional stress (Bridges et al. 2014). It is activated by 
limited ATP or increased ATP depletion. Whilst AMPK expression did not differ between 
treatments, ATPS expression was higher in the high metformin treatment indicating that 
metformin is causing stress in H. diversicolor leading to depletion of ATP. It is possible 
that longer exposure or higher concentrations could lead to AMPK activation as the result 
of ATP synthesis not being able to keep up with requirements. H. diversicolor individuals 
were collected from Paull (A1) where other pharmaceuticals were detected in surface 
water in Chapter 4, and Metformin has been detected in tributaries of the Humber (Burns 
et al. 2018). It is therefore plausible that metformin may be present at this site, and could 
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affect the expression of these genes as individuals may already be stressed, or may 
have acclimatised to the concentrations of these compounds.  
The effect of metformin on ATPS, a general biomarker for stress could be indicative of  
other negative effects occurring (Sokolova et al. 2012). Exposure to metformin has also 
caused reproductive changes including causing lower fecundity in intersex minnows (P. 
promelas; Niemuth and Klaper 2015), as well as increasing vitellogenin in mussels, 
(Mytilus edulis; Koagouw and Ciocan 2018). There are conflicting reports in the literature 
as to whether this is an expected (Crago et al. 2016) or unexpected (Sumpter et al. 2016) 
mechanism in non-target organisms. A therapeutic effect of metformin in humans is to 
reduce the androgen effects of polycystic ovaries to increase ovulation, however, the 
mechanism of action is poorly understood (Spritzer 2014). It is thought that this use is 
the result of lowered insulin, but it is also thought that metformin could also directly affect 
steroidogenesis (Lashen 2010). Sexual steroids also play a vital role in the reproduction 
of polychaetes including H. diversicolor, so this and depleted energy reserves have been 
shown to affect reproductive abilities in contaminated estuaries (Durou and Mouneyrac 
2007). As a result, further investigation into the pathways and effects of metformin on H. 
diversicolor reproduction is warranted.  
Many of the reproductive effects seen in experimental studies, were the result of 
exposure to very high concentrations of metformin to mussels (M. edulis; 40 µg l-1; 
;Koagouw and Ciocan, 2018) and fathead minnows, Pimphelas promelas (40 µg l-1; 
Niemuth et al. 2014, Niemuth and Klaper 2015). No differentiation was made in the 
inclusion of males and females in the present study, and if metformin does impact the 
reproductive system, it will affect each sex differently. Concentrations of 1 µg l-1 were 
seen to increase vitellogenin expression in juvenile fathead minnows, but no changes 
were seen at levels up to 100 µg l-1 in adults (Crago et al. 2016). This is the only study 
to investigate the age-dependent effects of metformin and introduces uncertainty 
surrounding the variability seen in mRNA expression, and whether this is natural 
variation or as the result of the range of sizes used in the exposures. The effects of 
metformin on glucose homeostasis in trout (Oncorhynchus mykiss) were seen after being 
fed or injected metformin at doses of approximately 50 mg kg-1 (Panserat et al. 2009; 
Polakof et al. 2009; Polakof et al. 2010). This is reflective of the large quantities of 
metformin (approximately 2.5 g per day), which are required to have a therapeutic effect 
in humans (Rena et al. 2013). Although metformin has been detected in surface waters 
at high concentrations in comparison to other compounds, the concentrations used in 
these studies (1 – 100 µg l-1) are similar to those seen in wastewater influent (2 – 129 µg 
l-1) and effluent (1.2 – 100 µg l-1), and those which have been measured in surface water 
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are much lower (< 3µg l-1; Bradley et al. 2016, Briones et al. 2016, Burns et al. 2018). 
Metformin has frequently been detected in surface water at approximately 1 µg l-1 
(Scheurer et al. 2012), but averages are far lower than this (Briones et al. 2016).  The 
effect on ATPS expression seen in the current study suggests that metformin could have 
an effect at peak environmental concentrations. Additionally, the potential role of 
metformin as an endocrine disruptor are concerning and this highlight the need for further 
investigation into whether these effects can be seen at concentrations regularly detected 
in the environment.  
5.4.4 Diclofenac 
Diclofenac didn’t have an effect on AMPK or ATPS expression at either low nominal (100 
ng l-1) or high nominal (1 µg l-1) concentrations. Similarly to mRNA expression in the 
metformin treatment, there was high within-treatment variability. However, size 
differences of H. diversicolor were non-significant between treatments so it is possible 
that these endpoints are not affected by diclofenac. These endpoints have not previously 
been measured in non-target species, however, there is some evidence that diclofenac, 
and other acidic nonsteroidal anti-inflammatories (NSAIDs) may activate AMPK in 
humans and mice, and it is thought that this could contribute to the anti-inflammatory and 
analgesic properties (King et al. 2015). Additionally, AMPK has been observed to be 
activated in mussels exposed to municipal effluent (Goodchild et al. 2015). Although it is 
a target of metformin, AMPK can also be a sign of environmental stress as the result of 
depleted energy reserves.  
Although H. diversicolor is a key species in estuarine environments, and has been 
suggested as a bioindicator of contaminated estuaries, few studies have researched the 
impact of pharmaceuticals on this or similar species (Catalano et al. 2012; Maranho et 
al. 2014). H. diversicolor exposed to ibuprofen has been found to result in the inhibition 
COX, leading to increased mitochondrial energy consumption and neuroendocrine 
effects (Maranho et al. 2015). Diclofenac is generally considered to be more toxic to 
organisms than other NSAIDs as evidenced by both acute (Sanderson and Thomsen 
2009; Vestel et al. 2016) and chronic toxicities (Du et al. 2016). Diclofenac has been 
shown to inhibit COX activity and prostaglandin synthesis in other aquatic invertebrates 
such as the mussels Mytilus galloprovincialis, and Perna perna (Courant et al. 2017; 
Fontes et al. 2018). As a result, it is also possible that diclofenac could inhibit COX 
activity in H. diversicolor, but this has not been studied in aquatic annelids. 
Prostaglandins not only play a role in inflammation response, but also in other 
physiological processes including osmoregulation, homeostasis and reproduction 
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(Ruggeri and Thoroughgood 1985). Most invertebrates only have one isoform of this 
enzyme, which is responsible for all of these processes, and as a result can be affected 
by diclofenac (Heckmann et al. 2008; Rowley et al. 2005). In vertebrates, diclofenac 
selectively inhibits COX-II, however, it is unknown how these base-line physiological 
processes will be affected in H. diversicolor. Interruption of these processes could lead 
to stres and increased ATP demand in order to survive. The variation seen in these 
experiments, could indicate that the toxicity of diclofenac could be dependent on other 
factors such as age, sex and size due to differences in metabolic requirements and prior 
exposure to contaminants as previously discussed.  
Diclofenac has been shown to cause oxidative stress in the zebra mussel, Dreissena 
polymorpha (Quinn et al. 2011), alter reproduction in mussels (Mytilus spp;. Schmidt et 
al. 2011), reduce hatching success in Daphnia magna (Lee et al. 2011), impact 
osmoregulation in the edible crab, Carcinus maenas (Eades and Waring 2010), and 
cause neurotoxic effects in M. galloprovincialis (Gonzalez-Rey and Bebianno 2012).  It 
has also been found to affect the motility of  annelid Arenicola marina sperm at 
concentrations of 100 ng l-1 (Mohd Zanuri et al. 2017). H. diversicolor reproduce, by 
males spawning into the water and females bringing sperm into the burrows where they 
have buried their eggs, diclofenac polluted waters could negatively affect this (Scaps 
2002). These studies are evidence that diclofenac can cause biological changes in 
aquatic organisms, and this has often been demonstrated to occur at concentrations 
similar to those found in surface water (Acuña et al. 2015). However, there has been a 
focus on the use of fish and bivalves, and it would be beneficial to improve information 
to account for the effects of diclofenac outside of these species.    
5.5 Conclusion 
This is the first study to investigate the effects of metformin or diclofenac on the estuarine 
polychaete H. diversicolor. Metformin was found to increase the expression of ATPS at 
the high nominal concentration (1 µg l-1) and the requirement to sustain high energy 
levels could have long term consequences in the environment. Metformin failed to alter 
the expression of AMPK, the target of metformin in vertebrates. As a result, there is a 
need for further investigation of metformin pathways in aquatic invertebrates, particularly 
at environmentally relevant concentrations. This could help to interpret the results seen 
in this study and determine how factors such as maturity and sex could affect toxicity of 
metformin and diclofenac.  The potential impact of metformin to biota is particularly 
concerning, as metformin in now one of the most widely used drugs globally and if recent 
trends continue, usage will rise leading to higher concentrations in surface water 
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(Oosterhuis et al. 2013). Diclofenac on the other hand, did not activate ATPS or AMPK 
at either concentration, indicating that diclofenac does not affect the energy balance in 
H. diversicolor. There is also a need to further investigate the effects of both these 
compounds at longer exposures in order to further understand the potential implications 
to long-term chronic exposures in the environment. 
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Chapter 6: Discussion  
The literature review in Chapter 1 highlights that there has been an increasing interest in 
the occurrence of pharmaceuticals in the aquatic environment. Reviews have succinctly 
covered the presence of these compounds in fresh (Hughes et al. 2013) and marine 
waters (Fabbri and Franzellitti 2016), but studies on the occurrence of pharmaceuticals 
in estuaries lag behind these environments. Estuaries act as a site of interaction between 
the freshwater and marine environments and play a role in the fate of pollutants (Ridgway 
and Shimmield 2002). They provide an important habitat for many organisms and provide 
commercially important resources such as food, transport and recreation, and as a result 
the presence of pollutants can have negative consequences (Monserrat et al. 2007). 
There is evidence that pharmaceuticals are biologically active, and have the potential to 
impact non-target organisms (Santos et al. 2010). However, there is still uncertainty over 
the pathways of these drugs and at which levels an effect will occur. The overarching 
aim of this thesis was to address these gaps, which were further discussed in Chapter 
1, and gain a deeper understanding surrounding the occurrence and effects of 
pharmaceuticals in estuaries, specifically by (1) assessing if prioritisation schemes 
accurate identify priority compounds (2) identifying pharmaceuticals of environmental 
concern (3) measuring the concentrations of pharmaceuticals and the spatial and 
temporal variations in their occurrence, and (4) determining their effects on non-target 
organisms.  
Chapters 3-5 have been separated by research themes, and the results and implications 
have been discussed within each of the preceding sections. This chapter of the thesis 
aims to collate the findings from each of these chapters and discuss them as a whole 
within the context of the original aims.  
 
6.1 Research Synthesis 
6.1.1 Evaluation of prioritisation schemes 
The prioritisation exercises carried out in Chapters 2 and 3 identified a range of 
compounds which have the potential to enter the environment and pose a risk to the 
environment. Chapter 3 included a more detailed assessment, where differences in 
predicted environmental concentration (PEC) calculations evaluated against each other, 
measured environmental concentrations (MECs), and the existing literature to determine 
the efficacy of the different methods in protecting the environment. PECA which included 
165 
 
excretion rates and critical environmental concentrations (CECs) were suggested as 
being the most conservative of the schemes. Whilst these two schemes may provide a 
useful tool for an initial assessment, they are not appropriate for all situations, and could 
be further improved to ensure compounds are not overlooked or unnecessarily flagged 
as a priority when they are not. Whichever methods are used, it is important to take a 
holistic approach to combine environmental and effects data, as some compounds, such 
as ethinylestradiol will illicit a biological response at concentrations much lower (less than 
10 ng l-1) than that of other compounds (Länge et al. 2010). Despite the limitations of the 
assessed prioritisation methods, antidepressants, antibiotics, ibuprofen, metformin, 
allopurinol and candesartan were not only highlighted as compounds of concern in 
Chapters 2 and 3, but also by the existing literature, emphasising the importance of 
directing research towards these areas (Linert et al. 2007; Besse et al. 2008, Kostich 
and Lazorchak 2008, Roos et al. 2012, Daouk et al. 2015).  
The largest differences arose in the results between the two chapters due to the inclusion 
of more compounds in chapter 2. Carbamazepine for instance, was ranked as the 65th 
most used drug in the UK, so as a result was not included in the assessments carried 
out in Chapter 3. Carbamazepine is one of the most well-studied compounds in existing 
freshwater literature and has been found at concentrations up to 11 µg l-1, and thought 
to cause harm at environmental concentrations (Martin-Diaz et al. 2009; Camacho-
Muñoz et al. 2010; Hughes et al. 2013). This shows it is important to consider that the 
number of compounds included in these schemes, yet a large variation (12 – 3000 
compounds) has been seen in the number of compounds included in previous 
prioritisation exercises (Sanderson et al. 2004; Donnachie et al. 2016). The number of 
compounds included must be enough to adequately protect the environment, but it also 
must be within time and financial resources to feasibly conduct the prioritisation exercise. 
It would therefore appear, that the inclusion of only 50 compounds in a broad assessment 
such as the one carried out in Chapter 3, does not strike this balance. In the context of 
this study, the excretion rates, cmax and logKOW values needed to calculate PECA and 
CECs are relatively easy to obtain, and therefore including more compounds would allow 
a more robust assessment, whilst also being feasible in terms of time and resources 
needed.   
Whilst the rankings of compounds by PECs appeared to accurately portray relative 
concentrations, they were largely inaccurate at predicting environmental concentrations. 
Comparing MECs to PECs can be challenging, as many of these measurements were 
limited by sample numbers and study locations. As is evidenced by the existing literature 
and results from the monitoring study in Chapter 4, there are many natural variations in 
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the occurrence of pharmaceuticals (Paíga et al. 2016; Cantwell et al. 2018; Munro et al. 
2019). The variation in these concentrations, highlights the difficulty in including PECs 
into risk quotients (RQs) and the fish plasma model (FPM). In section 3.4.2., the inclusion 
of local environmental criteria was suggested in order to provide more accurate PECs, 
however, the variation in these conditions could make this difficult to apply to a large 
number of compounds. Dilution appears to have been a key factor in determining the 
occurrence of pharmaceuticals in the aquatic environment, and its inclusion in PECs 
would be useful (Burns et al. 2018a). PECs in some studies have previously included 
site specific information on dilution, and have been found to be accurate predictors in 
some rivers (Burns et al. 2017) and accurate for some compounds, but not others in 
wastewater treatment plans (WWTPs) (Ferrari et al. 2004).  
Other differences arose in the prediction of toxicity of these compounds between the two 
chapters and existing literature. The main limitations of CECs and the FPM are that they 
are utilising mammalian data to predict possible concentrations at which compounds are 
thought to be likely to exert an effect on fish (Huggett et al. 2003). The implications of 
assessing potential toxicity to one trophic level could fail to identify compounds (such as 
antibiotics), which have shown greater toxicity to other organisms, and as a result 
predicted toxicities for multiple trophic levels should be included (Guo et al. 2015). Other 
assessments have done this through the use of experimental acute and chronic data 
(Dong et al. 2013), modelling predicted effects (Sangion and Gramatica 2016) and 
utilising information on pharmacological mode of action (MoA) (Besse et al. 2008). In 
Chapter 3, it was discussed that FPM and CECs were the most conservative and 
accurately identified compounds which posed a risk to multiple trophic levels. However, 
this is likely to fail when there are unexpected ecotoxicological effects of targets non-
conserved targets, such as the reproductive toxicity of metformin observed in P. 
promelas and Mytilus edulis (Niemuth et al. 2015; Koagouw and Ciocan 2018).  
Tiered risk assessments are used in ERAs (Hoyett et al. 2016) and are often utilised in 
the prioritisation literature (Besse et al. 2008). This could help overcome the limitations 
discussed previously of providing sufficient detail on a large number of chemicals. The 
schemes discussed in Chapter 3 (PECA and CEC) could provide a useful first tier 
assessment, but there would need to be further criteria to include assessments on the 
toxicity of the compounds to other trophic levels, whether this is through acute data or 
PNECs. The use of a tiered scheme could produce a smaller subset of compounds on 
which to do a more detailed assessment. Roos et al. (2012) assessed the use of different 
methods for prioritising pharmaceuticals in a Swedish context. They also found that these 
criteria accurately predicted the relative importance of several well-studied compounds, 
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and also suggested the use of QSAR and logKOW as alternatives. The use of QSAR has 
been widely debated (Schrieber et al. 2011, Nallani et al. 2016) and discussed in 
previous sections (1.1.2 and 3.4.3). Regardless of which is used, it needs to be chosen 
based on relevance to the rationale of why the assessment is being carried and to the 
compounds included, as well as available data.  
A first-tier assessment can be used to create a smaller sub-set of compounds upon which 
a more detailed assessment can be carried out. PECs can be further refined to include 
local data such as the number of prescriptions, population, WWTP removal, flow, and 
inputs. There are many different examples of calculations in the literature which include 
local information on input and flushing rates in rivers (Burns et al. 2017), fate calculations 
(Oldenkamp et al. 2013), and local usage (Helwig et al. 2016).  This could help to provide 
more reliable data for FPM and RQs.  
Other prioritisation schemes have used information on the pharmacological MoA to 
further assess the potential toxicity of chemicals, and those which had a relevant MoA 
were placed on a priority list (Besse et al. 2008), or through the use of adverse outcome 
pathways (Caldwell et al. 2014). The point based ranking system used in Chapter 2 
attempted to do this. It was adapted from a prioritisation exercise carried out by Capleton 
et al. (2006) to prioritise veterinary pharmaceuticals.  An assessment like this utilised 
pharmacological information in addition to data in the existing literature, but was time 
consuming to carry out on a large number of compounds. Further consideration into the 
adaption of such a method to a human pharmaceutical context, such as the weighting of 
different criteria and inclusion of more relevant endpoints could be beneficial. For 
example, adverse effects to reproduction are important as they could have population 
level effects and should be weighted appropriately (Ankley et al. 2010). Oxidative stress 
on the other hand, is an endpoint commonly used in the literature and is useful in 
determining stress caused by exposure to a pharmaceutical, however, the overall 
biological significance can be variable and therefore should be weighted differently 
(Regoli et al. 2002). Additionally, weighting for data quality such as concentrations which 
induce an effect or sample numbers should be considered 
6.1.2 Occurrence of pharmaceuticals in estuaries 
To date, relatively few studies have monitored pharmaceuticals in estuaries and those 
which have, have largely been limited to East Asia (13 studies), North America (10 
studies) and Europe (7 studies; Figure 6.1). Only the monitoring study in Chapter 4 and 
those conducted by Mijangos et al. (2018), Long et al. (2013) and Thomas and Hilton 
(2004) measured compounds in more than one estuary. Some patterns in the occurrence 
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of pharmaceuticals have evolved from these studies. Concentrations of pharmaceuticals 
decrease with increasing salinity, leading to dilution being named as the key factor 
influencing the fate of these compounds within estuaries (Cantwell et al. 2016, 2017). 
Other processes such as tides, water flow and rainfall also influence dilution and 
subsequent pharmaceutical concentrations (Benotti and Brownawell 2007, Mijangos et 
al. 2018). Sorption of pharmaceuticals to sediment and degradation have also been 
found to play a role in removal (Yang et al. 2011, Hedgespeth et al. 2012). However, due 
to the varying concentrations, limited study locations and complex interactions occurring 
in estuaries, there has been uncertainty over the magnitude of estuarine pharmaceutical 
pollution (Cantwell et al. 2018). The findings of this thesis help to put the wider problem 
of pharmaceutical contamination into context, by contributing to the overall picture on the 
global occurrence of pharmaceuticals, and what is currently known about the spatial and 
temporal patterns in estuaries. As illustrated by Figure 6.1, further monitoring needs to 
be conducted in order to fully understand the global scale of this issue.    
 
Figure 6.1 Number of studies conducted in each country monitoring pharmaceuticals in (A) 
surface Water and (B) sediment. Further information on pharmaceuticals monitored and 
concentrations can be found in appendices 1.1 and 1.2. 
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In Chapter 4, pharmaceutical pollution was found to be ubiquitous in the UK, which adds 
to the increasing literature that pharmaceuticals are not just present in freshwater (Fabbri 
and Franzellitti 2016, Gaw et al. 2016). The ability of these compounds to persist and 
their occurrence in the downstream most regions of estuaries and therefore likelihood of 
entering the marine environment shows that pharmaceuticals are widespread within the 
aquatic environment as a whole (Rocha et al. 2014). Ibuprofen, paracetamol and 
trimethoprim had the highest detection frequencies (90-100%) across UK estuaries and 
were present in nearly all of the samples collected. Whilst diclofenac and citalopram were 
highly detected in the Humber Estuary, they were only present in 25% and 50% of the 
12 estuaries sampled, respectively.  
In Chapter 3, PECs were calculated for the five compounds measured in these estuaries. 
These calculations predicted that paracetamol would be found at the highest 
concentrations (800 – 5740 ng l-1) followed in order by ibuprofen (1484 – 2968 ng l-1), 
diclofenac (112 – 488 ng l-1), trimethoprim (133 – 488 ng l-1) and citalopram (74 – 223 ng 
l-1). This order was mostly reflected in the concentrations of pharmaceuticals measured 
in UK estuaries, although ibuprofen was generally detected at higher concentrations than 
paracetamol. However, the resulting calculations were less accurate, which is 
unsurprising due to the temporal and spatial variations that were seen in Chapter 4, as 
well as in other monitoring studies (Conley et al. 2008, Wilkinson et al. 2017, Cantwell et 
al. 2018). As a result, it is most important that these schemes are sufficient for predicting 
the highest concentrations. The calculated PECs mostly underestimated the maximum 
concentrations by a factor of 2 – 10, but overestimated mean concentrations by a factor 
of 2 - 113, which was the case for many of the MECs in Chapter 3 (Figures 3.2 and 3.3). 
Most of the MECs used were measurements taken from rivers, and PECA was found to 
be the most conservative estimate. However, in the estuaries sampled, PECD accurately 
predicted maximum concentrations of paracetamol (916 ng l-1) and diclofenac (42.93 ng 
l-1) in the Humber Estuary, whilst PECB accurately predicted the maximum 
concentrations of trimethoprim (247 ng l-1). In the context of this thesis, PECA still 
provided the most conservative estimate for the compounds and would be useful to 
prioritise pharmaceuticals in the aquatic environment as a whole, but lacks detail to 
provide estimates in specific areas.  
The Humber Estuary, which is the second largest estuary in the UK and is the receiving 
environment for the sewage effluent for approximately 13.7 million population equivalent 
(PE; European Environment Agency 2017), had the highest overall levels of 
pharmaceuticals. Concentrations of ibuprofen in the Humber were the highest recorded 
in an estuary, globally (Table 4.1). Further large estuaries, including the Mersey (3.7 
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million PE) and Thames (16.5 million PE), also had relatively high concentrations of 
pharmaceuticals in comparison to the other estuaries sampled (European Environment 
Agency, 2017). A relationship between the amount of pharmaceuticals and densely 
populated catchment areas has been seen in other waterbodies; a monitoring study in 
the Jiulong River, China showed highest concentrations in urban areas in comparison to 
other land uses (Hong et al. 2018). Pharmaceuticals were also present in rural areas due 
to their combined usage as veterinary medicines and spreading of sludge and manure, 
however, pharmaceutical presence in areas with higher forest cover were much lower. 
A positive correlation between catchment population and pharmaceutical populations 
was also found in Japanese rivers (Hanamoto et al. 2018). This relationship was not 
observed in this thesis; the Cromarty Firth (92.3 km2; PE 156, 000), a relatively secluded 
estuary in the North of Scotland had the highest level of any pharmaceutical (ibuprofen 
– 210 ng l-1) measured in the August-September monitoring campaign, and was one of 
the few estuaries to contain diclofenac. This could, in part be due to differences in WWTP 
technology resulting in the lower removal of these compounds (Nebot et al. 2015). Septic 
tanks are likely to be higher in rural areas (which are not included in the calculated PE 
of each catchment) and have been attributed as a source of pharmaceuticals in rural 
areas in Canada (Comeau et al. 2008), Sweden (Magnér et al. 2010), and USA (Palmer 
et al. 2008). As a result countries with growing populations and inefficient or non-existent 
sewage removal (such as Bangladesh, Pakistan, China and India) could pose the biggest 
threat to water quality (Rehman et al. 2015). Not only are these countries the highest 
global consumers of pharmaceuticals, they also house many pharmaceutical 
manufacturing companies where there is a lack of regulation surrounding the emission 
of pharmaceutical waste (Ashfaq et al. 2017).  Few studies have measured 
pharmaceuticals in these regions, but diclofenac was found in Pakistan at levels of 0.1 
to 4.4 µg l-1 (Scheurell et al. 2009), and other pharmaceuticals were frequently detected 
above 1 µg l-1 in India (Mutiyar et al. 2018). These differences in land use, sewage 
treatment and pharmaceutical consumption in areas such as this can make it difficult to 
apply findings from this thesis to other countries. Pharmaceuticals have been detected 
at concentrations up to 500 ng l-1 in surface water and up to 87 µg l-1 in effluent in sub-
arctic locations (Faroe Islands, Iceland and Greenland), which have low populations 
(50,000 – 329,000 people), which shows the potential wide-reaching impacts of 
pharmaceuticals pollution and that monitoring studies shouldn’t be limited to urban areas 
(Huber et al. 2016).  
Geochronological sampling of estuarine sediment in New York has revealed that most 
pharmaceutical concentrations have increased over the last 50 years, with 
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concentrations doubling in the last ten years, a higher increase in comparison to previous 
decades (Lara-Martín et al. 2015). Four of the estuaries sampled in Chapter 4 (Mersey, 
Thames, Tees and Tyne) were previously sampled in 2002 (Thomas and Hilton 2004). 
It can be difficult to directly compare concentrations in these estuaries, due to seasonal 
and temporal variations, however, detection frequencies of ibuprofen, trimethoprim and 
paracetamol were higher than previously sampled. Particularly concerning, is the 
occurrence of paracetamol, which was completely absent in these estuaries, but is now 
the second most occurring compound 15 years later. Diclofenac concentrations 
measured in this thesis were similar and even lower than these previous measurements, 
however, due to low recovery, higher method quantification limit (MQL) and potential 
temporal variations of this compound, it may be too early to say concentrations are 
declining, particularly as it has recently been found in the Ouse (a tributary of the 
Humber) at concentrations up to 2.8 µg l-1 (Kay et al. 2017). In the UK, prescription rates 
of diclofenac have declined in recent years, and only  low doses are available over the 
counter (OTC), and as a result a decline in concentrations could be expected (National 
Health Service 2014). As for trimethoprim and ibuprofen, concentrations were higher in 
the Mersey (by a factor of 10) in 2002, but similar to the other estuaries sampled. 
Baseline data on the occurrence of pharmaceuticals in estuaries (or many other 
waterbodies) does not exist (Figure 6.1), yet is essential to determine if these levels are 
in fact rising. 
This variation in pharmaceutical levels could be the result of site selection (and distance 
to input sources), as well as variations in seasonal or diurnal concentrations as opposed 
to an overall decline. Thomas and Hilton (2004) collected samples in November, 
whereas the UK wide survey in Chapter 4 was conducted in August, when concentrations 
would be expected to be lowest. In the Humber, trimethoprim was the only compound to 
show seasonal difference, with highest concentrations in February, when highest overall 
pharmaceutical concentrations occurred, and December. Other studies have showed 
highest concentrations of pharmaceuticals, such as hydrochlorothiazide (which showed 
50% higher detection frequency) to be highest in winter as the result of colder 
temperatures, when degradation is lower, resulting in higher input, higher concentrations 
and more persistence (Cantwell et al. 2017). Previous studies have also identified the 
flow rate of an estuary to be an important factor in the fate of pharmaceuticals (Cantwell 
et al. 2016). This was not accounted for in the Humber or UK wide monitoring, but rainfall 
recorded in Yorkshire the previous years showed highest levels in June and August, 
which could also account for the low concentrations observed at sites furthest 
downstream (A3-A5) during these months (Tanguy et al. 2016). These complex 
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interactions between the input of pharmaceuticals, their removal and transport can make 
it difficult to predict these variations, as they can vary daily as well as seasonally.  
Total prescription numbers of the most commonly used pharmaceuticals in the UK have 
risen by a factor of 1.6  between 2005 and 2015 (National Health Service 2006, 2016), 
and if this increase remains constant, then over 1 billion prescriptions of these compound 
classes could be dispensed in 2025 (Figure 6.2). Further understanding of consumption 
patterns and prediction of environmental concentrations is needed in order to understand 
if this same increase could be reflected in surface water. The Lara-Martin et al. (2015) 
study showed higher increases in sediment over a ten year period, and as a result it isn’t 
unfeasible. If little is done to curb the rise of pharmaceutical levels, then they have the 
potential to become a problem in the future.  According to our current understanding of 
ecotoxicology, few pharmaceuticals pose a risk at the levels currently found in the 
environment, however detrimental effects could be seen if concentrations continue to 
increase at this rate (Taylor and Senac 2014).  
 
Figure 6.2 Annual prescription numbers for the most prescribed pharmaceuticals for 2005, 2010 
and 2015 taken from National Health Service (2006, 2011, 2016). Projected prescription numbers 




A better understanding of the spatial and temporal differences of pharmaceuticals and 
the factors which influence their fate can help to identify areas and organisms which 
could be most at risk from this pollution. In the Humber, the highest concentrations were 
observed in the 6 km section between R1 and R4. This was the likely the result of effluent 
discharged at R1, and sustained concentrations from this source. Other peak 
concentrations seen at R3 and R4 could have been the result of compounds transported 
from the River Hull. There are eight other WWTPs which discharge effluent into the 
Humber, the largest of which serves a PE of 500,000 (European Environment Agency 
2017). Improper disposal, agriculture and aquaculture have also been identified as 
sources of pharmaceuticals, as a result the spatial distribution of some compounds may 
differ depending on land use (Godoy et al. 2015). For instance, trimethoprim, which is 
also used in fish farming, has been found to be present at concentrations 2-3 times higher 
in seawater where farming was present than other areas (Kim et al. 2016). It is essential 
that monitoring campaigns are designed to include areas where concentrations are 
highest in order to gain a better understanding of risk in that area. An understanding of 
consumption patterns is also important when determining which pharmaceuticals to 
monitor;  prescriptions of lipid lowering agents, antidepressants, antihypertensives, 
mucosal protectants and antidiabetic drugs have experienced the highest rate of 
increase, doubling between 2005 and 2015 (Figure 6.2), and as a result, may be of 
interest for future monitoring work. However, as discussed previously in Chapter 2, it is 
essential to have an understanding on the effects of pharmaceuticals, when determining 
those which may be a priority.  
6.1.3 Biological effects of pharmaceuticals in estuaries 
Many pharmaceuticals exhibit temporal variations in their occurrence, and as a result, 
some pharmaceuticals may pose a greater risk at certain times of the year (Conley et al. 
2008). This can have implications for migratory species or biological processes which 
occur at certain times of the year. Reproductive processes often exhibit seasonal 
patterns, which could leave species more vulnerable during these periods (Milligan et al. 
2009). For example, recruitment for the ragworm, Hediste diversicolor occurs at different 
times of the year, depending on the population (Scaps 2002). In the Humber, populations 
near sites R1-R4 spawn around June (coinciding with highest levels of ibuprofen), 
whereas for populations near A3-A5, this occurs around February, when downstream 
concentrations of pharmaceuticals are highest. Diclofenac has been found to decrease 
sperm motility in the lugworm (Arenicola marina) at environmentally relevant 
concentrations (100 ng l-1), and high concentrations coinciding with spawning events 
could have implications on population numbers (Mohd Zanuri et al. 2017). Many other 
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pharmaceuticals (such as antidepressants) have been observed to negatively impact 
reproduction in fish (Overturf et al. 2015) and invertebrates (Fong and Ford 2014) in 
laboratory exposures.  The timing of reproductive events are often coordinated with 
events of other species. For instance, the recruitment periods of H. diversicolor, coincide 
with the highest feeding periods of one of their predators, sole (Solea solea) juveniles 
(Cabral 2000). This could result in increased pressure on the prey item (in this case, H. 
diversicolor), leading to population reductions, which would in turn impact the predator 
(in this case, S. solea).  
In chapter 5, H. diversicolor were exposed to two different concentrations of metformin 
and diclofenac (100ng l-1, 1µg l-1) for 7 days. Only the highest level of metformin was 
seen to alter ATPS after 7 days, and no effect was seen for AMPK in any treatment. 
However, the variation in gene expression in response to metformin exposure introduces 
uncertainty as to the full extent of the effect on energy status.  Levels of metformin have 
been found to be high, with concentrations in tributaries of the Humber (Rivers Ouse and 
Foss)  found at 2.3 µg l-1 in surface water and 6.1 µg l-1 in effluent, and a detection rate 
of 100% (Burns et al. 2017, 2018b). Globally concentrations are up to 1 µg l-1 in estuaries, 
3 µg l-1 in freshwater and 10 µg l-1 in effluent (Briones et al. 2016, Meador et al. 2017, 
Burns et al. 2018b). It is therefore plausible that concentrations could reach 1µg l-1 in the 
Humber, which could result in an increase of ATPS in H. diversicolor. However, these 
are likely to encompass peak concentrations in estuaries, and as a result are unlikely to 
continually be exposed at the levels.  
H. diversicolor are polychaetes, which are ubiquitous, and they are a key species in 
estuarine sediment in Europe and North America (Coelho et al. 2008). Closely related 
relatives, such as Hediste japonica and Hediste limnicola, are abundant in other regions, 
and it is possible that pathways in these species could be similar due to conserved 
targets, however differences in toxicity could also occur (Fong and Garthwaite 1994, 
Fabbri 2015). Additionally, H. diversicolor have been suggested as good indicators of 
estuarine pollution due to their susceptibility to effects of pollutants in estuaries (Scaps 
2002, Kalaman et al. 2009, Maranho et al. 2014). Due to the dynamic process in 
estuaries, these species often live at the edge of their tolerance zone for pH, salinity and 
dissolved oxygen, so further stress caused by contaminants has a greater impact on 
their physiology. Further to metformin, ibuprofen has been showed to have an effect on 
energy metabolism in H. diversicolor exposed to sediment spiked with 5 ng g-1 (Maranho 
et al. 2015). Organisms have limited energy for processes such as movement, 
reproduction and growth, so prolonged stress and increased energy requirements 
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caused by pharmaceuticals could prohibit them from sustaining these processes 
(Goodchild et al. 2015). 
Not only are H. diversicolor a commercially important species for bait, but effects to their 
populations can impact other important species (Rosa et al. 2008). H. diversicolor are an 
important prey for other species of commercial value such as the edible crab, Carcinus 
maenas and S. solea  (Cabral 2000, Baeta et al. 2006). They are also an important food 
source for water birds such as, dunlin (Calidris alpina), black headed gull (larus 
ridbundus),  grey plover (Pluvialis squatarola) and the bar tailed godwit (Limosa 
lapponica; Rosa et al. 2008). These species also feed on bivalves such as the clam, 
Scrobicularia plana, which have been found to accumulate carbamazepine (Almeida et 
al. 2017). The Humber Estuary is of ecological significance to many species of water 
birds, supporting approximately 150,000 individuals, including those mentioned 
previously, which rely on H. diversicolor as a prey item (Mander et al. 2007; Austin et al. 
2008). These species have accounted for 2% (C. alpina) to 13% (red knot, Calidris 
canutus) of the international population, however, many of these species have 
experienced a 25-50% of decline in population numbers between 1991 and 2006, and 
reduction in their food sources could add further pressure (Buck 1997; Stillman et al. 
2005; Austin et al. 2008). This trend is not seen in all species, and populations of some, 
such as L. lapponica have increased. The reduction in water bird species has been 
attributed to other anthropogenic threats such as habitat loss and decline in water quality, 
and the contamination of pharmaceuticals or other contaminants could add to this threat 
(Norris et al. 2004).  
There is evidence that many other emerging contaminants, such as flame retardants and 
plasticisers, transfer through the food chain (Nilsen et al. 2019). Laboratory and 
environmental studies on the trophic dynamics of pharmaceuticals are limited, however, 
there is little evidence for biomagnification of pharmaceuticals, and the main route of 
entry appears to be environmental exposure (Du et al. 2014, Boström et al. 2017, 
Haddad et al. 2018). Nonetheless, pharmaceutical pollution can have an effect on food 
chains, particularly as these pollutants have been found to be more bioavailable to the 
lower trophic organisms (Vernouillet et al. 2010, Lagesson et al. 2016). Reduction of 
lower trophic species will have a knock on effect on those which have an effect further 
up the food chain (Lagesson et al. 2016).  
The CECs calculated in Chapter 3, were exceeded by ibuprofen, diclofenac and 
citalopram in all estuaries sampled in Chapter 4. CECs are a prediction that these 
compounds will be taken up by fish, and not that they will necessarily cause an effect in 
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that organism (Huggett et al. 2003; Fick et al. 2010). Considering the large size of the 
Humber, it has a relatively small fish population (~28,000 individuals), compared to the 
Severn (~172,000) and Thames (~103,000), so these predictions may be more important 
for some estuaries than others (Environment Agency 2019)  The CECs for ibuprofen (0.2 
ng l-1), diclofenac (2.2 ng l-1), and citalopram (0.4 ng l-1), were low, yet there is currently 
no evidence that these compounds illicit a biological effect at these concentrations. Of 
the compounds assessed in the prioritisation scheme, 19 out of 50 had lowest LC50 
values for algae, showing they were most acutely sensitive to pharmaceuticals (Appendix 
3.4). This shows the importance in using multiple trophic levels in risk assessments and 
prioritisation schemes. Whilst trimethoprim had a high CEC (1.6 µg l-1), bacteria and 
algae are most sensitive to this drug (Vestel et al. 2016) which is further evidence that 
use of CECs alone in prioritisation schemes are not adequate predictors of 
environmental toxicity.  
Whilst diclofenac did not have an effect on H. diversicolor energy metabolism, as 
measured by ATPS and AMPK expression in Chapter 5, it has been shown to cause 
oxidative stress in tilapia (Oreochromis niloticus) and mussels (Mytilus galloprovincialis), 
reduce osmoregulation in shore crabs (C. maenas), and cause liver and kidney damage 
in trout (Salmo trutta) at concentrations under 1 µg l-1 (Hoeger et al. 2005, Eades and 
Waring 2010, Gonzalez-Rey and Bebianno 2014, Gröner et al. 2017). In 2013, diclofenac 
was placed on the watch list under the EU Water Framework Directive (WFD), with 
maximum allowable concentrations of 0.01 µg l-1 in marine waters; these levels were 
exceeded in the Humber, Thames and Cromarty (Lonappan et al. 2016). However, there 
is no evidence that negative effects will occur at concentrations this low, and in 2018 its 
removal from the watch list was recommended (Loos et al. 2018). 
The CECs for paracetamol were 35 µg l-1, however, there is evidence that aquatic 
invertebrates and fish accumulate and are affected by paracetamol at levels lower than 
this. Paracetamol was detected in the estuaries sampled in Chapter 4 at 13 - 916 ng l-1, 
which are consistent with levels that have been observed to cause adverse effects in 
freshwater species, such as neurotoxicity in the planarian worm (Dugesia japonica) and 
oxidative stress in Daphnia magna (Parolini et al. 2010, Wu and Li 2015). Many of the 
toxicity tests of paracetamol, focus on acute exposures, and due to its ubiquitous 
presence in the aquatic environment, further studies are needed for chronic low level 
exposures (Kim et al. 2007, Antunes et al. 2013). The pathways of paracetamol are 
thought to be similar in vertebrates as humans, and chronic exposures to moderate 
levels of paracetamol have cause hepatic toxicity in fish (Rhamdia quelen) exposed to 




6.2 Future direction for the management of pharmaceuticals in the environment 
If pharmaceutical concentrations in the environment continue to increase it is possible 
that they could become a global problem. Globally, rivers, estuaries and seas are facing 
growing pressure as the result of pollution, climate change and other anthropogenic 
pressures, and as a result could become more sensitive to contaminants such as 
pharmaceuticals (Chapman 2016). Therefore, the continued monitoring and 
investigation on pharmaceuticals is important. The previous sections have identified the 
potential ecological implications of pharmaceutical contamination, and whilst most 
pharmaceutical concentrations seen in the environment are too low to illicit biological 
effects seen in laboratory exposures, their impact in not yet fully understood. The WFD 
watch list was reviewed in 2018, and currently contains the following pharmaceuticals: 
17α-ethinylestradiol, 17β-estradiol, estrone, erythromycin, clarithromycin, azithromycin 
(Loos et al. 2018). Ibuprofen may also be of interest to regulators as the result of high 
levels found in this study, and the potential effects at these concentrations. There are 
further compounds which have been identified in the previous chapters, which have the 
potential to also pose a considerable risk. These include metformin, candesartan, 
allopurinol, antibiotics (particularly amoxicillin, flucloxacillin) and antidepressants 
(particularly citalopram, fluoxetine and amitriptyline). Due to the limited number of 
compounds included in the prioritisation exercise, this list will not be exhaustive, and if 
prescription numbers continue to rise, other compounds may become more of a priority. 
Additionally, this list will need to be adapted to different geographical areas based on 
consumption patterns and identification of potential sources. More research on these 
and other compounds is needed to determine the severity of the risk.  
The usage of some pharmaceuticals, particularly antidepressants and antibiotics, are 
growing in the UK (as evidenced by Figure 6.2) as well as globally, which can have 
implications on the environment (OECD, 2017). This growth is even more pronounced in 
areas such as Brazil, China or India which have growing populations and highest rate of 
antibiotic usage (Van Boeckel et al. 2014). ERAs for veterinary pharmaceuticals contain 
a risk-benefit analysis, which is not feasible for those used in human medicine, as human 
health will always be seen as overriding benefit (Pereira et al. 2017). Whilst not a 
complete solution in itself, awareness of the environmental effects of pharmaceuticals 
within the communities as well as to prescribers could help to lower the usage of some 
pharmaceuticals (Daughton and Ruhoy 2014). There are currently campaigns to reduce 
the unnecessary prescription of antibiotics to try and prevent resistance, and similar 
initiatives could be used for other pharmaceuticals (Edgar et al. 2009). Regulation of 
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OTC drugs could also reduce the environmental risk, but equally could have implication 
on an already overstretched medical system, resulting in an increased need for 
appointments and prescriptions (Daughton and Ruhoy 2014).  Additionally, 
pharmaceuticals are often disposed of inappropriately in household waste or down toilets 
and increased awareness of alternative disposal methods could help prevent this (Bound 
and Voulvoulis 2005). 
WWTPs have been found to remove pharmaceuticals with variable efficiency, and  since 
a primary route of pharmaceuticals into estuaries is through wastewater  improving this 
technology would be an important step to regulating the input of pharmaceuticals (Valdés 
et al. 2014, Munro et al. 2019). A significant amount of research has been put into the 
removal of not only pharmaceuticals, but other emerging contaminants, and the wide 
range of different types of compounds provides a challenge (Gavrilescu et al. 2015). 
Whilst this wouldn’t stop the input of all compounds, it could be an important step for 
effluent dominated estuaries. In some regions, there also needs to be improved 
regulation and infrastructure to prevent the discharge of untreated sewage into the 
environment. 
6.3 Limitations and future research 
6.3.1 Prioritisation of pharmaceuticals 
There were limitations in the studies conducted in chapters 3-5, and it is important to 
take these into consideration when interpreting the results. The schemes included in the 
assessment were not exhaustive of all those used in the literature, however those which 
were not included (such as QSARs and PBT assessments) have been covered in other 
prioritisation studies (Roos et al. 2012; Donnachie et al. 2016). A limitation of this study, 
was the number of compounds included. Whilst a smaller set of compounds made it 
easier to compare results, it may not have accurately identified all compounds which 
pose a risk to the environment. The limitations of the specific calculations have been 
discussed in previous section (3.4 and 6.1.1), and this highlights where further research 
needs to be done in order to increase accuracy. The study in Chapter 3 was conducted 
using prescription data to calculate PECs for the UK as a whole, and did not look at 
regional differences. Additionally, comparison with MECs were made across a large 
temporal and spatial scale. Further comparison with localised parameters and carefully 
designed sampling could help to provide further insight into how PECs could be 
improved. Consumption patterns have an influence on these calculations and 
concentrations seen in the environment, and it would be beneficial to further understand 
the trends behind this. Whilst overall prescription levels are increasing, the patterns of 
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some compounds are decreasing, and it may be a better use of resources to fund 
research into those which pose a greater risk in the future.  
Future research into improving predictions on the toxicity of pharmaceuticals to aquatic 
organisms needs to be conducted. As the FPM has been found to be a useful method in 
determining toxicity to fish, it would be useful to determine how to better read across this 
data to invertebrates (Roos et al. 2012). There is evidence that algae may be sensitive 
to some compounds such as antibiotics (Guo et al. 2015), statins (Brain et al. 2008) and 
allopurinol (Clode et al. 2009). Due to the importance of algae in aquatic ecosystems, a 
better method needs to be developed to predict the effects of pharmaceuticals to these 
organisms. In comparison to vertebrates and invertebrates, far less in known about 
impacts on marine algae, and this warrants further investigation. Future research on the 
occurrence of pharmaceuticals in estuaries and their biological effects are discussed in 
sections 6.3.2 and 6.3.3, and this knowledge is essential to improving prioritisation 
schemes.  
6.3.2 Occurrence of pharmaceuticals in estuaries 
The monitoring study was limited by the time taken to collect samples, which meant that 
all samples were taken from the North side of the Humber and from only one of the 
tributaries. In order to have a better understanding of the source of pharmaceuticals, 
monitoring studies should include as many points of input (such as tributaries, CSOs and 
areas where effluent is discharged) as possible. Estuaries undergo mixing between 
freshwater and marine, which will differ between estuaries and can determine the fate of 
compounds (Mijangos et al. 2018). All samples from this study were taken from the 
surface of the water column, close to the shore. Further studies should include samples 
from other compartments including sediment, within the water column and the middle of 
the estuary in order to understand the full exposure of organisms to these chemicals. 
Samples were collected at high tide partly to compare these concentrations, but also 
because most sites were inaccessible at low tide. It potentially could have accounted for 
low concentrations at the sites furthest downstream (A3-A5), and sampling at other times 
in the tidal cycle would help determine if the concentrations are observed are 
representative of this site as a whole. Salinity, pH and temperature measurements were 
taken with each of the samples. There was an attempt to collect information on turbidity, 
however, due to the limited access to sites, this was not possible. In order to gain a better 
understanding of the spatial and temporal variations, it would also be beneficial to collect 




This study was also limited by equipment difficulties and cost of external analysis, which 
led to a restriction on the number of samples which could be analysed. As a result sample 
replication was low, and peak concentrations in the estuaries sampled may not have 
been captured. Under optimum circumstances, replicates would be taken from each site 
during each sampling period in order to increase confidence in the concentrations of 
pharmaceuticals observed. Additionally, recoveries from spiked water samples were low 
and variable between samples, which could have accounted for some of the variability 
observed. Adjusting for recovery enables a more accurate overview on the levels of 
pharmaceuticals, however increasing recovery reduces uncertainty seen in any 
unexpected results. The low recovery of some compounds, particularly diclofenac, may 
have accounted for its low detection frequency. Differences in the recovery of 
compounds from solid phase extraction (SPE) occurred between Chapters 2 and 4. This 
could be explained by a change in the reconstitution of samples in methanol: water 
(10:90) instead of 100% methanol. The addition of TFA to the samples in Chapter 2 
improved recovery, however further acidification of acidic compounds such as diclofenac 
and ibuprofen may have affected their solubility.  
6.3.3 Biological effects of pharmaceuticals 
Adverse reactions have been seen in many organisms, but the pathways for many 
pharmaceuticals are poorly understood (Fabbri 2015). This is partially due to the 
endpoints chosen such as mortality, growth and oxidative stress, which are important in 
determining the effects of these compounds, but a deeper understanding on specific 
pathways is needed. Endpoints should be chosen based on the information on MoA in 
humans and applied to knowledge on the biology of the non-target species. Exposure 
experiments need to be more environmentally relevant in terms of treatment 
concentrations, and using multiple compounds. Even though some compounds may not 
illicit an adverse reaction in single ecotoxicity tests, they are present in the environment 
with other pollutants and anthropogenic pressures, which could make them more toxic 
(Di Poi et al. 2018). In other cases, pharmaceuticals have been observed to have a 
positive effect, metformin was found to have a protective effect on Daphnia against 
hypoxia (Sheng et al. 2012).  The use of pharmaceutical mixtures in effects based 
studies has been increasing, but still little is known about these effects (Backhaus and 
Faust 2012). However, there is evidence that pharmaceutical mixtures are toxic at levels 
where single substances are not, and as a result this is an important gap in the literature.  
(Cleuvers 2004). Most exposure experiments only include a single test species, when in 
reality, there are complex interactions between species and effects on one species, could 
have indirect implications on others. Few studies have determined the effect of 
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pharmaceuticals in mesocosms, which could provide further information on the potential 
effects of pharmaceuticals to an ecosystem (von der Ohe et al. 2011).  
In the environment, pharmaceuticals undergo a number of processes, which result in the 
formation of metabolites (Celiz et al. 2009). Often, these metabolites are inert, but some 
are pharmacologically active and have the potential to be more toxic than the parent 
compound, but relatively little is known about their occurrence, fate or effects (García-
Cambero et al. 2015). Many metabolites are found in the environment at concentrations 
in the same order of magnitude or higher than that of the parent compound, but their 
overall environmental relevance is not known (López-Serna et al. 2012). For example, 
10,11-Epoxi carbamazepine a biologically active metabolite was found at concentrations 
15 times higher than its parent compound carbamazepine in a river in Spain (López-
Serna et al. 2012).  Many metabolites have the same MoA as their parent compound, so 
if both are present in a mixture, the effect may be amplified (Besse et al. 2008) 
In order to be more environmentally relevant, exposures need to use a range of 
concentrations which include those found in the environment. It is also beneficial to have 
long-term as well as short-term studies, as exposure to pharmaceuticals is likely to be to 
low levels over a sustained period of time (Godoy et al. 2015). A time-dependent 
increase in effects has been seen in some exposures, for instance, Japanese medaka 
(Oryzias latipes) exposed to 1 µg l-1 diclofenac showed increased vitellogenin expression 
after 4 days of exposure, but not beforehand  (Hong et al. 2007). A longer exposure to 
metformin in Chapter 5 could help to determine if ATPS increase was the result of 
permanent stress and could lead to the activation of AMPK or if they will be able to adapt 
to the stress over time. H. diversicolor are sediment dwelling organisms, and as a result, 
it is likely they could also uptake pharmaceuticals from sediment, where concentrations 
of pharmaceuticals are likely to be found at lower concentrations than surface water. 
Environmental relevance could have been improved through the use of sediment found 
in the estuarine environment and appropriate dosing.  
There was variation seen in the relative gene expression within each of the treatments, 
which introduced uncertainty as to whether it was only metformin that was causing 
increased expression of ATPS, or another variable that wasn’t accounted for. Salinity, 
dissolved oxygen, temperature and pH were controlled for, however, the size of 
organisms varied between treatments. Confirmation of pharmaceutical concentrations in 
the exposure water or H. diversicolor could help to reduce this uncertainty. This 
information is often missing from ecotoxicology studies and could help to quantify 
bioaccumulation of compounds, which can help to put the effects seen into context and 
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help to extrapolate the effects to other species (Harris et al. 2014). Additionally, there are 
still gaps over the routes of uptake, bioaccumulation and transfer of pharmaceuticals to 
other trophic levels. Reproducibility of results is often a concern in ecotoxicological 
studies, and was a limit of the one carried out in Chapter 4, and the need for repeated 
studies have been highlighted by previous authors, and it could help reduce uncertainty 
over variable results (Sumpter et al. 2016).  
6.4 Conclusion 
This thesis has demonstrated that pharmaceuticals may pose a risk to estuaries. It 
quantified the concentrations of five pharmaceuticals – ibuprofen, paracetamol, 
diclofenac, trimethoprim and citalopram in twelve estuaries, which provides an important 
baseline on levels in the UK. Their presence in all of the estuaries sampled shows that 
they are not only present in large urban catchments, but also in rural estuaries, and as a 
result the implications of their presence could be wide reaching. Ibuprofen was found at 
levels up to 6.2 µg l-1, which to date is the highest level found in any estuary globally. 
The results from this thesis also show that based on current knowledge on the biological 
effects of pharmaceuticals that most pharmaceuticals are currently not present at 
concentrations high enough to cause a detrimental effects at a population level. Despite 
this, concentrations of pharmaceutical are high enough in some estuaries to be 
biologically active in organisms, but the overall implications are not fully understood. 
Metformin was found to increase the exposure of H. diversicolor at 1 µg l-1, which 
demonstrates that peak concentrations seen in surface waters have the potential to illicit 
this effect. Laboratory exposures are limited in length and the sustained long-term 
exposure of pharmaceuticals particularly when they are present in mixtures with other 
contaminants are relatively unknown.  
There is some evidence that pharmaceuticals levels are increasing with time, and as a 
result, concentrations need to be monitored and inputs reduced in order to prevent 
serious implications in the future. Pharmaceuticals exhibit spatio-temporal variations in 
their occurrence as the result of complex environmental interactions. The patterns seen 
in the Humber Estuary follow some patterns exhibited in other regions; wastewater 
effluent is a major source of pharmaceuticals in estuaries, and input through this route 
plays a role in the fate of pharmaceuticals. As a result, improvement of removal during 
wastewater treatment is an important step in reducing environmental concentrations. 
Prioritisation schemes can be useful tools in determining the relative exposure of 
pharmaceuticals in the aquative environment, but can not adequately protect the 
environment as a whole. Exposure predictions could be improved by including localised 
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information on usage, removal and environmental conditions. Additionally, many of the 
predictors of toxicity used in prioritisation schemes (CEC, FPM, LC50 and LogKOW) could 
not individually predict toxicity of pharmaceuticals. Futher understanding on the uptake, 
bioaccumulation and effects of pharmaceuticals at multiple trophic levels is needed to 
better inform these models An inclusive approach of multiple schemes and comparison 
with the experimental work highlighted metformin, antibiotics and antidepressants as a 
priority for research. Further to these compounds, this thesis identified allopurinol, anti-
hypertensives (candesartan and losartan) and lipid lower drugs (atorvastatin and 
simvastatin), which are largely absent from the literature. Further to these compounds, 
Chapter 3, identified ibuprofen as a compounds of potential interest to regulators as the 
result of its ranking across prioritisation schemes. The possible implications of this drug 
were further emphasised by the monitoring work, which observed some of the highest 
concentrations of ibuprofen observed in estuaries.  
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A2 Supporting Information for Chapter 2 
A2.1 Ranking of priority compounds 
Table A2.1: Scores of priority compounds based on PECs, wastewater removal, logKOW and 
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A3.2 Excretion and removal rates of pharmaceuticals 
 

































































A4 Supporting Information for Chapter 4 




















































A5 Supporting Information for Chapter 5 
A5.1 Primer design 




















(c) cAMP-activation protein kinase  
 
 
Figure A5.1: Alignment of multiple sequences for designing degenerate primers (green shaded 
boxes). Dashes represent gaps in the alignment and asterisks represent homology. Alignments 
were cropped and are not shown in full. (a) Elongation factor 1 (EF1) alignments with Aurelia 
aurita (GenBank Accession KC341734.1), Bombyx mori (NM_001044045.1), Mus musculus 
(BC050124.1), Helix pomatia (KX384883.1) and Oncorhynchus mykiss (NM_01124339.1). (b) 
ATP synthase (ATPS) alignments with Nephasoma pellucidum (GU592847.1), Nereis vexillosa 
(DQ087492.1), Ophelia limacina (GU592851.1) and Erobdella octoculata (GU592848.1). (c) 
cAMP-activation protein kinase (AMPK) alignments with Hydroides elegans (AB232160.1) and 




A5.2 PCR Gel Electrophoresis 
 
Figure A5.2: Image of a 1% agarose gel electrophoresis of PCR products. Top Row - Lane 1, 
EF1 housekeeping gene; Lane 2, 18S housekeeping gene; Lane 3, ATPS; Lane 4, AMPK; Lane 
5, 100 bp ladder. Bottom Row - Lane 1, EF1 negative; Lane 2, 18S negative; Lane 3, ATPS 
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